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ABSTRACT 
The gold standard of celiac disease diagnosis has for a long time been the demonstration 
of small-bowel mucosal villous atrophy with crypt hyperplasia in an endoscopic sample. 
Even if the biopsy is useful in diagnostics, the question whether it is mandatory also in 
the follow-up is more complex. Endoscopic follow-up one year after diagnosis has been 
seen essential to ensure treatment response, but evidence is scarce. Inadequately treated 
or non-responsive celiac disease may increase the risk of severe complications, further 
supporting the histological follow-up. Then again, a repeat biopsy taken after one year 
on gluten-free diet might not pick these rare cases among the non-complicated patients 
who have not reached full mucosal recovery at this point. Altogether, the significance of 
a repeat biopsy and the histological recovery after one year on diet to the long-term 
health outcomes have been scarcely studied. This is the case also on studies on the 
overall value of regular follow-up in celiac disease. 
This dissertation comprised three studies investigating the above-mentioned follow-
up issues. Study I was a prospective cohort study involving 263 adult celiac disease 
patients. Comprehensive clinical, serological and histological data were collected both at 
diagnosis and after one year on treatment, and the participants were divided into two 
groups based on the presence or lack of villous recovery in the repeat biopsy. In addition, 
long-term medical record data were collected to assess the possibly increased frequency 
of severe clinical outcomes such as mortality, malignancies and comorbidities. The 
results showed that more severe disease at diagnosis in terms of villous atrophy, 
symptoms and serology predicts incomplete mucosal recovery one year after the 
diagnosis. However, the lack of full histological recovery did not affect patients’ self-
experienced symptoms or quality of life at the time of repeat biopsy or increase the risk 
of poor long-term health outcomes. 
Study II comprised 760 previously diagnosed celiac disease patients participating in 
a follow-up study between 2006 and 2010. Medical records and personal interviews were 
used to collect clinical, histological and serological findings both at the time of diagnosis 
and later. During the study visit the participants fulfilled validated questionnaires for 
current gastrointestinal symptoms and quality of life and blood sample for serology was 
drawn to evaluate dietary adherence. For the subsequent study analyses, the participants 
were divided into two groups depending on whether or not they had undergone a repeat 
biopsy one year after diagnosis, and the biopsied patients further into two groups based 
on the degree of villous recovery as in Study I. More severe disease at diagnosis predicted 
both the existence of a repeat biopsy and incomplete histological recovery in it. There 
were no differences between re-biopsied and not re-biopsied patients in the prevalence 
of long-term complications or in current dietary adherence, quality of life and 
gastrointestinal symptoms. However, patients without repeat biopsy were more insecure 
about their gluten-free diet and more often seropositive. As in Study I, the degree of 
histological recovery was not associated with any of the long-term variables used in the 
study. 
Patients for study III were extracted from the same cohort as in study II. Altogether 
648 long-term treated participants were divided into two groups based on whether they 
had received a long-term (>2 yr) follow-up or not, and the groups underwent 
comparisons of the same variables as in Study II. The median duration of follow-up was 
10 years (range 2-38 years). Only 15% of the patients were found to have received long-
term follow-up, depending partly on the presence of coexisting chronic diseases. 
However, even if the majority of patients wished regular healthcare visits, the follow-up 
and no follow-up groups did not differ in the long-term management of their disease, 
positivity for celiac disease serology or quality of life. There was also no difference in 
current gastrointestinal symptoms when evaluated by structured questionnaire, although 
those without a follow-up reported more overall symptoms. 
The results of studies I-III indicate a need to re-evaluate the current follow-up 
strategies for celiac disease. More severe disease at diagnosis predicted both the presence 
of a repeat biopsy and incomplete villous architecture one year after diagnosis. However, 
but neither the biopsy and no biopsy nor the histological recovery and no recovery 
groups differed in the main long-term health and treatment outcomes, including quality 
of life, dietary adherence and frequency of complications. Similarly, although the 
prevalence of regular follow-up was markedly lower than recommended in the 
guidelines, again this did not affect important treatment outcomes such as dietary 
adherence and quality of life in the long term. Altogether, more personalized approach 
to follow-up in celiac disease is needed. 
TIIVISTELMÄ 
Keliakian diagnostisena kriteerinä on pitkään ollut ohutsuolesta otettu koepala, josta 
pystytään todentamaan suolinukan vaurio samanaikaisesti suolikuopakkeiden 
syventymisen kanssa. Vaikka koepalan rooli on vakiintunut diagnostiikassa, on sen asema 
keliakian seurannassa epäselvempi. Histologisen seurannan on yleisesti ajateltu olevan 
avainasemassa hoidon toteutumisen kannalta, mutta aiheesta on vain vähän tieteellistä 
näyttöä. Kultaisena standardina pidettyä ohutsuolikoepalaa vuoden gluteenittoman 
ruokavaliohoidon jälkeen puoltaa huonosti hoidettuun tai hoitoon reagoimattamaan 
keliakiaan liittyvä riski myöhempiin lisäongelmiin. Toisaalta vuoden kohdalla otettu 
koepala ei välttämättä pysty erittelemään näitä harvinaisia tapauksia siitä populaatiosta 
joilla suolinukan korjaantuminen tapahtuu luonnostaan hitaasti onnistuneesta hoidosta 
huolimatta. Paitsi seurantatähytyksestä, keliakiaseurannan toteutumisesta ja 
merkityksestä ylipäätään on niukasti tutkimuksia. 
Tutkimus perustui kolmeen erilliseen osatyöhön, joissa selvitettiin seurannan 
toteutumista, sen vaikutusta hoidon onnistumiseen ja merkitystä pitkällä aikavälillä. 
Osatyöhön I sisältyi 263 aikuiskeliaakikkoa. Potilaista kerättiin laajat kliiniset, serologiset 
ja histologiset tiedot sekä diagnoosihetkellä että vuoden ruokavaliohoidon jälkeen, ja 
heidät jaettiin kahteen ryhmään perustuen suolinukkavaurion parantumisen asteeseen 
vuoden kohdalla otetussa seurantakoepalassa. Lisäksi myöhempiä sairaskertomustietoja 
kerättiin mahdollisesti lisääntyneen kuolleisuuden ja liitännäissairauksien esiintymisen 
arvioimiseksi. Epätäydellistä suolinukan korjaantumista ennusti diagnoosivaiheessa 
suolinukkavaurioltaan, oireiltaan ja serologialtaan vaikeampi taudinkuva. Keskeneräisellä 
parantumisella vuoden kohdalla ei kuitenkaan ollut vaikutusta tutkittuihin kliinisiin 
muuttujiin, kuten potilaiden elämänlaatuun ja oireisiin, eikä myöhempään kuolleisuuteen 
tai liitännäissairauksien esiintyvyyteen 15 vuoden seurannassa. 
Osatyö II koostui 760 aiemmin diagnosoidusta aikuiskeliaakikosta, jotka osallistuivat 
seurantatutkimukseen vuosina 2006-2010. Kaikilta osallistujilta kerättiin haastatteluiden 
ja sairauskertomusten avulla keliakiaan liittyvät kliiniset, histologiset ja serologiset 
löydökset sekä sairastumishetkellä että myöhemmin. Lisäksi tutkimuskäynnillä mitattiin 
kyselyiden avulla oireita ja elämänlaatua, arvioitiin ruokavaliohoidon onnistumista ja 
mahdollisten komplikaatioiden ja liitännäissairauksien esiintyvyyttä, sekä otettiin 
keliakiavasta-aineet ruokavaliohoidon toteutumisen arvioimiseksi. Analyyseja varten 
osallistujat jaettiin kahteen ryhmään sen perusteella, oliko seurantakoepalaa otettu 
vuoden ruokavaliohoidon jälkeen. Lisäksi seurantatähystyksen läpikäyneitä potilaita 
vertailtiin koepalalöydöksen perusteella kuten osatyössä I. Sekä seurantakoepalan ottoa 
että keskeneräistä histologista paranemista ennustivat diagnoosihetken vaikeampi tauti. 
Pitkäaikaisseurannassa tähystämättättömät potilaat noudattivat gluteenitonta 
ruokavaliota yhtä tarkasti kuin seurantakoepaloissa käyneet, eikä ryhmien välillä ollut 
juurikaan eroja potilaiden elämänlaadussa, oireissa, liitännäissairauksien ja 
komplikaatioiden määrässä. He kuitenkin kokivat itsensä epävarmemmiksi ruokavalion 
noudattamisessa ja olivat seurantatähystettyjä potilaita useammin seropositiivisia. 
Histologisen paranemisen aste vuoden kohdalla ei vaikuttanut tässäkään osatyössä 
pitkäaikaisseurannan tulokseen. 
Osatyössä III käytettiin osin samaa aineistoa ja analysoitavia parametrejä kuin 
osatyössä II. Kaikkiaan 648 seurantatutkimukseen osallistunutta hoidossa olevaa 
keliakiapotilasta jaettiin vertailuja varten kahteen ryhmään sen perusteella, oliko heillä 
ollut sairauden pitkäaikaisseurantaa (>2 vuotta) vai ei. Keskimääräinen seuranta-aika oli 
10 vuotta (vaihteluväli 2-38 vuotta). Osallistujista kerättiin jälleen laajat diagnoosihetken 
ja seuranta-ajankohdan tiedot. Tulokset osoittivat pitkäaikaisseurannan toteutuneen vain 
15 % keliaakikoista, osin riippuen muista samanaikaisista sairauksista. Vaikka suurin osa 
potilaista toivoi seurantaa, ryhmien välillä ei ollut eroja seurantahetken ruokavaliohoidon 
osaamisessa tai tiukkuudessa, seropositiivisuudessa, elämänlaadussa tai strukturoidusti 
arvioiduissa suolisto-oireissa, joskin ilman seurantaa olleet raportoivat kokonaisuutena 
hieman enemmän oireita. 
Osatöiden I-III tulokset osoittivat, että keliakian seurantaa on tarve kehittää. Sekä 
vuoden kohdalla otetun seurantakoepalan ottamista että sen tulosta voidaan ennustaa 
sairauden vakuvuudella diagnoosihetkellä. Kuitenkaan pitkällä aikavälillä 
seurantakoepalan tuloksella tai edes kontrollitähystyksen poisjättämisellä ei näyttäisi 
olevan suurta vaikutusta potilaiden ruokavaliohoitoon sitoutumiseen, elämänlaatuun ja 
oireisiin, tai merkittäviin pitkäaikaismuuttujiin kuten kuolleisuuteen ja oheissairauksiin. 
Lisäksi, vaikka keliaakikoita seurataan selvästi suositeltua vähemmän, tälläkään ei ollut 
merkittävää vaikutusta ruokavaliohoidon onnistumiseen tai elämänlaatuun pitkällä 
aikavälillä. Seurantakoepalan roolia tulee tulevaisuudessa pohtia ja kehittää 
yksilöllisempiä tapoja keliakian seurantaan. 
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ABBREVIATIONS 
ACG  American College of Gastroenterology 
AGA  Anti-gliadin antibody 
ALAT   Alanine aminotransferase 
APC   Antigen-presenting cell 
ARA  Anti-reticulin antibody 
BMD  Bone mineral density 
BMI  Body mass index 
BSG  British Society of Gastroenterology 
CCG  Current Care Guideline 
DGP  Deaminated gluten peptide 
DH  Dermatitis herpetiformis 
ELISA  Enzyme linked immunosorbent assay 
EmA  Endomysium antibodies 
ESPGAN European Society of Pediatric Gastroenterology and Nutrition 
ESPGHAN European Society of Pediatric Gastroenterology, Hepatology and 
Nutrition 
FBC Full Blood Count 
GFD Gluten-free diet 
GIP  Gluten Immunogenic Peptide 
GSRS  Gastrointestinal Symptom Rating Scale 
H&E  Hematoxylin and eosin 
HLA  Human leucocyte antigen  
IELs  Intraepithelial lymphocytes  
IgA   Immunoglobulin A 
IgG  Immunoglobulin G 
IL-15   Interleukin-15 
NK   Natural killer 
PGWB  Psychological General Well-Being  
QoL  Quality of life 
RCD   Refractory celiac disease 
SF-36  Short-Form 36 
TCR   T cell receptor 
TG2  Transglutaminase 2  
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TG2-ab Transglutaminase 2 antibodies 
TSH  Thyroid stimulating hormone 
ULN  Upper limit of normal 
Vh/CrD Villous height crypt depth ratio 
WGO  World Gastroenterology Organization  
WHO  World Health Organization 
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INTRODUCTION 
Celiac disease is a chronic immune-mediated disorder caused by the ingestion of gluten 
in genetically predisposed individuals (Green and Cellier 2007). In adults, the diagnosis 
of celiac disease has thus far required the demonstration of villous atrophy and crypt 
hyperplasia in the small-bowel biopsy, whereas in children it is possible to establish the 
diagnosis in certain cases without biopsies (Husby 2012). Currently there is increasing 
trend towards less invasive diagnostics in adults too and, for the first time, serology-
based diagnosis has been made possible in the very recent Finnish guidelines (Rubio-
Tapia et al. 2013, Husby et al. 2012, Current Care Guideline 2018). The classical 
symptoms are diarrhea, stunting and malabsorption in childhood (Gee 1888, Visakorpi 
et al. 1970), but the disease can appear with varying symptoms at any age with an 
increasing prevalence through aging (Vilppula et al. 2009). During the last decades, with 
improved diagnostics and better understanding of the disease, the clinical presenation 
has become more heterogenous (Mäki et al. 1988a, Murray et al. 2003).  
Histological injury in celiac disease develops gradually. Elimination of dietary gluten 
by means of a gluten-free diet usually leads to rapid alleviation of symptoms and slower 
recovery of villous structure (Järvinen et al. 2003, Lähdeaho et al. 2011). However, in 
most literature complete mucosal recovery has been reached only in a minority of 
patients (Wahab et al. 2002, Tursi et al. 2006, Lanzini et al. 2009, Sharkey et al. 2013). 
The most common reason for incomplete mucosal recovery has usually been imperfect 
dietary adherence (Abdulkarim et al. 2002, Leffler et al. 2007, Sharkey et al. 2013).  
The main aims for follow-up in celiac disease are to ensure response to treatment and 
to find the rare cases with refractory celiac disease (RCD). In RCD, mucosal damage 
persists despite a strict gluten-free diet, increasing the risk of serious complications. A 
repeat biopsy one year after the celiac disease diagnosis is thus recommended in most 
guidelines, at least in patients with persistent symptoms. In Finland, the prevalence of 
strict dietary adherence is over 90% (Ukkola et al. 2011) and long-term histological 
recovery rate as high as 96% (Ilus et al. 2012). As as result, frequency of RCD was 
recently shown to be as low as 0.3% (Ilus et al. 2014) of all celiac disease patients, which 
calls for more personalized histological follow-up strategies. 
On the other hand, even without actual RCD, incomplete mucosal recovery in the 
repeat biopsy has been associated with adverse outcomes, such as osteoporosis and 
increased risk of lymphoma and mortality, although these results are controversial 
(Lebwohl et al. 2013b). Overall, the significance of a repeat biopsy in celiac disease 
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remains scarcely studied and is under discussion in expert panels (Ludvigsson et al. 
2014).  
Strict adherence to gluten-free diet is vital for mucosal healing and symptom 
alleviation. It has been argued that having access to healthcare and regular follow-up 
improves the adherence to gluten-free diet (Bardella et al. 1994, Haines et al. 2008), but 
these studies have been carried out on small samples and in populations with often poor 
overall adherence. Altogether, evidence on the optimal timing, actual content end even 
the necessity of follow-up remains scarse (Bai et al. 2013, Ludvigsson et al. 2013c, Rubio-
Tapia et al. 2013, Current Care Guideline 2010). 
The main aim of the present study was to investigate the implementation and 
significance of routine repeat biopsy one year after celiac disease diagnosis. This was 
accomplished by comparing a variety of short- and long-term health and treatment 
outcomes between large cohorts of celiac disease patients. We focused on the features 
predicting the aquiring of a repeat biopsy after one year on gluten-free diet. If the 
endoscopy was conducted, we investigated the features predicting the result of the repeat 
biopsy as well as its effect on long term health between those with and without 
histological recovery. Furthermore, the effect of a regular long-term (>2 yr) follow-up 
of celiac disease to the aforesaid health and treatment outcomes was investigated. 
 
 
 
  
 15 
LIST OF ORIGINAL PUBLICATIONS 
This thesis is based on the following original publications, referred to in the text by 
Roman numerals I-III: 
 
I Pekki H, Kurppa K, Mäki M, Huhtala H, Sievänen H, Laurila K, Collin P, Kaukinen 
K (2015): Predictors and Significance of Incomplete Mucosal Recovery in Celiac Disease 
After 1 Year on a Gluten-Free Diet. Am J Gastroenterol. 110:1078-1085. 
II Pekki H, Kurppa K, Mäki M, Huhtala H, Laurila K, Ilus T, Kaukinen K (2017): 
Performing Routine Follow-up Biopsy 1 Year After Diagnosis Does Not Affect Long-
term Outcomes in Coeliac Disease. Aliment Pharmacol Ther. 45:1459-1468.  
III Pekki H, Kaukinen K, Ilus T, Mäki M, Huhtala H, Laurila K, Kurppa K (2018): 
Long-term Follow-up in Adults with Coeliac Disease: Predictors and Effect on Health 
Outcomes. Dig Liv Dis. 50:1189-1194.  
 16 
REVIEW OF THE LITERE 
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1 History  
First alleged description of celiac disease was written by Aretaeus of Cappadocia in the 
1st century B.C. (Adams 1856). Since the causative dietary agent, gluten, is present only 
in wheat, rye and barley, at its earliest celiac disease could have evolved only after the 
development of agriculture in Mesopotamia approximately 10 000 years ago (Harlan 
1966). Up to the last few centuries grains contained relatively low amounts of gluten 
(Belderok 2000, Kasadra 2013), which may explain the lack of medical reports of celiac 
disease before the beginning of the 19th century (Baillie 1815). The earliest scientific 
report was written by Samuel Gee (1888). A variety of dietary treatments were attempted 
during the first half of the 20th century, but the actual cause of celiac disease remained 
unknown. The main disese driver, gluten, was found after World War II by Dicke et al. 
(1953), which finally enabled targeted treatment of celiac disease.  
A year later, in 1954, the characteristic histopathologic changes, i.e. small-bowel 
mucosal villous atrophy and crypt hyperplasia, were discovered (Paulley 1954). 
Endoscopic biopsy techniques were introduced during the next few years (Royer 1955 
and Shiner 1956). The first serum antibodies were described in 1958 (Berger 1958), and 
the main autoantigen of the disease in 1997 (Dieterich et al. 1997). The suggestion that 
celiac disease as an autoimmune disease was also made in the 1990’s (Mäki 1991 ja Mäki 
1994). Finding serological markers paved the way to wide-scale screening studies, which 
revealed the wide clinical spectrum and  
high prevalence of the disease. Nowadays celiac disease is recognized to be one of 
the most common chronic gastrointestinal conditions in the Western world (Mäki et al. 
2003, Fasano et al. 2003, Lohi et al. 2007).  
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2 Epidemiology 
For a long time, celiac disease has apparently been a very rare condition (Guandalini 
2008). One of the oldest epidemiological reports approximated the incidence of celiac-
like sprue syndrome to be between 1:10000 and 1:5000 in Great Britain (Davidson and 
Fountain 1950). Reports since have varied depending on the diagnostic criteria and 
nation in question, but a considerable increase in the prevalence took place in the 1980s, 
as the understanding of the diverse presentation increased and celiac disease was found 
also in adults (Logan et al. 1983, Mäki et al. 1988). The main contributor to this change 
was improvements in diagnostic methods, but studies indicate also a rise in the true 
prevalence of celiac disease (Lohi et al. 2007, Rubio-Tapia 2009, Ludvigsson 2013a, 
Choung et al. 2017).  
Recent screening studies have shown an approximate prevalence of 1% for celiac 
disease in both children (Hoffenberg 2003, Mäki et al. 2003) and adults (Fasano 2003, 
West et al. 2004, Walker et al. 2010). In Finland, the prevalence has been found to be 
even higher, reaching approximately 2% in adults (Lohi et al. 2007). The prevalence 
increases through aging and is up to 2.7% in the elderly Finnish population (Vilppula et 
al. 2009). The highest prevalence in the world thus far, 5.6%, has been found among 
Saharawi children in Algeria (Catassi 1999). Due to the rarity of the predisposing genes 
in the population (Chapter 3.2), the disease is rare in China and virtually absent in Japan 
(Cummins and Roberts-Thompson 2009).  
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3 Pathogenic Background 
3.1 Genetics  
The prevalence of celiac disease varies between 3% and 10% in first-degree relatives of 
the patients (Mäki et al 1991, Singh et al. 2015). The genetic risk is largely associated with 
gene areas encoding human leucocyte antigens (HLA), which are necessary but not 
sufficient for celiac disease to develop. HLA genes are polymorphic genes located in a 
gene cluster called the major histocompatibility complex. One of these genes on 
chromosome 6p21.3 has been associated with celiac disease already in 1970s (Stokes 
1972). The HLA locus and, more specifically, its alleles found in 1972 were later defined 
to encode HLA-DQ2 and DQ8 molecules on the antigen-presenting cells (Sollid et al. 
1989, Sollid 2000). HLA-DQ2 homozygosity increases the disease risk of five-fold 
compared to heterozygotes (Murray 2007, Koskinen 2009). Approximately 90% of celiac 
disease patients express the HLA-DQ2 haplotype (DQA1*0501/DQB1*0201). Five 
percent of patients have the HLA-DQ8 haplotype (DQA1*0301/DQB1*0302) and 
almost all remaining subjects have at least one of the two genes encoding the DQ2 ơƢ-
heterodimer (DQB1*0201 or DQA1*0501) (Karell et al. 2003).    
Approximately a third of the population carry the DQ2 or DQ8 alleles thus being at 
genetic risk for celiac disease, but for yet unknown reasons only about 3-4% percent of 
people with these haplotypes develop the condition (Jabri and Sollid 2009). In addition 
to the HLA alleles, a large number of non-HLA susceptibility loci have been proposed 
to be involved in the pathogenesis of celiac disease (Dubois et al. 2010, Romanos et al. 
2014), and also non-coding DNA may participate at some level (Vaira et al. 2014). 
 
3.2 Environmental Factors 
Environmental factors are needed for the development of celiac disease, particularly 
gluten without which the disease cannot develop. The term gluten is a general heading 
for insoluble prolamine peptides, namely gliadin in wheat, hordein in barley and secalin 
in rye (Platt and Kasarda 1971). In wheat, prolamins function as storage proteins (Anand 
et al. 1978). Gluten is rich in proline (15%), making it resistant to luminal degradation 
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by gastrointestinal enzymes and thus increasing its pathogenicity (Frazer et al. 1959, Jabri 
2009). The three-dimensional structure of gliadin enhances the baking properties of 
dough so that, unfortunately for celiac disease patients, cereals containing it are favored 
in the food industry (Molberg et al. 2003). 
In addition to the necessary gluten as a disease driver, it seems evident that there are 
also other environmental triggers. This would explain why only a part of the genetically 
predisposed people get the disease, as well as the increase in the true prevalence (Lohi 
et al. 2007). Also differences in the prevalence between genetically similar populations 
with different living environments support the hypothesis of additional triggers 
(Khondrasova et al. 2009). 
Breastfeeding has been studied in this context and has been thought to offer 
protection against the development of celiac disease (Ivarsson et al. 2002), but this matter 
is still under debate (Lionetti et al. 2014, Vriezinga et al. 2014). The effect of age at gluten 
introduction is ambivalent, but the amount of gluten used at the time seems to be 
connected to an increased risk (Ivarsson et al. 2002, Aronsson et al. 2016).  
Adeno- and rotavirusinfections have been suggested to increase the risk of celiac 
disease, possibly through molecular mimicry (Stene et al. 2006). The role of rotavirus is 
supported by the reduced risk in vaccinated children. (Kemppainen et al. 2017). In the 
viral hypothesis, it is thought that particularly the age in which an infant gets certain 
types of infections affect the likelihood to develop celiac disease. This is somewhat 
supported by the observed seasonal pattern in celiac disease, as the incidence varies 
depending the month of birth. (Ivarsson et al. 2003). A recent study found reovirus 
infections to suppress certain types of T-cells, thus potentially triggering celiac disease 
(Bouziat et al. 2017). 
Interestingly, the prevalence of celiac disease has increased more in developed 
countries than in developing countries (Kang et al 2013). Consequently, a concept 
known as the “hygiene hypothesis” has gained popularity as a possible cause for this 
phenomenon (Lohi et al. 2007, Kondrashova et al. 2008). In this hypothesis, the lack of 
microbial exposure in developed countries increases the prevalence of autoimmune 
diseases, as the human immune system reacts to self-antigens in the lack of infectious 
agents (Strachan 1989, Bodansky et al. 1992, Lohi et al. 2007).  
3.3 Pathogenesis 
Celiac disease is thought to be one of the best understood autoimmune diseases as 
regards to pathogenesis (Lindfors et al. 2010, Sollid and Jabri 2011). Gluten plays a key 
role in the development of mucosal inflammation in affected patients. The ensuing 
immune reaction from the ingestion of gluten eventually leads to villous atrophy with 
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crypt hyperplasia. Adaptive immunity was thought to be the main pathway to mucosal 
destruction, but more recent studies have found the process to be a combination of 
adaptive and innate immunity (Sollid and Jabri 2011). In active celiac disease the barrier 
between the gut lumen and the rest of the body is though to be damaged. The 
immunogenic peptides cross the epithelial barrier to the lamina propria either through 
paracellular route due to increased epithelial permeability, or via transcellular route with 
the help of secretory immunoglobulin A (IgA) (Sapone et al. 2008, Rauhavirta 2014).  
After the entrance to the lamina propria, the peptides are deamidated by 
transglutaminase 2 (TG2), which further activates the adaptive T-helper cell 1 type pro-
inflammatory response (Sollid 2000). This causes various pro-inflammatory cytokines, 
particularly interferon ƣ, to begin a cascade resulting in the disruption of small-bowel 
mucosal structure (Sollid et al. 1989). TG2 is a multifunctional enzyme present mainly 
intracellularly in the gut, although the enzyme can be located also in other places around 
the body (Sollid and Jabri 2011). Under tissue-damaging conditions, such as 
gastrointestinal infections, the tolerance to native gluten peptides breaks and TG2 is 
released extracellularly (Siegel et al. 2008). The gliadin peptides are next processed and 
presented by the HLA-DQ8 or DQ2 molecules on antigen-presenting cells (APCs) and 
recognized by the gluten-specific CD4+ T cells (Molberg et al. 1998). In the end, crypt 
hyperplasia and villous atrophy develop through direct cytotoxicity and by activation of 
matrix metalloproteinases (Pender et al. 1997, Jabri 2009).  
For yet unclear reasons, specific autoantibodies are developed against TG2 (TG2-
ab). These antibodies are assumed to cause extraintestinal manifestations by depositing 
in different tissues such as the liver, skeletal muscle and brain (Korponay-Szabo et al. 
2004, Hadjivassilou et al. 2006). These effects may in part be due to disrupted 
angiogenesis by TG2-ab (Myrsky et al. 2008). Additionally, TG2-ab may promote celiac 
disease progression by inhibiting the differentiation of epithelial cells and thus increasing 
their proliferation (Halttunen and Mäki 1999 Barone et al. 2007). Nowadays TG2-ab 
also have a major role in the diagnostics of celiac disease (Chapter 6.1.1) 
Gliadin may also induce mucosal damage via a non-T-cell-dependent innate pathway, 
particularly by activating interleukin-15 (IL-15) (Maiuri et al. 2003). There is a variety of 
intraepithelial lymphocytes (IELs) in the small-intestinal mucosa, in celiac disease most 
importantly the CD8+ T cells presenting T cell receptor (TCR) ơƢ+. Many of these TCR 
ơƢ+ cells also express natural killer (NK) cell receptors, which act by lowering the 
threshold for T cell activation at stressful times (Bauer et al. 1999). IL-15 up-regulates 
IELs to express high levels of activating NK receptors (Meresse et al. 2004). In 
enterocytes, IL-15 up-regulates the expression of their ligands resulting in an increase in 
the production of proinflammatory cytokines and cytolytic enzymes leading to apoptosis 
and mucosal damage (Figure 1) (Hüe et al. 2004, Jabri et al. 2000). IELs have also recently 
 22 
been shown to gain malignant features in some patients with untreated celiac disease 
(Ettersperger et al. 2016).  
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4 Clinical Features 
4.1 Classic Manifestations 
Historically, as celiac disease was thought to be a solely pediatric condition, the classic 
signs and symptoms were poor growth, persistent diarrhea, and signs of malabsorption 
(Visakorpi and Mäki 1994). Due to malabsorption, patients often had deficiencies of fat-
soluble vitamins D, E, A and K, as well as important trace elements iron, calcium, zinc, 
folate and vitamin B12, and subsequently complications such as anemia, rickets, poor 
growth, short stature and delayed puberty (Visakorpi and Mäki 1994). The classic 
manifestations became less frequent in the 1980s as more patients with milder or non-
classical symptoms were found (Logan et al. 1983, Mäki et al. 1988, Kivelä et al 2015). 
Nowadays celiac disease patients often suffer only from mild abdominal symptoms, such 
as loose stools, abdominal discomfort and flatulence or have only extraintestinal 
symptoms (Volta et al. 2014, Agardh et al. 2015). 
4.2 Extraintestinal Manifestations and Complications 
Celiac disease can manifest with a variety of extraintestinal symptoms. The line between 
an extraintestinal manifestation and a complication is often obscure and depends on how 
these are defined. Due to the changing clinical spectrum of celiac disease the term 
‘atypical’ is no longer considered valid in patient with only extraintestinal symptoms 
(Collin et al. 1999, Kaukinen et al. 2010, Ludvigsson et al 2012). 
4.2.1 Extraintestinal Manifestations 
One of the most common extraintestinal symptoms of celiac disease, which is sometimes 
even seen as its own disease entity, is dermatitis herpetiformis (DH), which manifests 
itself on the skin as a polymorphic blistering rash on elbows, knees, buttocks and scalp 
(Duhring 1884).  The condition is rare in childhood, the mean age of onset being usually 
between 30 and 40 years with a slight male predominance (Salmi et al. 2014).  
Neurological symptoms include gluten ataxia (Hadjivassiliou et al. 1996), peripheral 
neuropathy, encephalopathy, myopathy (Hadjivassiliou et al. 2010) and migraine 
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(Gabrielli 2003). An increased prevalence of epilepsy has also been associated with celiac 
disease (Cooke and Smith 1966, Ranua et al. 2009). Alzheimer’s disease and celiac disease 
overlap genetically and thus may be associated to some extent, even if patients with celiac 
disease do not seem to have significantly increased risk for dementia (Lebwohl et al. 
2016) 
Celiac disease patients may also suffer from severe psychiatric problems such as 
anxiety, depression and schizophrenia (Kalaydjian et al. 2009). Particularly depression 
seems to be more prevalent in both adults and adolescents with untreated celiac disease 
(Pynnönen et al. 2004, Ludvigsson et al. 2007). A gluten-free diet may alleviate both 
depression and anxiety (Addolorato et al. 2001).  
Untreated celiac disease can contribute to gynecological maladies such as 
unexplainable infertility (Morris et al. 1970), delayed menarche, secondary amenorrhea 
and early menopause (Moleski et al. 2015). These risks significantly decrease on a gluten-
free diet (Tersigni et al 2014). In recent studies no differences on pregnancy outcomes 
were found in patients with treated celiac disease when compared to the general 
population (Tersigni et al. 2014, Saccone et al. 2016).  
Hepatic conditions are common in celiac disease (Farre et al. 2002). The hepatic 
injury seems to be gluten-sensitive and its severity may vary from only slightly elevated 
transaminases, which decrease after the introduction of a gluten-free diet, to severe liver 
failure requiring transplantation (Kaukinen et al 2002). In Finland, the latest estimate of 
elevated liver enzymes in untreated patients is between 10% and 15% (Korpimäki et al. 
2011, Äärelä et al. 2016), but globally this percentage is as high as 40-50% (Castillo et al. 
2015, Vajro et al. 2013).   
Another frequently observed extraintestinal manifestation of celiac disease is 
permanent damage of dental enamel defects, which, like many other extraintestinal 
symptom, can also be seen as a complication (Aine et al. 1996). Other extraintestinal 
manifestations possibly associated with celiac disease are for example recurrent aphthous 
ulcerations (Ferguson et al. 1976), arthritis (Mäki et al. 1988b, Collin et al. 1992a) and 
alopecia areata (Corazza et al. 1995a). 
4.2.2 Complications 
Of the conditions considered more often as a complication than extraintestinal 
manifestation, the association between bone disorders and celiac disease has been long 
known (Salvesen and Boe 1953). However, the formerly common osteomalacia and 
rickets have given way to osteoporosis at least in developed countries (Valdimarsson et 
al. 1994, Tikkakoski et al 2007). Both children and adults with celiac disease may present 
lower bone mineral density (BMD) than healthy controls (Tau et al. 2006, Corazza et al. 
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1995b), although in a recent study this was not seen in women diagnosed over at 40 
years of age (Kamycheva et al 2017). In a recent meta-analysis, the risk of osteoporotic 
fractures is significantly increased in celiac disease (Heikkilä et al. 2015). The evident 
cause for osteoporosis in celiac disease would be malabsorption, and indeed more 
advanced histological disease at diagnosis is associated with lower BMD (Abu Daya et 
al. 2013). However, low BMD can be present even when the villous structure is still 
morphologically normal (Kurppa et al. 2010a), and it has been suggested that mucosal 
inflammation causing chronic release of proinflammatory cytokines would disturb the 
balance of bone remodeling (Riches et al. 2009, Hård et al. 2018).  
Some malignancies have been found more prevalent in patients with celiac disease, 
especially in older studies. However, this feared complication may have been 
overrepresented due to detection bias, as only symptomatic patients were actively 
sought. In more recent studies the malignancy risk has decreased, the highest risk ratio 
being 1.9-5.8 of non-Hodgkin lymphomas (Grainge et al. 2012, Ilus et al 2014). The risk 
of lymphoma is greatest during the first years after the diagnosis of celiac disease, but it 
has been reported to remain elevated for up to 15 years (Grainge et al. 2012). The 
elevated risk may still at least partly be due to selection bias, as the clinical detection rate 
of celiac disease in those studies was much lower than the previously reported serological 
prevalence, and the patients thus could have been those with the most severe 
presentation (Catassi et al 2002, Lohi et al. 2009). 
Of other malignancies, the risk for esophageal cancer is up to 4-fold and for stomach 
cancer up to 3-fold in untreated celiac disease (Askling et al. 2002, West et al. 2004a). As 
regards to colon and hepatic cancers, the results are controversial (Askling et al. 2002, 
Viljamaa et al. 2006, Elfström et al. 2012). Interestingly, the risk of all malignancies 
among celiac disease patients has been seen to decrease after the year 2000, which may 
be due to increased detection rates of patients with milder symptoms and/or because of 
shorter diagnostic delay and improved adherence to dietary treatment (Eigner et al. 2017, 
Ludvigsson et al 2012).  
Recent studies have shown the mortality of untreated celiac disease patients to be 
comparable with the general population (Lohi et al. 2009, Godfrey et al. 2010, Chounq 
et al. 2017). This is contradictory to earlier findings in which especially disease patients 
with malabsorptive symptoms were reported to have increased mortality (Corraro et al. 
2001, Viljamaa et al. 2006). However, the mortality has remained elevated among 
patients with RCD (Biagi et al. 2014).  
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4.3 Associated Diseases  
In certain diseases an unusually high prevalence of celiac disease has been observed; 
most notably approximately 20-30% of celiac disease patients have a coexisting 
autoimmune disorder (Viljamaa et al. 2005b, Cosnes et al. 2008). Common autoimmune 
comorbidities are type 1 diabetes (Visakorpi 1969), autoimmune thyroidal diseases 
(Kuitunen et al. 1971) and Sjögren´s syndrome (Viljamaa et al. 2005a). Autoimmune 
diseases share genetic risks, but it is possible that other pathogenetic mechanisms are 
also involved (Collin et al. 1994, Viljamaa et al. 2005b). Celiac disease is also linked with 
selective IgA deficiency (Collin et al 1992), which is clinically important as IgA-class 
antibodies are routinely used for the screening of celiac disease (Meini et al. 1996).  
Celiac disease has been associated also with several other gastrointestinal diseases and 
dermatological diseases. The former includes particularly microscopic colitis (Matteoni 
et al. 2001), autoimmune liver diseases and atrophic gastritis. Of dermatological diseases, 
for example alopecia areata, dermatomyositis, scleroderma, psoriasis and vitiligo have 
been reported to be overrepresented in celiac disease (Peña 1987, Abenavoli et al. 2010). 
Oral diseases such as geographic tongue and lichen also seem to be more common in 
celiac disease patients than in the population (Ciglic et al 2015, Ciglic et al. 2016), and 
this could be the case also with Down´s and Turner´s syndromes and myasthenia gravis 
(Book et al. 2003, Sagodi et al. 2006, Freeman et al. 2009). 
4.4 Silent Celiac Disease and Screening 
Clinically silent celiac disease with positive celiac disease serology and small-bowel 
mucosal atrophy but no apparent symptoms is nowadays a frequent phenomenon 
(Kurppa et al 2014, Ludvigsson et al. 2013b). This phenotype is more often seen in 
screen-detected at-risk patients (Current Care Guideline 2010, Rubio-Tapia et al. 2012, 
Ludvigsson et al. 2013c, Bai and Ciacci 2017).  
There are contradictory findings on whether the symptoms correlate with the other 
disease features; i.e. milder symptoms do not automatically mean less severe histological 
and serological disease (Brar et al. 2007, Murray et al. 2008, Taavela et al 2013a). On the 
other hand, asymptomatic subjects seem to have lower risk of intestinal lymphomas than 
clinically detected patients, and the restricting gluten-free diet may decrease quality of 
life (Ukkola et al. 2011, Mearin et al. 2006, US Preventive Services Task Force 2017). 
When applying WHO standards, screening in high risk groups might be appropriate, but 
further evidence for mass screenings of the general population is needed (Viljamaa et al. 
2005b, Ludvigsson et al. 2015). However, data suggest that, on a general level, screen-
detected patients benefit from a gluten-free diet similarly to symptomatic patients, 
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although individual differences exist (Kurppa et al. 2014, Mustalahti et al. 2002). 
Interestingly, when assessed systematically by validated questionnaires, screen-detected 
patients may in fact have as severe symptoms as clinically detected patients (Paavola et 
al. 2012). Based on these findings, prediction of the risk of celiac disease on basis of 
symptoms is difficult (Kårhus et al. 2016, Kivelä et al. 2017) 
4.5 Potential Celiac Disease 
Owing to the increasing serological screening, patients with positive celiac 
autoantibodies but normal mucosal architecture are increasingly found, such situation 
having been common already for a long time among DH patients (Reunala 2001, Mäki 
et al. 2003, Kurppa et al. 2010b). Sometimes the antibodies may be false positive 
especially in low titres, but in many cases seropositivity appears to be an early 
phenomenon in the disease continuum (Korponay-Szabo et al. 2004, Ferrara et al. 2010, 
Simell et al. 2010). In a randomized trial, most participants with positive endomysium 
antibodies (EmA) developed duodenal atrophy within one year on a gluten-containing 
diet, showing that the serology can be elevated before the appearance of morphological 
mucosal damage (Kurppa et al 2009). Patients may also present with symptoms and sings 
of celiac disease and benefit from a gluten-free diet before the development of evident 
villous damage (Repo et al. 2017, Volta et al. 2016).  
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5 Quality of Life and Persistent Symptoms 
5.1 Quality of Life 
WHO defines health-related quality of life as an individual’s overall satisfaction with life 
in the context of the culture in which he lives and as a sense of general personal well-
being comprising physical, social and psychological aspects and also general sense of 
well-being and somatic sensations affected by one’s health status (WHO 1997). 
Reproducible and validated methods should be used when quantifying the effect of a 
disease on the quality of life. In celiac disease research, frequently used quality of life 
questionnaires include Psychological General Well-Being (PGWB) (Dupuy et al. 1984) 
and the 36-item short-form (SF-36) (Ware and Sherbourne 1992). Studies assessing long-
term quality of life in celiac disease patients have been mostly cross-sectional (Lohiniemi 
et al. 2000, Nachman et al. 2009) (Table. 1) 
In most studies, the quality of life of untreated celiac disease patients has been 
decreased compared to both healthy controls and the general population (Johnston et 
al. 2004, Viljamaa et al. 2005b, Nachman et al. 2009). It seems that concomitant 
gastrointestinal disorders predispose to more severe symptoms and poorer quality of life 
at diagnosis (Usai et al. 2002, Nachman 2009, Kurien et al. 2011). As previously 
mentioned, a substantial part of the so called ‘asymptomatic patients’ found through 
screening actually have symptoms when systematically inquired. However, these 
symptoms seem to impair quality of life only in clinically-detected patients, possibly 
because of their overall more severe presentation (Paavola et al. 2012).  Furthermore, 
the psyche seems to play a significant role on quality of life, as depression has a stronger 
correlation with reduced quality of life than gastrointestinal symptoms (Sainsbury et al. 
2013a). In untreated patients, female gender and psychiatric, neurologic or 
gastrointestinal comorbidities seem to increase the risk for reduced quality of life (Usai 
et al. 2002, Hallert et al. 2002a, Paarlahti et al. 2013). Long diagnostic delay also seems 
to affect quality of life adversely (Norström et al. 2011, Fuchs et al. 2018). 
Most studies have shown improved quality of life on a gluten-free diet (Lohiniemi et 
al. 2000, Nachman et al. 2009, Borghini et al. 2017, Hughey et al. 2017), although this is 
more prominent with originally symptomatic patients (Ukkola et al. 2011, Mahadev et 
al. 2016). Long-term gluten-free diet does not seem to decrease the quality of life even 
in screen-detected patients (Viljamaa et al. 2005b, Kurppa et al. 2012), giving further 
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justification to recommend the diet to this patient group. Female gender seems to be 
connected with lower quality of life also in treated celiac disease, females expressing 
more concern about the impact on socializing with friends and having to abstain from 
important things in life (Hallert et al. 2002). For many patients, celiac disease diagnosis 
is a relief, but some experience problems adjusting to a chronic illness and the diagnosis 
has been reported to be even a shock to 6% of patients (Ukkola et al. 2012). Besides the 
burden of the diet, the quality of life in long-treated celiac disease patients may be 
somewhat impaired due to increased anxiety related to possible accidental ingestion of 
gluten (Leffler et al. 2017).  
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Table 1. Long-term cross-sectional studies on the quality of life (QoL) and symptoms in treated adult celiac 
disease patients 
Author Country N:o of patients 
N:o of 
controls Method(s) 
GFD, 
yrs Findings 
Hallert et al. 
1998 Sweden 89 - SF-36, GSRS 10 
Women with celiac disease had lower 
QoL compared to general population 
Lohiniemi et 
al. 2000 Finland 58 110 GSRS, PGWB 10 
No differences in QoL between 
patients and non-celiac controls 
Usai et al. 
2002 Italy 66 136 SF-36 >2 
Celiac disease patients had lower QoL 
compared to non-celiac controls 
Fera et al. 
2003 Italy 100 100 
SF-36, IBQ, 
SCID, M-SDS, 
STAI 
9 
Celiac disease patients had more 
depression and anxiety than controls; 
no association with dietary compliance 
O’Leary 2004 Ireland 50 - SF-36 28 No difference in QoL between celiac disease patients and general population 
Viljamaa 
2005 Finland 53 110 
SF-36, PGWB, 
GSRS 14 
No difference in QoL between celiac 
disease patients and controls 
Häuser 2006 Germany 446 - SF-36, HADS, GSCL 9 
Celiac disease patients had lower QoL 
compared to the general population 
Häuser 2007 Germany 516 - HADS. SF-36 
No 
data 
Mental disorders, dietary lapses and 
dissatisfaction with physician predicted 
reduced QoL in celiac disease 
Nachman 
2010 Argentina 53 - SF-36 4 
QoL increased after diagnosis and 
remained higher than at diagnosis even 
if decreased in a 4-year follow-up 
Barratt 2011 UK 573 - SF-36, HADS 8 Difficulties in dietary adherence predicted reduced QoL 
Zampieron 
2011 Italy 187 - CD-QOL 10 
Women and symptomatic celiac 
disease patients had reduced QoL 
compared to asymptomatic patients 
Paavola 2012 Finland 366 110 GSRS, PGWB 7-9 
Symptomatic celiac disease patients 
had reduced QoL; no difference 
between screened patients and 
controls 
Paarlahti 
2013 Finland 596 - GSRS, PGWB 11 
Long-lasting and severe symptoms 
before diagnosis predicted persistent 
symptoms and reduced QoL 
Mahadev 
2016 USA 211 - 
CD-QOL, 
PGWB,CDAT 4 
Screen-detected patients do not differ 
from symptom-detected in QoL or 
long-term GFD adherence 
Hughey 2017 USA 1832 - CSI, CD-QOL No data 
Reduced QoL improved and 
symptoms alleviated on a long-term 
GFD 
GFD, gluten-free diet; SF-36, Short Form 36 Health Survey; GSRS, Gastrointestinal Symptoms Rating Scale; 
PGWB, Psychological General Well-Being Index; IBQ, Illness Behavior Questionnaire; SCID, Structured Clinical 
Interview for DSM; M-SDS, modified version of the Zung Self-Rating Depression Scale; STAI, State and Trait 
Anxiety Inventory; HADS, The Hospital Anxiety & Depression Scale; GSCL, Giesen Symptom Check List; CSI, 
Celiac Disease Specific Symptoms; CDAT, Celiac Disease Adherence Test; CD-QOL, Celiac Disease and Quality 
of Life 
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5.2 Persistent Symptoms  
Failure to reach expected clinical response to gluten-free diet is most commonly defined 
as persistent gastro-intestinal symptoms (Abdulkarim et al. 2002, Dewar et al. 2012). 
Several cross-sectional studies have examined the long-term symptoms in celiac disease 
(Table 1). An identifiable cause can be found in over 90% of cases, the most common 
being dietary lapses (Abdlukarim et al. 2002, Dewar et al. 2012, Stasi et al.  2016).  
Symptoms may also be caused for example by coexisting lactose intolerance, irritable 
bowel syndrome, eating disorders, gastroesophageal reflux, microscopic colitis, 
giardiasis, inflammatory bowel disease, small intestinal bacterial overgrowth, thyroid 
impairment and pancreatic insufficiency (Abdulkarim et al. 2002, Leffler et al. 2007, Stasi 
et al. 2016). Even without any of the aforementioned diseases, celiac disease patients 
may have more gastrointestinal symptoms than the general population despite a strict 
gluten-free diet (Laurikka et al. 2016).  
In recent studies, the prevalence of persistent symptoms has been approximately 20% 
(Paavola et al. 2012, Laurikka et al. 2016, Stasi et al. 2016), although this may be 
overestimation as the symptom alleviation can continue a rather long time (Hughey et 
al. 2017). Diagnosis at working age, lower socioeconomic status, long duration and 
severe symptoms before diagnosis, along with the presence of coexisting thyroidal 
disease, non-celiac food intolerance or gastrointestinal morbidities, have been associated 
with the persistence of symptoms (Paarlahti et al. 2013, Oza et al. 2016). There are 
indications that patients who reach national recommended fiber intake have less often 
persistent symptoms (Laurikka et al. 2019). 
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6 Diagnosis 
The suspicion of celiac disease can be based on several issues, including clinical 
symptoms, existence of associated comorbidities and family history for the disease. As 
serology is quite sensitive and specific, it can be used to target patients into further 
invasive studies, but, if clinical suspicion is high, even seronegative patients should be 
endoscopied (Current Care Guideline 2010, Salmi et al. 2006). In Finland patients who 
belong to at-risk groups are recommended to be screened comprehensively and, if 
necessary, repeatedly (Current Care Guideline 2010). The antibodies are also 
recommended to be measured with low treshold even from individuals with mild or 
extraintestinal symptoms.  
 
6.1 Celiac Disease Specific Antibodies  
Antibodies against dietary gluten and certain tissue structures were discovered from the 
sera of untreated celiac disease patients already in 1950s (Berger 1958) and were later 
developed into noninvasive screening tools. The first clinically relevant antibodies were 
called antigliadin antibodies (AGA) (Seah et al. 1971). Unfortunately, these were present 
in also several other conditions, such as food-allergies and post-infectious sprue 
(Unsworth et al. 1983). The sensitivity and specificity varied from about 30% up to 97% 
(Mäki et al. 1991b, Sulkanen et al. 1998). Nevertheless these were widely used before the 
more accurate serological test became available (Hill et al. 2005). 
The first celiac autoantibodies were the R1- type antireticulin antibodies (ARA) 
discovered in 1971, which reacted against the reticular fibres of the connective tissue 
(Seah et al. 1971). Even if the sensitivity of ARA was only moderate, being more specific 
than AGA it was used until the late 1990’s (Lock et al. 1999). More sensitive EmA were 
established in 1983 and thereafter gradually replaced ARA. Later an improved EmA 
methodology using human umbilical chord as a substract was developed (Ladinser et al. 
1994). Due to their excellent accuracy, tests for EmA remain to be used in the diagnostics 
of celiac disease (Chorzelski et al. 1984). 
The diagnostic approach of celiac disease revolutionized after the recognizion of 
transglutaminase as an autoantigen of EmA, as this enabled the utilization of practical 
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enzyme linked immunosorbent assay (ELISA) for quantitative measurement of the 
antibody values (Dieterich et al 1997, Sulkanen et al. 1998). As the accuracy of the 
serological tests has improved, it has been discussed if high levels of serum TG2-ab and 
EmA would be diagnostic by themselves (See 6.3).  
6.1.1 Current Antibody-Based Tests 
In most studies TG2-ab has been more sensitive (93-98%) than EmA (84-95%), but 
slightly less specific (95-98% vs. 99-100%) (Sulkanen et al. 1998). False-positive TG2-ab 
results may be due to inflammatory bowel disease, infections and chronic liver disease 
(Ferrara et al. 2010, Bizzarro et al. 2006). Possibility to use practical high-troughput 
method for TG2-ab measurements has made it as the first-line screening method for 
celiac disease. It is important to note that celiac disease patients have a higher tendency 
for IgA deficiency and that the total IgA should be tested with a low threshold to exclude 
this condition (Savilahti et al. 1971). In case of IgA deficiency, the TG2-ab should be 
measured in IgG class (Collin et al. 1992b, Sulkanen et al. 1998a). 
The AGA were later replaced by improved antibodies against deamidated gliadin 
peptides (DGP), which are superior in accuracy (Kaukinen et al. 2007a). Tests measuring 
antibodies to DGP have proved to be almost as good as TG2-ab, both in children and 
in adults, and can be used in IgG class for IgA-deficient patients (Kurppa et al. 2011). 
However, the use of DGP still looks for its place in clinical practice, as the benefits of 
DGP compared to TG2-ab seem to be relatively minute. 
Rapid point-of-care tests to measure celiac antibodies from a fingertip sample have 
also been developed to reduce costs, make testing possible without specialized 
laboratories and to shorten the diagnostic delay (Korponay-Szabo et al. 2005, Popp et 
al. 2013). Currently, however, the accury of these tests is not compatible with laboratory-
based TG2-ab and EmA (Nemec et al. 2006, Popp et al. 2013), and their clinical 
significance remains to be seen. 
6.2 Histology 
The development of peroral biopsy devices in the 1950’s enabled the assessment of the 
intestinal mucosa in living persons. It was discovered that, while in healthy patients the 
mucosa of the small-intestine has long finger-like or leaflet-like villi and short crypts, 
characteristic to untreated celiac disease is villous atrophy and crypt hyperplasia (Shiner 
1957). The most seriously affected areas are usually the duodenum and the proximal part 
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of jejunum, but the mucosal lesion may be patchy and variable along the whole length 
of the small intestine (MacDonald et al. 1964, Scott and Losowsky 1976).  
6.2.1 Mucosal Morphology 
The first classification of small-bowel mucosal sections in celiac disease was set by 
Doniach and Shiner in 1957 and subsequently acknowledged by European Society of 
Pediatric Gastroenterology and Nutrition (ESPGAN) as the standard (Meeuwisse 1970). 
Properly orientated biopsy specimen are vital for correct diagnostics, as poor orientation 
can lead to false positive and false negative findings (Taavela et al. 2013b). In 1992 a new 
grouped classification was introduced, as Marsh presented three phases from normal (0) 
to mucosal atrophy (III) in the development of celiac disease (Marsh 1992). Type III, 
which represents the lesion diagnostic for celiac disease, was later divided by Oberhuber 
into subgroups of IIIa, IIIb and IIIc (Oberhuber et al. 1999). These are approximately 
equivalent to partial, subtotal and total villous atrophy.  
 In addition to the categorical classifications, Shiner and Doniach (1960) gave precise 
values for villous height and crypt depth ratio (Vh/CrD). This method was further 
developed by Kuitunen and associates (1982) and Taavela and associates (2013b). The 
cut-off for normal VH/CrD is still under discussion, as in literature the used ratios range 
from 1.0 to 3.0 (Chang et al. 2005, Wahab et al. 2002, Corazza and Villanacci 2005). In 
a Finnish study, healthy controls were found to have ratios from 1.8 to 3.3 (Kuitunen et 
al. 1982).  As a result, ratio 2.0 has been in use as cut-off in the Tampere Celiac Disease 
Research Group. Supporting this treshold, it has been shown to be in line with other 
celiac disease markers (Holm 1993, Koskinen et al. 2010). The Vh/CrD is superior in its 
repeatability but more laborious than the categorized classifications.  
6.2.2 Intraepithelial Lymphocytes 
Small number of mucosal IELs are seen even in helathy subjects, but in celiac disease 
these cells are significantly overrepresented. The reference value has traditionally been 
defined as below 40 IELs/100 epithelial cells (EC) in hematoxyclin-eosin staining 
(Ferguson et al. 1971), but recent studies suggest a lower cut-off of 25 IELs/100 ECs 
(Hayat et al. 2002). Intraepithelial lymphocytocis has been considered to carry weight 
also in celiac disease diagnostics, even if its specifity is rather poor (Oberhuber et al. 
1999).  
Immunohistochemistry can be used in borderline cases and in academic and 
pharmacological studies, but use of this methodology requires special expertise (Järvinen 
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et al. 2003, Collin et al. 2005). By immunohistochemistry, IELs can also be counted from 
frozen samples as CD3+ IELs as well as ơƢ- and ƣƤ- IELs (Ferguson and Murray 1971, 
Kuitunen et al. 1982, Järvinen et al. 2003 Veress et al. 2004, Mino et al. 2003). The 
abnormally high numbers of especially ƣƤ+ IELs are quite specific for celiac disease 
(Mäki et al. 1991c, Holm et al. 1992, Järvinen et al. 2003). 
 
6.2.3 Diagnostic Characteristics and Challenges in Biopsy Samples 
The small-bowel mucosal deterioration in celiac disease develops gradually from a 
completely normal mucosa to increased density of IELs, hyperplasic crypts, and 
eventually to different states of villous atrophy (Marsh 1992). 
Although considered diagnostic, villous atrophy is not specific for celiac disease, 
being possible also in disorders such as rotavirus infection, cow's milk allergy, 
autoimmune enteropathy, giardiasis, tuberculosis, Crohn´s disease, acquired 
immunodeficiency syndrome, small-intestinal bacterial overgrowth, Whipple´s disease, 
collagenous sprue, eosinophilic enteritis, intestinal lymphoma, infectious enteritis, graft 
versus host disease and acquired immune deficiency syndrome (Rubio-Tapia et al. 2013, 
Green and Cellier 2007, Rubio-Tapia et al. 2010). Furthermore, there is evidence that 
the angiotensin II receptor blockers may cause severe enteropathy resembling celiac 
disease (Rubio-Tapia et al. 2012).  
6.3 Diagnostic Guidelines 
The first diagnostic criteria for celiac disease were presented in 1969 by ESPGAN. These 
criteria were revised in 1990 by the follower of ESPGAN, the European Society of 
Pediatric, Gastroenterology, Hepatology and Nutrition (ESPGHAN) (Walker-Smith et 
al. 1990). No united European guidelines on adult celiac disease have been introduced 
to date.  
The main consensus in current adult guidelines is that the suspicion of celiac disease 
should be based on a combination of physical signs such as diarrhea, bloating, signs of 
malabsorption or postprandial abdominal pain, compatible medical history such as first-
degree family members with celiac disease or concomitant diseases associated with celiac 
disease, and positive serology. The confirmation of the diagnosis is recommended to be 
done upon endoscopically obtained duodenal biopsies while on normal gluten-
containing diet. Multiple samples are suggested to improve sensitivity, but already one 
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sample presenting with villous atrophy is diagnostic (Rubio-Tapia et al. 2013, Ludvigsson 
et al. 2015).  
Since the current tests for EmA and TG2-ab demonstrate such a good specificity 
celiac disease, ESPGHAN proposed in 2012 that the diagnosis of pediatric celiac disease 
could be set without an intestinal biopsy in symptomatic children with TG2-ab levels 
over ten times the upper limit of normal (ULN), positive EMA and presence of HLA 
DQ2 or DQ8 (Husby et al. 2012).  
Finland has had its own Current Care Guidelines (Käypähoito) for celiac disease since 
1997 (Collin et al. 1997). In the most recent version of the guidelines, approach to 
pediatric celiac disease diagnosis corresponds to that of ESPGHAN, except that 
symptoms and HLA-testing are not mandatory for the serology-based diagnosis. In 
addition, for the first time in the world, it is now possible to establish celiac disease 
diagnosis in a part of the adults without biopsy using similar criteria as in children 
(Current Care Guideline 2018). 
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7 Treatment 
Since the early 1960’s the cornerstone of the treatment of celiac disease has been a strict 
gluten-free diet (Collins et al. 1964). This approach is sufficient to most patients 
excluding those with RCD (Chapter 8). At present, gluten-free diet is the only officially 
accepted treatment, but there is ongoing research for additional non-dietary treatments 
(Mäki 2014).  
7.1 Dietary Treatment 
Gluten is nowadays added to a wide variety of food products. Daily intake of 10-30 
milligrams of gluten is estimated to be safe for celiac disease patients, whereas normal 
western diet contains 15-20 grams of gluten per day (van Overbeek et al. 1997, Collin et 
al. 2004, Catassi et al. 2007, Lähdeaho 2011). Patients with DH seem to be particularly 
sensitive to trace amounts of gluten, and additive anti-inflammatory dapsone medication 
is often required for the first few years following the diagnosis (Kruizinga and 
Hamminga 1953, Reunala 2001). 
The initiation of a gluten-free diet alleviates gastrointestinal symptoms usually within 
days or weeks and decreases antibody titers within months. Also the small-bowel 
histological damage starts to improve rapidly, although complete healing of the mucosa 
may take several years (Yardley et al. 1962, Ilus et al 2014).  
Dietary treatment usually alleviates also the extraintestinal manifestations and 
complications of celiac disease, which is why proper treatment is important in cases of 
for instance gynecological and obstetric problems (Smecuol et al. 1996, West et al. 2004, 
Tersigni et al. 2014). A gluten-free diet also seems to reduce the risk of malignant diseases 
(Holmes et al. 1989) and overall mortality compared to untreated patients (Corrao et al. 
2001). Decreased BMD usually increases while on diet (Valdimarsson et al. 1994, Tau et 
al. 2006, Zanchetta et al. 2016), but to ensure normal bone accurual the treatment should 
be started as early as possible (Tau et al. 2006).  
Long-term adherence to the gluten-free diet has varied substantially in different 
studies ranging from 42% to 96% (Fabiani et al. 2000, Whitaker et al. 2009, Hall et al. 
2009, Ilus et al. 2014), suggesting that there is a need for other treatment options. 
Notably, in Finland the percentage of strictly adherent patients is high. Adolescent and 
screen-detected patients are usually considered to have increased risk for low dietary 
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adherence, although in some studies screened patients have shown similar or even higher 
adherence than symptom-detected patients (Kurppa et al. 2012, Kivelä et al. 2017). 
The use of oats as a part of the gluten-free diet has been under debate, but prospective 
studies have proven purified oats products to be safe for most patients (Sey et al. 2011, 
Janatuinen et al. 1995, Högberg et al. 2004). Oats could provide health benefits and can 
increase fiber intake in celiac disease patients (Kaukinen et al. 2013). It has also been 
discussed whether only naturally gluten-free products should be allowed, but several 
studies have shown that industrially purified products are safe for celiac disease patients 
(Kaukinen et al. 1999, Lohiniemi et al. 2000).   
It is important to note that, despite the aforementioned benefits, lifelong gluten-free 
diet is expensive, difficult to maintain and may involve social restrictions (Singh et al. 
2011, Villafuerte-Galvez et al 2015). In addition, along with poor fiber intake, the diet 
may induce an undesirable intake of fat and sugar (Wild et al. 2010). The unfavorable 
dietary content can eventually lead to detrimental weight gain (Dickey and Kearney 2006) 
and poor vitamin status (Hallert et al. 2002b). 
7.2 Novel Therapies  
The demand for alternative therapeutic approaches in celiac disease is high. This is 
especially true for patients frequently visiting restaurants, those dissatisfied with the cost 
of gluten-free diet and for those with decreased quality of life due to dietary restrictions 
(Tennyson et al. 2013). Several new drugs and devices have entered in phase 1 and 2 
clinical trials (Hindryckx et al. 2018). As celiac disease already has an effective and safe 
dietary treatment, defining satisfactory outcomes for drugs has been under discussion. 
Small intestinal mucosal improvement has been suggested as a primary endpoint in 
phases 1 and 2, while the effect on patient-reported outcomes, such as symptom relief, 
should be emphasized in later stages of clinical trials (Ludvigsson et al. 2018). 
Selecting, breeding and genetically modifying wheat to be safe for celiac disease 
patients could be one approach (Schuppan et al. 2009, Kaukinen et al. 2014) and also 
different ways to degrade harmful gluten peptides before they enter the gut have been 
considered (Gianfrani et al. 2017). Various bacteria, funghi, probiotics and parasites have 
been found to be capable of degrading gluten, but thus far clinical trials have been 
disappointing (Daveson et al. 2011, Smecuol et al. 2013, Tack et al. 2013, Tye-Din et al. 
2010). Polymeric binders, TG2-inhibitors and blocking HLA-DQ2 and DQ8 are other 
pharmaceutical approaches which have been under research (Molberg et al 1998, 
Rauhavirta et al. 2013, Kaukinen et al. 2014). Furthermore, a desenzitising vaccine to 
restore oral tolerance is under development (Goel et al. 2017). 
 
 39 
8 Non-Responsive and Refractory Celiac Disease 
Non-responsive celiac disease is defined as continuation of symptoms or clinical 
manifestations suggestive of celiac disease despite a gluten-free diet (Leffler et al. 2007). 
Non-responsive celiac disease is globally quite common, the main reason behind it being 
ongoing advertent or inadvertent gluten consumption. Only a minority of non-
responsive patients have actual RCD (Ilus et al. 2012), which is defined as presence of 
persistent symptoms, signs of malabsorption and villous atrophy despite a strict gluten-
free diet for at least 6-12 months (Rubio-Tapia and Murray 2010). Other possible 
etiologies for villous atrophy should be excluded. The symptoms of RCD are often 
severe and require additional therapeutic interventions (Rubio-Tapia and Murray 2010).  
Celiac disease patients homozygous for HLA-DQ2 are more susceptible to RCD 
(Malamut et al. 2009). RCD is divided into type I and type II, of which the latter is a 
severe condition predisposing to malignancies, notably enteropathy-associated T cell 
lymphoma (EATL) (Malamut et al. 2009). RCD I is usually treated with topical steroids 
and budesonide, at least if rigorously strict gluten-free diet is not enough, but also more 
potent treatments such as azathioprine may be needed (Maurino et al. 2002, Goerres et 
al. 2003). In comparison, RCD II is usually resistant to all treatment. Treatment with 
cytotoxic chemotherapeutic agents can be tried to delay the inevitable development of 
EATL (Kelly et al. 2015). Due to its malignant outcomes, the potential risk of RCD is 
often considered a major indication to ensure response to dietary treatment and mucosal 
healing by repeat endoscopies.  
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9 Follow-Up  
Experts agree that the main goals of dietary treatment in celiac disease are the healing of 
the small-bowel mucosal damage, the disappearance of symptoms and the prevention of 
complications (Ludvigsson et al. 2014). The success of the treatment is recommended 
to be confirmed by histological follow-up, serological tests, dietary evaluation and 
clinical follow-up, but scientific evidence behind these guidelines is scarce. Furthermore, 
the lack of sensitive non-invasive methods to assess dietary adherence comprises a major 
challenge in the follow-up. Endoscopy is burdensome and uncomfortable for patients 
and the data on its necessity remain insufficient. In particular, there is a paucity of studies 
regarding optimal timing and effect of the results of follow-up biopsies on patients’ long-
term health and treatment outcomes.  
Some studies suggest that patients without follow-up have more dietary lapses 
(Viljamaa et al. 2005b, Leffler et al. 2007). As regards to systematic international 
guidelines for celiac disease follow-up, there are currently no unified European 
guidelines for adults, although there are several national guidelines, including those 
assembled in the United Kingdom, Finland, Norway, Denmark and Russia (Fluge et al. 
1997, Current Care Guideline 2010, Ludvigsson et al 2014, Parfenov et al. 2017). United 
States has their own quideline made by the American College of Gastroenterology 
(Rubio-Tapia et al. 2013). The Oslo definitions for celiac disease and related terms comes 
closest to a unified international statement (Ludvigsson et al 2014). The main 
reccomendations on follow-up in recent guidelines are shown in Table 2. 
The 2010 Finnish Current Care Guidelines suggested a repeat biopsy one year after 
diagnosis and clinical and serological follow-up at 2-3-year intervals (Table 2). For most 
patients, long-term follow-up can be organized in primary healthcare with a possibility 
to consult a dietitian. Problematic cases, such as patients with persistent symptoms 
despite gluten-free diet and those with possible severe complications, are referred to 
secondary and tertiary centers (Current Care Guideline 2010). In the very recent revision 
of the guidelines, the follow-up recommendations remained otherwise similar, but repeat 
biopsy is not considered mandatory in clinically and serologically recoverd patients 
(Current Care Guideline 2018). 
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Table 2. Follow-up recommendations for adult celiac disease patients in recent guidelines 
 Year Country Frequency Clinician visits 
Dietician 
visits 
Repeat 
biopsy 
Celiac 
serology 
Other laboratory 
parameters 
WGO1 2017 Global Every 1-2 years 
Every 
time 
Every 1-2 
years 
If no 
clinical 
response 
During 
every 
visits 
Until normalized 
at the intervals of 
3-6 months 
AGG2 2013 USA Annually Annually If adherence problems 
After 1 
year Annually 
Abnormal baseline 
values until 
normalized 
BSG3 2014 UK Annually  Annually If adherence problems 
If no 
clinical 
response 
Annually 
Annually FBC, iron 
status, folate, TSH, 
ALAT, vitamin D 
and B12, calcium  
CCG4 2010 Finland Every 2-3 years 
Every 
time 
If adherence 
problems 
After 1 
year 
During 
every visit 
If clinical suspicion 
arises 
FBC, full blood count; TSH, thyroid stimulating hormone; ALAT, alanine aminotransferase; BMD, bone mineral 
density, WGO, World Gastroenterology Organization; ACG, American College of Gastroenterology; BSG, 
British Society of Gastroenterology, CGG, Current Care Guidelines 
1Bai et al. 2017; 2Rubio-Tapia et al. 2013; 3Ludvigsson et al. 2014; 4Current Care Guideline 2010 
9.1 Clinical Follow-Up 
Clinical follow-up is essential for the evaluation of dietary adherence, as well as to 
evaluate patients’ burden of illness, quality of life and possible ongoing symptoms. 
Gastrointestinal symptoms alleviate within weeks in the majority of celiac disease 
patients who commence a strict gluten-free diet (Murray et al. 2004), whereas the 
improvement of extra-intestinal symptoms is more variable. Elevated liver enzymes 
usually normalize within a year, whereas improvement of BMD can take several years 
and remain incomplete (Bardella et al. 1995, Grace-Farfaglia 2015). Most guidelines 
suggest permanent clinical follow-up, starting approximately three to six months after 
the diagnosis and then continue on regular intervals of 1-2 years (Table 2). 
9.2 Mucosal Recovery 
Currently most celiac disease guidelines recommend a repeat biopsy to be taken at least 
from patients without full clinical recovery approximately one year after the diagnosis 
(Table 2). It has been suggested that a repeat biopsy should be done as early as after 6 
months, but there are indications that complete histological normalization of the small-
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intestinal mucosa can be reached only in 8-60% of the adult patients during such a short 
period of time, the median recovery time being from two to four years (Lanzini et al 
2009, Tursi et al 2006, Sharkey et al. 2013). In countries with high dietary adherence, it 
is possible to reach recovery figures of as high as 94-96% in the long run (Ilus et al. 2012, 
Ilus et al. 2014). Some evidence suggests that particularly slow histological recovery can 
be expected when the mucosal damage is severe at diagnosis and there is a long history 
of gluten exposure (Tursi et al. 2006, Rubio-Tapia et al. 2010). 
Incomplete mucosal recovery has been associated with increased morbidity and 
mortality in celiac disease, the most important causes of death being malignancies and 
infections (Rubio-Tapia et al. 2010, Catassi et al. 2002). However, in a recent study no 
such association was seen (Lebwohl et al. 2013a). Persistent villous atrophy may also 
increase the risk of osteoporosis (Kaukinen et al. 2007b). 
In children, routine follow-up biopsies are no longer recommended. Interestingly, 
due to lack of evidence on its necessity, also recent adult guidelines have questioned the 
necessity of a follow-up biopsy. The World Gastroenterology Organization (WGO) gave 
its own guidelines in 2013, being the first guideline that did not recommend a systematic 
follow-up biopsy in all patients (Bai et al. 2013). Also the British Society of 
Gastroenterology (BSG) suggests that follow-up biopsies can be omitted if patients are 
asymptomatic on a gluten-free diet and there are no signs of complications (Ludvigsson 
et al. 2014). The WGO guideline was renewed in 2017, currently stating that follow-up 
biopsies should be mandatory in symptomatic patients despite strict adherence to gluten-
free diet, but not in asymptomatic patients (Table 2). These recommendations, however, 
are based on expert opinions and have not been backed with solid scientific evidence. 
9.3 Serology and Other Laboratory Parameters 
Serology and other laboratory parameters are recommended to be monitored at 
intervals of 6-12 months after starting gluten free diet (Rubio-Tapia et al. 2013, Current 
Care Guideline 2010, Ludvigsson et al. 2013). Serum celiac antibodies are used primarily 
to reveal dietary transgressions, although they have rather poor sensitivity and may be 
negative despite ongoing dietary lapses and mucosal damage (Silvester et al. 2017). 
Altogether, studies on the utility of serology in the long-term follow-up of celiac disease 
are scant.  
Other laboratory parameters such as full blood count, iron status and vitamin levels 
are mostly used to confirm the disappearance of signs of malabsorption, as well as to 
monitor the normalization of possible abnormal results at diagnosis (Table 2). 
Various other non-invasive markers to assess dietary adherence have been developed, 
but most of these remain too insensitive or unspecific for clinical use (Vives-Pi et al. 
2013). Measurement of gluten immunogenic peptides from urine or feces seems to be 
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the most promising recent technique, but additional research is needed (Moreno et al. 
2017). 
9.4 Long-Term Follow-Up 
Short-term follow-up of celiac disease is focused mainly on ensuring treatment response 
and patients’ competence in managing the dietary treatment. After these are achieved, in 
the following years the focus shifts to maintaining the results and intervening if problems 
occur. 
Perhaps the most thorough follow-up routine is suggested by the BSG (Table 2) 
(Ludvigsson et al. 2014). The review by Haines and colleagues (2008) comes close, as 
they suggest annual follow-up of patients by physician or dietitian, regular measurement 
of laboratory parameters, and even bone densitometry at 3-5-year intervals in patients 
with high-risk for osteoporosis. American College of Gastroenterology (ACG) and 
WGO suggest somewhat lighter follow-up protocols (Table 2).  
In Finland, long-term follow-up of adult celiac disease has been recommended to be 
organized at 2-3 years intervals (Table 2). In these occasions, serology can be used to 
monitor diet if the autoantibody values have been elevated before diagnosis. If clinical 
response is incomplete, the patient reports maintaing gluten-free diet problematic or 
serology is constantly elevated, dietician’s consultation is recommended. Long-term 
follow-up should be organized mostly in primary healthcare Current Care Guideline 
2010 and 2018).  
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THE PRESENT STUDY 
1  Aims 
A follow-up biopsy to confirm histological recovery has been considered the gold 
standard of celiac disease follow-up, usually recommended to be taken one year after 
diagnosis, or at least in clinically non-recovered patients. The procedure is invasive, 
uncomfortable to the patient and expensive. At present, expert opinions vary on the 
necessity of follow-up biopsies on all patients, and scientific evidence is scarce.  In 
addition, optimal timing and significance of repeat biopsy, if taken, to the long-term 
outcomes in celiac disease remain obscure. In fact, the implementation and overall value 
of even regular long-term follow-up in celiac disease is scarcely studied. We aimed to 
investigate the significance of a repeat biopsy, short-term mucosal healing and regular 
follow-up to the long-term health and treatment outcomes in adult celiac disease 
patients.  
The specific aims were to: 
1. Find patient- and disease-related factors associated with and the significance of 
incomplete small-bowel mucosal recovery one year after the celiac disease 
diagnosis (studies I-II). 
2. Study factors associated with and the significance of repeat biopsy one year after 
the celiac disease diagnosis on patients’ long-term dietary compliance and health 
outcomes (II). 
3. Investigate the overall implementation of a regular long-term follow-up and its 
value on the long-term health and treatment outcomes in celiac disease (III) 
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2     MATERIAL AND METHODS 
2.1 Patients 
All study patients were adults with a histologically verified celiac disease. They were 
diagnosed and repeat biopsies were taken either in the Department of Gastroenterology 
and Alimentary Track Surgery in Tampere University Hospital (I) or also in other 
facilities performing upper gastrointestinal endoscopies across all levels of heathcare (II-
III). Patients were recruited to the studies directly from the hospital clinic (I), through 
newspaper advertisements, or with the help of local celiac disease societies (II-III). 
2.2 Clinical Data 
Study I comprised of patients selected from the Celiac Disease Research Group’s 
prospective patient series collected between 1996 and 2009. Additional long-term data 
of 200 patients were collected from medical records to study whether the follow-up 
biopsy result affects to the risk of severe complications. Only cases with a repeat biopsy 
carried out after one year on a gluten-free diet were included. Patients using angiotensin 
receptor blockers were excluded since this class of drugs may cause severe enteropathy 
resembling celiac disease (Rubio-Tapia et al. 2012).  
The material for the studies (II) and (III) was collected from a nationwide cross-
sectional study conducted in Tampere University Hospital. The participants had a 
biopsy-proven celiac disease diagnosis established at least two years before the study. 
Subjects with unclear diagnosis or substantially lacking medical information were 
excluded. The possible use of angiotensin receptor blockers was again considered an 
exclusion criterion. In Study III also patients with concomitant DH were excluded.  
The participants were interviewed either at the time of the celiac disease diagnosis 
and after one year on a gluten-free diet (I) or at the time of the follow-up study (II-III). 
Demographic data, family history of celiac disease and celiac disease-associated and 
other significant co-morbidities were recorded, as well as clinical manifestations such as 
anemia, malabsorption, diarrhea, and possible presence of extraintestinal manifestations 
such as arthritis, gynecological problems or neurological symptoms. Duration and 
severity of symptoms before diagnosis were also assessed and the latter further 
 46 
categorized as mild (occasionally disturbing gastrointestinal or extra-intestinal 
symptoms), moderate (a combination of them) and severe (symptoms seriously 
disturbing daily life or requiring inpatient treatment). 
The participants also completed validated questionnaires for current symptoms and 
health-related quality of life, neither at diagnosis and after one year on dietary treatment 
(I) or at the time of study (III) (Chapter 2.4). Dietary adherence was assessed 
systematically by an experienced dietitian or study nurse. In addition, order to confirm 
the diagnosis and to complement medical data and laboratory parameters in Studies II 
and III, blood samples were drawn for celiac disease serology and patient records were 
reviewed.  
In Study I patients were divided into two groups based on whether they had 
(Recovery) or had not (Atrophy) reached mucosal recovery one year after diagnosis 
(Figure 1). In Study II patients were divided to those with and those without a repeat 
biopsy acquired approximately one year after the diagnosis. Patients with a repeat biopsy 
were further divided into two groups based on the presence or absence of mucosal 
recovery similarly as in Study I. In Study III patients were divided into those with regular 
healthcare follow-up for more than two years after the diagnosis and those with only 
shorter follow-up. These groups where then compared to each other, as well as those 
without any follow-up (Figure 1). 
 
 
 
 
 
Study 1: Mucosal 
healing on diet
Incomplete 
mucosal recovery
Complete mucosal 
recovery
Study II: Presence 
of follow-up biopsy
Follow-up biopsy 
taken
Incomplete 
mucosal recovery
Complete mucosal 
recoveryFollow-up biopsy 
not taken
Study III: Presence of 
long-term follow-up
Received long-term 
follow-up
No long-term-
follow-up
Only short-term 
follow-up
No follow-up at all
Figure 1. Categoriziation of patients for subsequent analyses in Studies I-III. 
Aim Groups Subgroups 
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2.3 Small-Bowel Mucosal Biopsies 
In Study I, a minimum of six biopsy specimens were taken from the distal duodenum 
upon esophagogastroduodenoscopy. Three specimens were carefully orientated, 
processed and stained with hematoxylin and eosin (H&E) and analyzed under light 
microscopy. The Vh/CrD was calculated by measuring the mean height of a villus and 
the adjacent crypt from at least three well-orientated villus-crypt units. The final 
morphological analysis was conducted from the most severely damaged specimen 
(Taavela et al. 2013b). Normal Vh/CrD was considered to be over 2.0 (Kuitunen et al. 
1982).  
The degree of small-bowel mucosal inflammation was determined by measuring the 
density of IELs (Taavela et al. 2013a). The IELs were counted in both H&E-stained and 
frozen sections with a 100× flat-field light microscope objective. Immunohistochemical 
studies were made from frozen 5-Ƭm-thick sections and CD3+ IELs were stained using 
the monoclonal antibody Leu-4 (Becton Dickinson, San Jose, CA). The density of H&E 
stained IELs was expressed as cells/100 epithelial cells (reference value over 30 per 100 
enterocytes) and density of CD3+ IELs as cells/mm (reference value 37 cells/mm).In 
addition, ơƢ+ IELs were stained from frozen sections using monoclonal antibody ơF1 
(T Cell Diagnostics, Woburn, MA), and ƣƤ+ IELs with T-cell receptor-bearing cell ƣ 
antibody (T Cell Diagnostics) and then counted.  
In studies II and III, the histopathological data were collected from patient records. 
At least four small-bowel mucosal biopsies should have been taken both in the 
diagnostic and follow-up endoscopy according to our national guidelines (Current Care 
Guideline 2010). All samples were evaluated in the department of pathology from well-
orientated and representative cuttings.  
The severity of mucosal damage was graded using either quantitative VH/CrD as 
stated above (I) or by dividing the finding into normal, partial, subtotal or total villous 
atrophy based on the original pathology reports (II-III). The latter grading corresponds 
approximately Marsh-Oberhuber scores I-II (normal), IIIA (partial atrophy), IIIB 
(subtotal atrophy) and IIIC (total atrophy). In order to see if there was a dose response 
to the outcome measures in Study I, the Atrophy group was retrospectively categorized 
also in this study into those with subtotal or total villous atrophy (Vh/CrD below 0.9) 
and to those with only partial atrophy (Vh/CrD 0.9-1.9). 
2.4 Serology and Laboratory Parameters 
Serum IgA-class TG2-ab were measured in Study I by ELISA (Celikey; Phadia, GmbH, 
Freiburg, Germany) considering values >5.0 U/L positive according to manufacturer’s 
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instructions. In studies II-III the corresponding antibodies were measured by another 
commercial ELISA (QUANTA Lite h-tTG IgA, INOVA Diagnostics, San Diego, CA), 
in which values >30.0 U/ were rated positive. Serum EmA were assessed by an indirect 
immunofluorescence method on human umbilical cord (I-II) (Ladinser et al. 1994). 
EmA titers 1: 5 were considered positive and further were diluted to 1:50, 1:100, 1:200, 
1:500, 1:1000, 1:2000 and 1:4000 until negative. In cases of selective IgA deficiency, the 
corresponding IgG-class antibodies were applied (Kurppa et al. 2014). The following 
laboratory parameters were measured using standard laboratory methods: blood 
hemoglobin (reference values: men >134 g/l; women >117 g/l) (I-II), mean corpuscular 
volume (82-98 fl), ionized calcium (1.16-1.30 mmol/l), parathyroid hormone (1.0-7.5 
pmol/l), serum total iron (9-34 umol/l), erythrocyte folic acid (200-700 nmol/l) and 
serum vitamin B12 (>150pmol/l) (I). 
2.5 Bone Mineral Density and BMI (I) 
BMD was measured from the lumbar spine and femoral neck by dual energy X-ray 
absorptiometry following our standard procedures (Sievänen et al. 1996). Expressed 
values are standard deviation scores comparing individual values with either that of 
healthy young adults (T-score) or the age and genger-matched population (Z-score). 
Osteoporosis was defined according to the recommendation of the World Health 
Organization as T-score -2.5 and osteopenia as T-score -2.4-(-1.0), respectively (World 
Healt Organization 1994). Body mass index (BMI) was calculated as weight divided by 
the square of height (kg/m2). 
2.6 Gastrointestinal Symptoms and Quality of life (I-III) 
Gastrointestinal Symptoms Rating Scale (GSRS) (Svedlund et al 1988) was used to 
evaluate the self-perceived severity of patients’ gastrointestinal symptoms either both at 
diagnosis and after one year on treatment (I) or after long-term follow-up (II-III). The 
scale is well-validated and widely applied in celiac disease (Dimenäs et al. 1996, Kurppa 
et al. 2010). GSRS consists of 15 separate items which can be counted for an average as 
a total score and divided into five sub-dimensions measuring abdominal pain, gastro-
esophageal reflux, indigestion, diarrhea and constipation. The scoring is based on a 7-
grade Likert scale where higher scores stand for more severe gastrointestinal symptoms.   
The Psychological General Well-Being Index (PGWB) was used to measure self-
perceived psychological well-being and quality of life at the same time points as GSRS 
(Studies I-III). There are 22 items in PGWB, which can be added together as a total 
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score and divided into seven sub-dimensions measuring anxiety, depression, well-being, 
self-control, general health and vitality. The questions use a 6-grade Likert scale where 
high scores indicate better well-being and quality of life. PGWB is well-validated and 
widely used in celiac disease (Viljamaa et al. 2005b, Ukkola et al. 2011, Nachman et al. 
2009). 
SF-36 was used in Studies II and III. It comprises of 36 separate questions which 
can be divided into eight domains measuring physical functioning, role limitations due 
to physical problems, bodily pain, general health, vitality, social functioning, role 
limitations due to emotional problems and mental health (Haere et al. 2016, McHorney 
et al. 1994). Items are re-scored from 0 to 100, higher scores indicating better health and 
quality of life.  
In Studies II and III patients were also asked to evaluate the amount of overall 
symptoms subjectively. Patients were given four categories: no symptoms, mild 
symptoms, moderate symptoms and severe symptoms. For statistical analysis mild and 
moderate symptoms were grouped under slight symptoms. 
2.7 Adherence to Gluten-Free Diet 
In study I dietary advice was routinely given to all patients at celiac disease diagnosis by 
a dietitian with expertise in celiac disease. In studies II and III provision of professional 
dietary advice was verified by patient interview and from the patient records. Adherence 
to the diet was evaluated by a dietician after one year (I) or by an experienced study 
nurse at time of study (II-III). In all studies patients were categorized as adherent (no 
gluten or only a minor inadvertent gluten intake less than once per month) and as non-
adherent (more lapses).  
2.8 Statistical Analysis 
Statistical testing was done using PASW version 18 (IBM, New York, NY, USA) (Study 
I) or SPSS version 20 (IBM) (Studies II-III). Results on continuous variables are shown 
either as medians with lower and upper quartiles, (Q1-Q3) or medians with range. Mann-
Whitney U test was used in statistical comparisons between groups in continuous 
variables. Categorical variables are presented as percentages and number of patients. Chi-
square test was used in comparisons between binomial and categorical variables (I-III). 
Multivariable analysis was further applied for variables with statistical significance (I). A 
p-value <0.05 was considered statistically significant in all analyses.  
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2.9 Ethics 
Patient collection was conducted with the permission and according to the guidelines of 
the Ethical Committee of Tampere University Hospital and the Declaration of Helsinki 
(World Medical Association 1964). All participants gave written informed consent 
before data collection (I-III). Further, the collection of long-term follow-up data from 
the medical records (Study I) were conducted with the permission of the Department of 
Internal Medicine, Tampere University Hospital. 
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3 RESULTS 
Study I comprised of altogether 263 adults with biopsy-proven celiac disease. Their 
median age was 45 (range 15–79) years and 68 % were female. Long-term follow-up data 
on the patients’ mortality, malignancies other gastrointestinal diseases and osteoporosis 
after a median of 16 years (range 15-17 years) after the diagnosis was available from 205 
(78%) out of the 263 patients, as well as the GSRS and PGWB results from a subgroup 
of 44 patients with a median of five years after the diagnosis. 
Altogether 760 individuals fulfilled the inclusion criteria in Study II. The population 
comprised 78% females and had a median age of 44 (range 18-84) years. The median 
time on a gluten-free diet prior to the study enrollment was eight years (range 1-38 years).  
Study III included 648 participants with a median age of 44 (range 22–89) years and 
80% female predominance. The median follow-up time for the whole cohort was 10 
years (range 2-38 years).  
3.1  Incomplete Mucosal Recovery (I-II) 
Altogether 178 (68%) subjects in Study I had and 85 (32%) had not reached a full 
histological recovery after one year on a gluten-free diet (Table 1 in the original 
publication I). The corresponding figures in Study II were 276 (58%) and 200 (42%) out 
of those 476 patients who had the follow-up histology result available. Diagnostic factors 
predicting incomplete mucosal healing after one year on diet in both studies were 
presence of malabsorption, severe mucosal damage (measured either qualitatively or 
quantitatively with Vh/CrD), high levels of serum TG2ab or EmA and low hemoglobin 
in women, and in Study I also low values of serum total iron and lumbar and femoral 
BMD T-scores (Table 3). In neither study, patients with and without mucosal recovery 
differed in age, gender, clinical presentation other than malabsorption, proportion of 
screened patients, severity nor duration of symptoms before diagnosis, family history for 
celiac disease and presence of coexisting chronic conditions (Table 1 in the original 
publication I). 
There was a significant difference in the speed of mucosal recovery between groups 
in Study I, measured as the change in Vh/CrD between the diagnostic biopsy and the 
one taken after one year on a gluten-free diet. This improved more among histologically 
healed than the still atrophic patients (changes in median ratio on diet 2.1 vs. 0.9, p 
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<0.001). Six patients did not reach any increase in Vh/CrD during one year despite a 
strict gluten-free diet. Of these, one patient later developed RCD type I without 
lymphoma or signs of RCD type II. Detailed data on these six cases are presented in the 
original article I. 
After one year on a gluten-free diet in Study I, there was still significant difference 
between the recovery and atrophy group in TG2ab, VH/CrD, blood hemoglobin in 
women and femoral T-score, and now also in CD3+ IELs, whereas the groups were 
comparable in the density of H&E stained IELs, other laboratory values and all GSRS 
and PGWB scores (Tables 2-4 in the original publication I). The atrophy group had 
significantly lower adherence to the gluten-free diet, although this was excellent in both 
groups (87% vs. 97%, p<0.001). 
As regards to the long-term significance of mucosal recovery one year after the 
diagnosis in Study I, no differences were seen between the atrophy and recovery groups 
in mortality or prevalences of coexiting chronic gastrointestinal diseases, osteoporosis 
and malignancies, and the median GSRS and PGWB scores and hemoblobin were also 
comparable (Table 5 in the original publication I). In Study II, patients with incomplete 
recovery after one year had more concomitant respiratory (15% vs. 22%, P = 0.031) and 
dermatological conditions (17% vs. 10%, P = 0.043, whereas there were no differences 
in the frequency of other chronic comorbidities, strictness or capability to manage 
gluten-free diet, use of purified oats, presence of regular follow-up and frequence of 
TG2ab positivity, malignancies or fractures (Table 5 in the original publication II). 
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Table 3. Selected diagnostic factors that were either investigated both in Studies I and II or were significantly 
associated with incomplete mucosal recovery one year after the celiac disease diagnosis on a gluten-free diet. 
Results are given in percentages or in medians and quartiles, except age which is given in median and range. 
  Study I   Study II  
 Atrophy n=85  Recovery n=178 P-value Atrophy n=200 
Recovery 
n=276  P-value 
Females, % 65 70 0.420 82 81 0.951 
Age, years 48 (18-77) 44 (15-79) 0.068 57 (25-84) 54 (21-77) 0.532 
At-risk group1, % 37 47 0.129 24 33 0.152 
Clinical presentation, %       
Malabsorption 60 34 0.001 55 41 0.003 
Screen-detected 22 29 0.543 10 10 0.733 
Severity of histopathology       
VH/CrD 0.2 (0.1-0.4) 0.4 (0.1-0.8) 0.003 ND ND ND 
TVA, % ND ND  32 19 <0.001 
TG2ab, U/l 57 (19–100) 30 (8–71) 0.017 ND ND  
High2 EmA value, % 66 52 0.069 46 25 <0.001 
Blood hemoglobin, g/l        
Women 119 (112–126) 131 (125–139) <0.001 123 (112-130) 127 (114-134) 0.071 
Men 142 (135-148) 149 (144-153) 0.056 Data too few Data too few  
Serum iron, Ƭmol/l, 12.0 (8.8–17.6) 18.0 (12.2–21.6) 0.001 ND ND ND 
Bone mineral density       
Lumbar T-score -1.5 (-2.2 to-0.4) -1.0 (-1.8 to 0.2) 0.022 ND ND ND 
Femoral T-score -1.2 (-1.9 to -0.5) -0.7 (-1.5 to 0.0) 0.016 ND ND ND 
The results except percentages are shown as median and quartiles; 1Celiac disease in relatives; 2Titer >1:200; 3data 
were available only from 286 patients 
EmA, endomysial antibodies; ND, no data; TG2-ab, transglutaminase-2 antibodies; TVA, total villous atrophy; 
VH/CrD, villous height crypt depth ratio 
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3.2  The Follow-Up Biopsy (II) 
Altogether 516 (68%) participants in Study II had and 244 (32%) had not undergone a 
follow-up biopsy after a median of one year. A record of repeat biopsy was significantly 
associated with the presence of malabsorption and more severe villous atrophy at 
diagnosis, along with coexisting Sjögren’s syndrome and gastroenterological and 
musculoskeletal diseases, whereas the biopsy was omitted more often in patients 
detected by screening or in the private sector (Table 4). The repeat biopsy and no repeat 
biopsy groups were similar when it comes to the prevalence of gastro-intestinal or 
extraintestinal symptoms and EmA titers at diagnosis, the duration of symptoms before 
diagnosis, presence of symptoms in childhood, family history for celiac disease, 
prevalence of coexisting thyroidal, gynecological, neurological or psychiatric diseases and 
frequency of malignancies or fractures (Tables 1-2 in the original publication II).  
Rebiopsied and non-rebiopsied patients had also received similar amounts of dietary 
advice (p=0.683) and were equally strict of their gluten-free diet (p=0.374), but subjects 
in the latter group felt less often capable to manage their diet (p=0.002) (Table 3 in the 
original publication II). The non biopsied patients also had more often current EmA 
positivity (p=0.012), while in TG2ab the difference was not significant (p=0.139) (Table 
3 in the original publication II). 
Patients who had undergone the follow-up biopsy reported more indigestion based 
on GSRS and more bodily pain and lower physical functioning based on SF-36, whereas 
the repeat and no-repeat biopsy groups did not differ in PGWB or other GSRS and SF-
36 scores (Table 4 in the original publication II).  
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Table 4. Diagnostic characteristics and comorbidities that were significantly associated with the existence of a 
repeat biopsy one year after diagnosis in Study II. 
  No repeat biopsy  (N=244)   
Repeat biopsy  
(N=516)   
 N % N % P-value 
Clinical presentation      
Malabsorption 80 33 235 46 0.001 
Screen-detected 39 16 49 10 0.010 
Degree of villous atrophy     <0.001 
Total 42 24 124 26  
Subtotal 58 34 196 42  
Partial 73 42 149 32  
Site of celiac disease diagnosis     <0.001 
Primary care 41 17 79 15  
Private care 57 23 58 11  
Secondary care 108 44 250 49  
Tertiary care 38 17 125 24  
Comorbidities      
Sjögren’s syndrome 1 0 14 3 0.033 
Musculoskeletal disease1 66 27 182 36 0.023 
Gastroenterological disease2 78 32 203 40 0.049 
1E.g. arthritis, osteoporosis; 2E.g. reflux, lactose intolerance, gastritis 
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3.3 Regular Follow-Up (III) 
In total, 99 (15%) of the 677 participants in Study III had and 578 (85%) had not 
received long-term follow-up for coeliac disease. Factors predicting the follow-up were 
coexisting immunological (35% vs. 24%, P=0.020) and circulatory disease (20% vs. 12%, 
p=0.010) while it was less common in subjects who had musculoskeletal disease (23% 
vs. 34%, P=0.045) or did not belong to any at-risk group (Table 1 in the original 
publication III). The follow-up and no follow-up groups did not differ in the presence 
of other co-morbidities, site of diagnosis, smoking, family risk for celiac disease or 
duration of symptoms and presence of symptoms in childhood, or in demographic data, 
seropositivity, severity of histopathology and clinical presentation at diagnosis (Table 1 
in the original publication III). 
At the time of the study, participants in both follow-up and no-follow up groups had 
comparable dietary adherence and ability to manage the gluten-free diet, use of purified 
oats and positivity to celiac autoantibodies (Figure 2), as well as equal health-related 
quality of life based on SF-36 and PGWB scores (Table 3 in the original publication III). 
There was also no difference between the groups in gastrointestinal symptoms as 
measured by GSRS (Table 3 in the original publication), but those without follow-up 
had significantly more self-perceived subjective overall symptoms (Figure 2).   
The majority of the patients with or without regular follow-up wished for it in the 
future, this percentage being significantly higher in those with follow-up (Figure 2). Most 
of these patients wished the follow-up to be organized in public healthcare (Figure 1 in 
the original publication III), whereas there was no major difference regarding who 
should be in charge of the follow-up (Figure 2 in the original publication III).  
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Figure 2. Comparison of major long-term outcomes between patients with and without 
reglular long-term follow-up in coeliac disease. 
GFD, Gluten-free diet; EmA, Endomysium antibodies; TG2-ab, transglutaminase-2 antibodies. The minimum 
number of patients for each variable was 508 patients. 
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4 Discussion 
4.1 Short-Term Clinical and Endoscopic Follow-up 
4.1.1 Short-term Follow-up and Treatment Outcomes 
Clinical evaluation of patients’ early response and adherence to gluten-free diet has been 
emphasized in previous guidelines for celiac disease (Rubio-Tapia et al. 2010, Bai et al. 
2013, Ludvigsson et al. 2014), but there is little scientific evidence on by what means and 
how often should short-term follow-up of the disease be organized. Perhaps an even 
more debated issue among experts is the signifcance of endoscopic follow-up to the 
treatment outcomes (Ludvigsson et al. 2014, Bai et al. 2017).  
Some studies have indicated poor dietary adherence among celiac disease patients 
without follow-up but, on the other hand, the serological renspose to the treatment has 
been unsatisfactory also in regularly followed patients (Barnea et al. 2014, Zanini et al. 
2009). In contrast, patients of the present study reported excellent adherence to the 
gluten-free diet irrespective of the existence of short-term follow-up, the accuracy of this 
self-assesment being further enforced by the low prevalence of seropositivity in both 
follow-up and no-follow up groups. It seems that, at least in the Finnish population, the 
association between follow-up and results of the treatment are not as straightforward as 
previously assumed (Zanini et al. 2010, Barnea et al. 2014, Hall et al. 2009).  
4.1.2 Predictors for Repeat Biopsy One Year after the Diagnosis 
In many chronic diseases, such as chronic pulmonary disease, physicians seem to favor 
more intense follow-up for patients with a more severe disease presentation at diagnosis, 
as these cases supposedly have an increased risk of long-term complications (van de 
Bemt et al. 2009). Accordingly, we found that the repeat biopsy one year after the celiac 
disease diagnosis was undertaken especially for clinically-detected patients with advanced 
histological damage and severe symptoms, while the biopsy was done less frequently in 
screen-detected cases who often have milder presentation at diagnosis. This difference 
might also be partially explained by the lower willingness of these patients to undergo 
an unpleasant repeat biopsy. Accordingly, the often screen-detected celiac disease 
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patients with a coexisting type 1 diabetes (Laitinen et al. 2017) were also less likely to 
undergo a repeat biopsy. In contrast, patients with gastro-intestinal and musculoskeletal 
comorbidities had higher likelihood for endoscopic follow-up. This suggests that the 
procedure is carried out with a lower threshold among patients who have incomplete 
clinical response to gluten-free diet or who have frequent healthcare visit due to the 
comorbidities.  
The repeat biopsy was also omitted more often among celiac disease patients 
diagnosed in the private sector than those diagnosed in the public healthcare. One reason 
for this difference might be the costs of endoscopy in private care for patienst without 
health insurance covering the procedure. In addition, the role of the public healthcare 
has traditionally been strong in Finland (Fuchs et al. 2014), whereas private sector is 
more focused on the frontline screening than final diagnostics and follow-up of chonic 
diseases (Häkkinen et al. 2005). It is thus possible that different results would be obtained 
in countries where the private sector plays a larger role in healthcare, such as in the USA 
(Ridic et al. 2012).  
Another important observation here was the lack of differences in the rate of re-
biopsy between primary, secondary and tertiary healthcare settings. This somewhat 
unexpected finding might be explained by the long tradition of decentralization of celiac 
disease diagnostics and follow-up in Finland (Häkkinen et al. 2005, Collin et al 2010).  
      4.1.3    The Impact of Repeat Biopsy on Long-Term Treatment Outcomes 
The omission of a repeat biopsy one year after the diagnosis did not affect long-term 
dietary adherence of the celiac disease patients. This surprising result suggests that the 
invasive follow-up does not play a major role in the commitment to the gluten-free diet. 
It must, however, be realized that the diet is relatively easy to maintain in Finland 
(Kaukinen et al. 2010, Ilus et al. 2014), and the situation might be different in countries 
where maintaining a strict adherence is more challenging (Bardella et al. 1994, Leffler et 
al. 2007, Zanini et al. 2010). In addition, despite the generally good dietary adherence, 
we found subjects without a repeat biopsy to be more uncertain of their capability to 
manage the gluten-free diet and to be more often seropositive. This indicates that a 
subgroup of celiac disease patients having challenges with gluten-free diet might still 
benefit from the endoscopic follow-up. On the other hand, it is unclear whether the 
repeat biopsy is in fact the main issue here, or whether other means of follow-up, such 
as enhanced dietary counselling, would be equally effective (See et al. 2015, Sainsbury et 
al. 2013b).  
There was also no significant difference between the repeat biopsy and no repeat 
biopsy groups in psychological well-being as measured by the validated PGWB 
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questionnaire. The differences between follow-up and no follow-up groups in the 
prevalence of reported bodily pain and physical functioning can be explained to some 
extent by the higher prevalence of musculoskeletal comorbidities among patients with 
an ongoing long-term follow-up.  
However, celiac disease patients who underwent a repeat biopsy had more often self-
perceived symptoms on long term than those without the repeat biopsy. This could, to 
some extent, be explained by the higher prevalence of gastrointestinal comorbidities 
among the re-biopsied patients. In addition, there is evidence that celiac disease patients 
with a severe presentation at diagnosis, i.e. similar subjects that had undergone a follow-
up biopsy more often in the present study, could have increased risk for persistent 
symptoms despite a strict gluten-free diet (Paarlahti et al. 2013). In previous studies the 
persistence of symptom has been associated with reduced self-perceived well-being and 
quality of life (Paarlahti et al. 2013, Paavola et al. 2012, Nachman et al. 2010). As 
mentioned, similar association was not seen in the present study, but here the design was 
different and the symptoms, in general, rather mild. 
4.2 Mucosal Recovery in the Repeat Biopsy 
4.2.1    Prevalence of Incomplete Mucosal Recovery 
Patients with incomplete mucosal recovery one year after the celiac disease diagnosis 
represented 33% (Study I) and 42% (Study II) of the study populations, respectively. 
Althoug a seemingly large percentage, these figures are actually low in global comparison 
(Wahab et al. 2002, Rubio-Tapia et al. 2010, Sharkey et al. 2013), probably reflecting the 
generally high dietary adherence in Finland (Ilus et al. 2012). Furthemore, only 2.3% of 
all patients in Study I showed no signs of histological improvement after one year on a 
gluten-free diet, and only one patient developed RCD. This excellent result is in 
accordance with a previous Finnish study, in which 96% of celiac disease patients 
reached complete histological recovery in the long run, only 0.3% eventually having 
RCD (Ilus et al. 2012, Ilus et al. 2014). The good availability and strict labeling of gluten-
free products and the (now removed) financial subsidy by the government are all likely 
to reduce inadvertent and advertent gluten intake (Abdulkarim et al. 2002), these being 
by far the most common reasons for non-responsive celiac disease globally (Rubio-Tapia 
et al. 2010, Leffler et al. 2007). 
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4.2.2. Predictors of Incomplete Mucosal Recovery 
The most conspicuous factor predicting incomplete histological recovery on a gluten-
free diet was the presence of more severe celiac disease at diagnosis in terms of histology, 
serology and signs of malabsorption. Despite the differences in histology, the clinical 
parameters were similary improved in both groups after one year, suggesting that it just 
takes longer for severily damaged mucosa to heal even on diet, which is in accord with 
a recent Norweigian study (Haere et al. 2016). Furthermore, in Study I we quantitatively 
assessed the actual speed (ƅVh/CrD) of mucosal recovery, and found also this to be 
lower in patients with incomplete than complete recovery. The slower speed of recovery, 
along with more severe atrophy at diagnosis, readily explain why these patients had not 
attained mucosal recovery in one year despite strict dietary adherence. A few previous 
studies have investigated this issue indirectly (Wahab et al. 2002, Rubio-Tapia et al. 2010, 
Lanzini et al. 2009). The results have been somewhat controversial, which might be 
explained by differences in dietary adherence and by the use of less precise grouped 
classifications for assessment of histopathology (Taavela et al. 2013). 
Another indicator of the presence of more severe disease at diagnosis among those 
with incomplete histological recovery after one year was their higher levels of celiac 
disease antibodies at diagnosis, although the correlation between the antibody values and 
the severity of histological and clinical disease is rather low in individual patients (Sharkey 
et al. 2013. These patients had significantly higher levels of antibodies also after one year, 
but the actual difference in numbers was small, the median values in both groups were 
already within normal limits and the great majority had already turned seronegative. This 
indicates that, although in some patients with high baseline values, the normalization of 
the serology may take more than a year, it still occurs faster than mucosal healing. 
However, we cannot fully exclude the possibility for more frequent gluten intake in the 
histologically non-recovered group (Hollon et al. 2013).  
The only clinical parameters at diagnosis associated with with incomplete histological 
recovery were the presence of anemia and lower BMD T-scores. In line, previous studies 
in both children and adults have reported an association between the presence of anemia 
and more severe histological and clinical presentation at celiac disease diagnosis (Taavela 
et al. 2013b, Abu Daya et al. 2013, Saukkonen et al. 2016). Again, despite the differences 
in mucosal healing, after one year on a gluten-free diet the recovery and no recovery 
groups were comparable in all laboratory values except for a minor difference in 
hemoglobin, demonstrating that, as with serology, laboratory abnormalities recover 
faster than the histology. In contrast, the median BMD remained lower even after one 
year on diet. This might be explained by the slow turnover rate of bone tissue, causing 
the normalization of BMD to take longer than our study period. Especially if the 
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absorption capacity of relevant micronutrients in the intestine remains sub-optimal due 
to ongoing mucosal recovery.   
4.2.3 Long-Term Effects of Incomplete Mucosal Recovery after One Year 
Normalization of the small-bowel mucosal damage is considered an important long-term 
goal in celiac disease, as incomplete histological recovery is thought to predispose 
patients to severe complications such as malignancies and RCD (Ilus et al. 2014, 
Lebwohl et al. 2013a, Kaukinen et al. 2010). As mentioned, only one subject out of the 
cohort of 263 patients in Study I later developed type I RCD, and it is likely that this 
case would have been anyway detected due to lack of clinical response to gluten-free 
diet. Furthermore, the result of histology one year after the diagnosis was not associated 
with the risk of malignancies in a 15-year follow-up, further indicating that prediction of 
forthcoming severe complications cannot justify the repeat biopsy by itself. 
When considering the effect of the celiac disease diagnosis and gluten-free diet on 
the daily live of patients, it is essential to study not only the clinical, histological and 
serological improvement, but also the general quality of life, as celiac disease affects a 
fundamental part of patients’ lives and adhering to the diet can be stressing and socially 
limiting (Shah et al. 2012, See et al. 2015). Particularly non-responsive disease with 
ongoing symptoms can have adverse effects on patients’ quality of life (Paarlahti et al. 
2013). In our study patients had similar quality of life and frequency of gastro-intestinal 
symptoms irrespective of mucosal status both one year after the diagnosis and in the 
long run, even if those with incomplete villous recovery had poorer GSRS and PGWB 
values at baseline. This is in line with the abovementioned observation of the healing of 
the small-bowel mucosa lagging behind clinical recovery.  
Altogether, these findings indicate that the result of the repeat biopsy after one year 
correlates poorly with both the clinical outcome and the long-term prognosis in celiac 
disease.  Instead, it can be seen representing only a “snapshot” rather than the end-point 
of the still ongoing mucosal healing, thus not giving much additional value for the long-
term management of the patients. Hence, it seems that more individualized approaches 
for the endoscopic follow-up in celiac disease are required. In fact, based on the already 
published articles of this dissertation, the repeat biopsy was not anymore considered 
mandatory to clinically and serologically recoved patients in the very recently revised 
Finnish Current Care Guidelines. (Curren Care Guideline 2018) 
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4.3 Long-Term Management of Celiac Disease 
There is a clear demand for improved non-invasive methods to evaluate dietary 
adherence and long-term histological recovery in celiac disease. Unfortunately, neither 
the current serological tests, self-reported adherence nor even a standardized evaluation 
by a dietitian are sensitive enough to detect all dietary lapses (Moreno et al. 2017, Leffler 
et al. 2007). Another problem is that the effects of long-term management and follow-
up on the health outcomes have not been comprehensively studied and expert opinions 
vary. There has been scarcity of evidence particularly on how this follow-up is carried 
out in clinical practice and what factors affect its execution. Altogther, the data on how 
follow-up, or lack of it, affects long-term outcomes such as dietary adherence, frequency 
of complications and quality of life, have been insufficient (Hall et al. 2009, Leffler et al. 
2008, Herman et al. 2012, Haines et al. 2014). 
4.3.1 Prevalence, Predictors and Demand of Long-Term Follow-Up 
The presence of a regular long-term follow-up for celiac disease was surprising low 
(15%), particularly when considering that it is recommended to all Finnish patients and 
since the majority of the study participants wished for it. This is also a very low 
percentage compared to previous reports (Bebb et al. 2006, Bardella et al. 1994). 
Although our national guidelines recommend regular follow-up for celiac disease 
patients, it has not been clarified on how this should be arranged. The lack of a clear 
follow-up protocol in the guidelines, along with the generally good knowledge of celiac 
disease among the patients and the easy availability of the gluiten-free products, may 
explain the result as it is much up to patients’ own activity to arrange the control visits 
(Ilus et al. 2014). It could be hard to find time and motivation e.g. to annual follow-up 
visits for a disease that is felt to be in remission and does not cause marked stress in daily 
life.  
Of the predictors of the presence of long-term follow-up, it was less common in 
patients who did not belong to any risk group of celiac disease, excluding those with 
family history for the disease who actually had more frequent control visits. Although 
there are some previous studies about the association between patient-derived factors 
and follow-up, thus far no systematic reports on this issue have been published (Bardella 
et al. 1994, Bebb et al. 2006). In a study by Bebb et al. (2006) the most popular method 
of follow-up among patients was a dietitian’s interview with a doctor available if needed. 
Here patients rather wanted the follow-up to be organized in the primary care than in 
expert clinics, although one third of patients would want the follow-up to be arranged 
to an internal physician. This result could be due to the the strong position of primary 
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health care in Finland. In fact, this may also, to some extent, explain the low percentage 
of long-term follow-up, as the general practitioners treat the majority of patients’ 
illnesses and it is thus possible that a part of the celiac disease follow-up is carried out 
during healthcare visits that were initially arranged due to some other chronic disease. 
Also, due to the generally high level of knowledge amont the patients, it may be that 
physicians trust them to be in contact if any problems appear. Celiac disease may also be 
seen as a rather bening disease without much need for follow-up when patients remain 
symptomless. 
4.3.2 Significance of Long-Term Follow-Up 
There was no difference between celiac disease patients in the follow-up group and no 
follow-up group in the adhererence to the gluten-free diet, and the long-term quality of 
life and severerity of gastrointestinal symptoms as measured by validated GSRS were 
also comparable. The former finding is in contrast with the previous studies, in which 
the presence of regular follow-up has been associated with better dietary compliance 
(Villafuerte-Galvez et al. 2015, Hall et al. 2009, Leffler et al. 2008). This difference might 
be caused by the generally high dietary adherence and easy availability of gluten-free 
products in Finland (Ilus et al. 2012). Nevertheless, we still found patients without long-
term follow-up to report more overall symptoms and lower self-perceived capability to 
manage the diet compared with the followed subjects. The feeling of better competence 
with the dietary treatment among the followed subjects might be explained by an 
enhanced sense of self-capability when patients receive positive feedback during regular 
healthcare visits. Of note, neither the adherence nor capability to manage a gluten-free 
diet was affected by who gave the initial dietary information (physician, nurse, dietician). 
This information is helpful when planning cost-effective follow-up strategies, although 
possible differences between healtcare settings should be acknowledged. 
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4.4 Strengths and Limitations of the Study 
Major strength of the present study is the large number of well-defined celiac disease 
patients and the high number of different outcome variables. Furhermore, the use of 
validated questionnaires for symptoms and quality of life makes the results more reliable 
and repeatable. The fact that the repeat biopsies were taken systematically after one year 
on a gluten-free diet, as well as utilization of quantitative morphometry in the histologic 
evalution, reduces the risk of misclassification bias in Study I (Taavela et al. 2012). 
Further strength of Study I was the comprehensive data on mortality and long-term 
complications. The excellent adherence to gluten-free diet observed in Studies I and II 
enabled us to evaluate other causes behind histological non-recovery than the often 
dominating high frequence of compliance problems, although this makes the results less 
applicable to countries where dietary lapses are more common (Oxetenko et al 2014). 
Another major streght of the present study is the large number of celiac disease patients 
diagnosed on different levels of healthcare in Studies II and III, whereas Study I was 
limited to tertiary care settings.  
As a limitation, we were not able to compare the details of celiac disease patients who 
underwent a repeat biopsy and those who refused follow-up (approximately 15% of all 
subjects in our center). In theory, the non-compliant patients may be more prone to 
refuse repeat biopsy. Another limitation is the lack of systematic endoscopic follow-up 
in patients with incomplete mucosal recovery after one year on a gluten-free diet. This 
was mostly due to the decentralization of long-term follow-up in our settings; in other 
words patients with uncomplicated celiac disease are usually followed non-invasively in 
primary care (if they are followed). Nevertheless, according to our national guidelines, 
celiac disease patients with poor and unexplained response to gluten-free diet should be 
referred to secondary or tertiary centers for further evaluation. 
Morever, the retrospective analysis of serious long-term outcomes is prone to 
survival bias, as the study patients were not categorized already at the time of the repeat 
biopsy. The recruitment of a substantial part of the participants via celiac societies may 
increase the risk of responder bias, since patients belonging to such organisations might 
be more committed to the treatment of their disease. The information of these studies 
also may not have reached all age groups equally. We also did not have data on the 
patients’ socio-economic status, which has been considered important in some previous 
studies on follow-up (Ciacci et al. 2002, Artama et al. 2016). Furthermore, mortality data 
were lacking from studies II and III and, in all studies, the self-reported symptoms scale 
had only three levels, making it possibly too imprescise a measurement, even if the results 
were in line with the GSRS scores in Study III. 
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Finally, all three substudies of the present dissertation were carried out before the 
recommendation to take routine biopsies also from the duodenal bulb (Ludvigsson et 
al. 2014). It is therefore possible that some cases with partially incomplete histological 
recovery on a gluten-free diet have been missed (Evans et al. 2011). Nevertheless, at 
present the role of bulb biopsies in the diagnostics and follow-up of celiac disease 
remains controversial (Taavela et al. 2016).  
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5 Summary and Conclusions 
A repeat biopsy one year after celiac disease diagnosis for at least symptomatic subjects, 
as well as regular long-term follow-up on a gluten-free diet, have been considered 
essential due to the possible adverse outcomes of unsuccessful treatment (Bai et al. 2017, 
Current Care Guideline 2010, Ludvigsson et al. 2013c, Rubio-Tapia et al 2010). 
However, we found neither the existence nor result of a repeat biopsy, nor even the 
presence of regular follow-up, to have major effects on the long-term health and 
treatement outcomes. In addition, one year may be too short of a time on a gluten-free 
diet for some patients, particularly among those with a severe form of the disease at 
diagnosis in terms of histology, serology and signs of malabsorption, to reach full 
morphological recovery of the small-bowel mucosa. This seems to be the case even if 
we know that the great majority of also these cases reach recovery in the long run (Ilus 
et al. 2012). Together these results indicate that, in contrast to most of the current 
recommendations, the long-term follow-up of celiac disease, including the decision to 
conduct a repeat biopsy, could be more personalized. I could also be based on the 
individual capabilities to maintain a gluten-free diet and to the short-term treatment 
response.   
This dissertation paves the way to further studies on the short- and long-term follow-
up in celiac disease. Future research should focus particularly on questions of which 
patients would benefit from a more systematic follow-up, and who should undergo a 
repeat biopsy on gluten-free diet. More accurate non-invasive markers for the dietary 
adherence and mucosal healing should also be and are being developed, including for 
example HLA-DQ:gluten tetramer test in blood (Sarna et al. 2018), although they have 
not yet found their place in clinical practice. These improvements could be expected to 
provide easier and more cost-effective approach to the follow-up of celiac disease.  
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APPENDIX 1 
THE GASTROINTESTINAL SYMPTOM RATING SCALE 
(GSRS) 
 
Nimi______________________________________________ 
 
Lue tämä ensin: 
Tutkimus sisältää kysymyksiä voinnistasi ja tilastasi kuluneen viikon aikana. 
Merkitse rastilla (X) 
se vaihtoehto, joka sopii parhaiten sinuun ja tilaasi. 
 
1. Onko Sinulla ollut VATSAKIPUJA kuluneen viikon aikana? (Vatsakivuilla 
tarkoitetaan 
kaikenlaista kipua tai särkyä vatsassa.) 
 Ei minkäänlaisia vaivoja 
 Vähäpätöisiä vaivoja 
 Lieviä vaivoja 
 Kohtalaisia vaivoja 
 Melko pahoja vaivoja 
 Pahoja vaivoja 
 Erittäin pahoja vaivoja 
 
2. Onko Sinulla ollut NÄRÄSTYSTÄ kuluneen viikon aikana? (Närästyksellä 
tarkoitetaan kirvelevää 
tai polttavaa pahanolontunnetta rintalastan takana.) 
 Ei minkäänlaisia vaivoja 
 Vähäpätöisiä vaivoja 
 Lieviä vaivoja 
 Kohtalaisia vaivoja 
 Melko pahoja vaivoja 
 Pahoja vaivoja 
 Erittäin pahoja vaivoja 

J. Svedlund, E. Dimenäs, I. Wiklund 1995 
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3. Onko Sinulla ollut HAPPAMIA RÖYHTÄISYJÄ kuluneen viikon aikana? 
(Happamilla röyhtäisyillä 
tarkoitetaan äkillisiä, hapanta vatsanestettä sisältäviä röyhtäisyjä.) 
 Ei minkäänlaisia vaivoja 
 Vähäpätöisiä vaivoja 
 Lieviä vaivoja 
 Kohtalaisia vaivoja 
 Melko pahoja vaivoja 
 Pahoja vaivoja 
 Erittäin pahoja vaivoja 
 
4. Onko Sinua HIUKAISSUT kuluneen viikon aikana? (Hiukaisulla tarkoitetaan 
vatsassa olevaa 
hiukovaa tunnetta, johon liittyy tarve syödä aterioiden välillä.) 
 Ei minkäänlaisia vaivoja 
 Vähäpätöisiä vaivoja 
 Lieviä vaivoja 
 Kohtalaisia vaivoja 
 Melko pahoja vaivoja 
 Pahoja vaivoja 
 Erittäin pahoja vaivoja 
 
5. Onko Sinulla ollut PAHOINVOINTIA kuluneen viikon aikana? (Pahoinvoinnilla 
tarkoitetaan 
pahanolontunnetta, joka saattaa muuttua kuvotukseksi tai oksentamiseksi.) 
 Ei minkäänlaisia vaivoja 
 Vähäpätöisiä vaivoja 
 Lieviä vaivoja 
 Kohtalaisia vaivoja 
 Melko pahoja vaivoja 
 Pahoja vaivoja 
 Erittäin pahoja vaivoja 
 


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6. Onko vatsasi KURISSUT kuluneen viikon aikana? (Kurinalla tarkoitetaan 
vatsassa tuntuvaa 
värinää tai ”murinaa”.) 
 Ei minkäänlaisia vaivoja 
 Vähäpätöisiä vaivoja 
 Lieviä vaivoja 
 Kohtalaisia vaivoja 
 Melko pahoja vaivoja 
 Pahoja vaivoja 
 Erittäin pahoja vaivoja 
 
7. Onko vatsaasi TURVOTTANUT kuluneen viikon aikana? (Turvotuksella  
arkoitetaan vatsassa 
tuntuvaa pingotusta, johon usein liittyy tuntemuksia ilmavaivoista.) 
 Ei minkäänlaisia vaivoja 
 Vähäpätöisiä vaivoja 
 Lieviä vaivoja 
 Kohtalaisia vaivoja 
 Melko pahoja vaivoja 
 Pahoja vaivoja 
 Erittäin pahoja vaivoja 
 
8. Onko Sinua vaivannut RÖYHTÄILY kuluneen viikon aikana? (Röyhtäilyllä 
tarkoitetaan tarvetta 
päästää ilmaa suun kautta, minkä yhteydessä vatsassa tuntuva pingotus usein 
helpottuu.) 
 Ei minkäänlaisia vaivoja 
 Vähäpätöisiä vaivoja 
 Lieviä vaivoja 
 Kohtalaisia vaivoja 
 Melko pahoja vaivoja 
 Pahoja vaivoja 
 Erittäin pahoja vaivoja 
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9. Onko Sinulla ollut ILMAVAIVOJA kuluneen viikon aikana? (Ilmavaivoilla 
tarkoitetaan tässä 
tarvetta päästää ilmaa, jonka yhteydessä vatsassa tuntuva pingotus usein 
helpottuu.) 
 Ei minkäänlaisia vaivoja 
 Vähäpätöisiä vaivoja 
 Lieviä vaivoja 
 Kohtalaisia vaivoja 
 Melko pahoja vaivoja 
 Pahoja vaivoja 
 Erittäin pahoja vaivoja 
 
10. Onko Sinua vaivannut UMMETUS kuluneen viikon aikana? (Ummetuksella 
tarkoitetaan 
ulostuskertojen harventumista.) 
 Ei minkäänlaisia vaivoja 
 Vähäpätöisiä vaivoja 
 Lieviä vaivoja 
 Kohtalaisia vaivoja 
 Melko pahoja vaivoja 
 Pahoja vaivoja 
 Erittäin pahoja vaivoja 
 
11. Onko Sinua vaivannut RIPULI kuluneen viikon aikana? (Ripulilla tarkoitetaan 
ulostuskertojen 
lisääntymistä.) 
 Ei minkäänlaisia vaivoja 
 Vähäpätöisiä vaivoja 
 Lieviä vaivoja 
 Kohtalaisia vaivoja 
 Melko pahoja vaivoja 
 Pahoja vaivoja 
 Erittäin pahoja vaivoja 
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12. Onko Sinua vaivannut LÖYSÄ VATSA kuluneen viikon aikana? (Jos ulosteesi 
on välillä ollut 
kovaa ja välillä löysää, ilmoita vain, missä määrin ulosteesi löysyys on Sinua 
vaivannut.) 
 Ei minkäänlaisia vaivoja 
 Vähäpätöisiä vaivoja 
 Lieviä vaivoja 
 Kohtalaisia vaivoja 
 Melko pahoja vaivoja 
 Pahoja vaivoja 
 Erittäin pahoja vaivoja 
 
13. Onko Sinua vaivannut KOVA VATSA kuluneen viikon aikana? (Jos ulosteesi 
on välillä ollut kovaa 
ja välillä löysää, ilmoita vain, missä määrin ulosteesi kovuus on Sinua 
vaivannut.) 
 Ei minkäänlaisia vaivoja 
 Vähäpätöisiä vaivoja 
 Lieviä vaivoja 
 Kohtalaisia vaivoja 
 Melko pahoja vaivoja 
 Pahoja vaivoja 
 Erittäin pahoja vaivoja 
 
14. Onko Sinua vaivannut kuluneen viikon aikana PAKOTTAVA ULOSTAMISEN 
TARVE? (Pakottavalla 
ulostamisen tarpeella tarkoitetaan äkillistä tarvetta käydä WC:ssä. Siihen liittyy 
usein 
puutteellisen pidättämiskyvyn tunne.) 
 Ei minkäänlaisia vaivoja 
 Vähäpätöisiä vaivoja 
 Lieviä vaivoja 
 Kohtalaisia vaivoja 
 Melko pahoja vaivoja 
 Pahoja vaivoja 
 Erittäin pahoja vaivoja 
J. Svedlund, E. Dimenäs, I. Wiklund 1995 GSRS (F) 
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15. Onko Sinulla kuluneen viikon aikana ollut ULOSTAMISEN YHTEYDESSÄ 
TUNNE, ETTÄ SUOLI EI 
OLE TYHJENTYNYT KOKONAAN? (Tällä tarkoitetaan, että suoli ei ponnistuksista 
huolimatta 
tunnu tyhjentyneen kunnolla.) 
 Ei minkäänlaisia vaivoja 
 Vähäpätöisiä vaivoja 
 Lieviä vaivoja 
 Kohtalaisia vaivoja 
 Melko pahoja vaivoja 
 Pahoja vaivoja 
 Erittäin pahoja vaivoja 
 
16. ONKO SINULLA VIIMEISEN KUUKAUDEN AIKANA ESIINTYNYT SEURAAVIA 
OIREITA 
(rengasta sopivat vaihtoehdot) 
  kielikipuja 
  haavaumia suussa 
  luustokipuja 
  puutumista 
  muuta, mitä 
______________________________________________________________ 
TARKISTA, ETTÄ OLET VASTANNUT KAIKKIIN KYSYMYKSIIN, ENNEN KUIN 
PALAUTAT LOMAKKEEN. 
KIITOS AVUSTASI! 
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APPENDIX 2 
 
PGWB INDEX 
 
Nimi______________________________________________ 
 
Tutkimuksen tämä osa sisältää kysymyksiä siitä, miltä Teistä tuntuu ja kuinka 
Teillä on mennyt 
 
VIIMEKSI KULUNEEN VIIKON AIKANA. Jokaisen kysymyksen osalta rastittakaa 
(X) se vaihtoehto, 
joka parhaiten sopii Teidän kohdallenne. 
 
1. Miltä Teistä on YLEISESTI ottaen TUNTUNUT viimeksi kuluneen viikon 
aikana? 
 Mielialani on ollut erinomainen 
 Mielialani on ollut oikein hyvä 
 Mielialani on ollut enimmäkseen hyvä 
 Mielialani on vaihdellut paljon 
 Mielialani on ollut enimmäkseen huono 
 Mielialani on ollut hyvin huono 
 
2. Kuinka usein Teitä on VAIVANNUT JOKIN SAIRAUS, RUUMIILLINEN VAIVA, 
SÄRYT tai KIVUT 
viimeksi kuluneen viikon aikana? 
 Joka päivä 
 Melkein joka päivä 
 Noin puolet ajasta 
 Silloin tällöin, mutta vähemmän kuin puolet ajasta 
 Harvoin 
 Ei koskaan 
 



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3. Tunsitteko itsenne MASENTUNEEKSI viimeksi kuluneen viikon aikana? 
 Kyllä – niin paljon, että minusta tuntui siltä, että ottaisin itseni hengiltä 
 Kyllä – niin paljon, etten välittänyt mistään 
 Kyllä – hyvin masentuneeksi melkein joka päivä 
 Kyllä – melko masentuneeksi useita kertoja 
 Kyllä – lievästi masentuneeksi silloin tällöin 
 Ei – en ole kertaakaan tuntenut itseäni lainkaan masentuneeksi 
 
4. Oletteko pystynyt HALLITSEMAAN KÄYTTÄYTYMISTÄNNE, AJATUKSIANNE, 
MIELIALOJANNE tai 
TUNTEITANNE viimeksi kuluneen viikon aikana? 
 Kyllä, ehdottomasti 
 Kyllä – useimmiten 
 Yleensä 
 En kovin hyvin 
 En, ja se häiritsee minua jonkin verran 
 En, ja se häiritsee minua kovasti 
 
5. Onko Teitä vaivannut HERMOSTUNEISUUS tai LEVOTTOMUUS viimeksi 
kuluneen viikon aikana? 
 Erittäin paljon, jopa niin, että en ole voinut tehdä työtä tai huolehtia 
asioista 
 Hyvin paljon 
 Melko paljon 
 Jonkin verran, niin että se on vaivannut minua 
 Vähän 
 Ei lainkaan 
 
 

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6. Kuinka paljon TARMOA, PIRTEYTTÄ tai ELINVOIMAA Teillä on ollut viimeksi 
kuluneen viikon 
aikana? 
 Hyvin täynnä tarmoa – erittäin pirteä 
 Melko tarmokas suurimman osan ajasta 
 Tarmokkuuteni on vaihdellut melkoisesti 
 Yleensä vähän tarmoa tai pirteyttä 
 Hyvin vähän elinvoimaa tai tarmoa suurimman osan ajasta 
 Ei lainkaan tarmoa tai elinvoimaa – olen tuntenut itseni loppuun ajetuksi tai 
loppuun 
kuluneeksi 
 
7. Olen tuntenut itseni ALAKULOISEKSI JA SYNKKÄMIELISEKSI viimeksi kuluneen 
viikon aikana? 
 En kertaakaan 
 Vähän tänä aikana 
 Jonkin verran tänä aikana 
 Melkoisen osan tästä ajasta 
 Suurimman osan tästä ajasta 
 Koko ajan 
 
8. Oletteko yleisesti ollut KIREÄ tai tuntenut itsenne JÄNNITTYNEEKSI viimeksi 
kuluneen viikon 
aikana? 
 Kyllä, erittäin jännittyneeksi suurimman osan ajasta tai koko ajan 
 Kyllä, hyvin jännittyneeksi suurimman osan ajasta 
 En ole ollut koko ajan kireä, mutta olen tuntenut itseni melko jännittyneeksi 
useita kertoja 
 Olen tuntenut itseni vähän jännittyneeksi muutamia kertoja 
 En ole yleensä tuntenut itseäni jännittyneeksi 
 En ole lainkaan tuntenut itseäni jännittyneeksi 
 
 
 

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9. Kuinka ONNELLINEN, TYYTYVÄINEN tai MIELISSÄNNE olette ollut viimeksi 
kuluneen viikon 
aikana? 
 Erittäin onnellinen, en olisi voinut olla tyytyväisempi tai enemmän 
mielissäni 
 Hyvin onnellinen suurimman osan ajasta 
 Yleensä tyytyväinen ja mielissäni 
 Joskus melko onnellinen ja joskus melko onneton 
 Yleensä tyytymätön ja onneton 
 Hyvin tyytymätön tai onneton suurimman osan ajasta tai koko ajan 
 
10. Oletteko tuntenut itsenne riittävän TERVEEKSI tekemään asioita, joita 
haluatte tehdä tai 
Teidän on ollut pakko tehdä viimeksi kuluneen viikon aikana? 
 Kyllä, ehdottomasti 
 Suurimman osan ajasta 
 Terveysongelmat ovat merkittävästi rajoittaneet minua 
 Olen ollut vain niin terve, että olen voinut huolehtia itsestäni 
 Olen tarvinnut jonkin verran apua itseni huolehtimisessa 
 Olen tarvinnut toista henkilöä auttamaan itseäni useimmissa tai kaikissa 
asioissa, joita 
minun on täytynyt tehdä 
 
11. Oletteko tuntenut itsenne niin SURULLISEKSI, LANNISTUNEEKSI tai 
TOIVOTTOMAKSI, että 
olette miettinyt, onko millään mitään merkitystä viimeksi kuluneen viikon 
aikana? 
 Erittäin paljon – niin paljon, että olen ollut valmis luovuttamaan 
 Hyvin paljon 
 Melko lailla 
 Jonkin verran – sen verran, että se on vaivannut minua 
 Vähän 
 En lainkaan 
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12. Oletteko herännyt PIRTEÄNÄ ja LEVÄNNEENÄ viimeksi kuluneen viikon 
aikana? 
 En kertaakaan 
 Muutaman harvan kerran 
 Joitakin kertoja 
 Aika monta kertaa 
 Useimmiten 
 Joka kerta 
 
13. Oletteko ollut HUOLISSANNE tai LEVOTON TERVEYDESTÄNNE viimeksi 
kuluneen viikon aikana? 
 Erittäin paljon 
 Hyvin paljon 
 Melko paljon 
 Jonkin verran, mutta en kovin paljon 
 Käytännöllisesti katsoen en koskaan 
 En lainkaan 
 
14. Onko Teistä tuntunut siltä, että olisitte ”MENETTÄMÄSSÄ JÄRKENNE” tai 
KONTROLLINNE siitä, 
miten TOIMITTE, PUHUTTE, AJATTELETTE, TUNNETTE tai MITÄ MUISTATTE 
viimeksi kuluneen 
viikon aikana? 
 Ei lainkaan 
 Vain vähän 
 Jonkin verran, mutta ei niin paljon, että olisin ollut huolissani tai levoton 
siitä 
 Jonkin verran ja olen ollut vähän huolissani 
 Jonkin verran ja olen ollut melko huolissani 
 Kyllä, hyvin paljon ja olen ollut hyvin huolissani 
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15. Päivittäinen elämäni on ollut TÄYNNÄ minua KIINNOSTAVIA ASIOITA 
viimeksi kuluneen viikon 
aikana? 
 Ei lainkaan tänä aikana 
 Vain pienen osan tästä ajasta 
 Joskus 
 Melkoisen osan tästä ajasta 
 Suurimman osan tästä ajasta 
 Koko ajan 
 
16. Oletteko tuntenut itsenne AKTIIVISEKSI/TARMOKKAAKSI tai 
TYLSÄKSI/VELTOKSI viimeksi 
kuluneen viikon aikana? 
 Hyvin aktiiviseksi/tarmokkaaksi joka päivä 
 Enimmäkseen aktiiviseksi/tarmokkaaksi – en koskaan tylsäksi/veltoksi 
 Melko aktiiviseksi/tarmokkaaksi – harvoin tylsäksi/veltoksi 
 Melko tylsäksi/veltoksi – harvoin aktiiviseksi/tarmokkaaksi 
 Enimmäkseen tylsäksi/veltoksi – en koskaan aktiiviseksi/tarmokkaaksi 
 Hyvin tylsäksi/veltoksi joka päivä 
 
17. Oletteko ollut HUOLESTUNUT, HARMISSANNE tai AHDISTUNUT viimeksi 
kuluneen viikon 
aikana? 
 Erittäin paljon – niin paljon, että olen tuntenut itseni melkein sairaaksi 
huolestuneisuudesta 
 Hyvin paljon 
 Melko lailla 
 Jonkin verran – sen verran, että se on vaivannut minua 
 Vähän 
 En lainkaan 
 
 
 

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18. Olen tuntenut itseni TASAPAINOISEKSI ja VARMAKSI viimeksi kuluneen 
viikon aikana? 
 En lainkaan tänä aikana 
 Pienen osan tästä ajasta 
 Joskus 
 Huomattavan osan tästä ajasta 
 Suurimman osan tästä ajasta 
 Koko ajan 
 
19. Oletteko tuntenut itsenne LEVOLLISEKSI/HUOJENTUNEEKSI vai 
PINGOTTUNEEKSI/KIREÄKSI 
viimeksi kuluneen viikon aikana? 
 Olen tuntenut itseni levolliseksi ja huojentuneeksi koko viikon 
 Olen tuntenut itseni levolliseksi ja huojentuneeksi suurimman osan ajasta 
 Yleensä olen tuntenut itseni levolliseksi, mutta ajoittain olen tuntenut itseni 
melko 
pingottuneeksi 
 Yleensä olen tuntenut itseni pingottuneeksi, mutta ajoittain olen tuntenut 
itseni melko 
levolliseksi 
 Olen tuntenut itseni pingottuneeksi/kireäksi suurimman osan ajasta 
 Olen tuntenut itseni hyvin pingottuneeksi/kireäksi koko ajan 
 
20. Olen tuntenut itseni ILOISEKSI/HUOLETTOMAKSI viimeksi kuluneen viikon 
aikana? 
 En lainkaan tänä aikana 
 Pienen osan tästä ajasta 
 Joskus 
 Melkoisen osan tästä ajasta 
 Suurimman osan tästä ajasta 
 Koko ajan 
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21. Olen tuntenut itseni VÄSYNEEKSI ja LOPPUUN KULUNEEKSI viimeksi 
kuluneen viikon aikana? 
 En lainkaan tänä aikana 
 Pienen osan tästä ajasta 
 Joskus 
 Melkoisen osan tästä ajasta 
 Suurimman osan tästä ajasta 
 Koko ajan 
 
22. Oletteko tuntenut itsenne ”STRESSAANTUNEEKSI”, RASITTUNEEKSI tai 
PAINEEN ALAISEKSI 
viimeksi kuluneen viikon aikana? 
 Kyllä, melkein enemmän kuin voin sietää tai kestää 
 Kyllä melko lailla 
 Kyllä, jonkin verran – enemmän kuin tavallisesti 
 Kyllä, jonkin verran – kuten tavallisesti 
 Kyllä, vähän 
 En lainkaan 
 
TARKISTAKAA, ETTÄ OLETTE VASTANNUT KAIKKIIN KYSYMYKSIIN! 
KIITOS HYVÄSTÄ YHTEISTYÖSTÄ 
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 INTRODUCTION
 Celiac disease is a lifelong gluten-induced enteropathy with a 
prevalence of up to 2% in Caucasian populations ( 1,2 ). Th e only 
current treatment for the condition is lifelong adherence to a 
gluten-free diet, the eff ectiveness of which is shown by a high 
rate of symptom alleviation on a strict diet ( 2,3 ). Th e demonstra-
tion of gluten-induced small-bowel mucosal damage and crypt 
hyperplasia upon intestinal biopsy is required for the diagnosis, 
but current guidelines are somewhat contradictory as to whether 
the biopsy should be repeated aft er 1 year on dietary treatment 
( 3–7 ). Th e main reasons for routine follow-up biopsy would be 
to monitor histological recovery and dietary adherence, as well 
as to exclude serious complications such as refractory celiac dis-
ease in non-responsive patients. However, a substantial propor-
tion of celiac disease patients have not reached complete mucosal 
recovery aft er 1 year, whereas in the long run it is seen in up 
to 96% of patients ( 8–12 ). Th e challenge is thus to distinguish 
patients with simply a slow histological response from those 
with true refractory celiac disease. Ill-timed endoscopic studies 
comprise a major burden for patients and health care, and the 
 Predictors and Signiﬁ cance of Incomplete Mucosal 
Recovery in Celiac Disease After 1 Year on 
a Gluten-Free Diet
 Henna  Pekki ,  BM 1 ,  Kalle  Kurppa ,  MD, PhD 2 ,  Markku  Mäki ,  MD, PhD 2 ,  Heini  Huhtala ,  MSc 3 ,  Harri  Sievänen ,  PhD 4 ,  Kaija  Laurila ,  MSc 2 , 
 Pekka  Collin ,  MD, PhD 1  ,  5 and  Katri  Kaukinen ,  MD, PhD 1  ,  6 
 OBJECTIVES:  In celiac disease, a follow-up biopsy taken 1 year after diagnosis is considered important in 
monitoring histological recovery. In many cases, recovery is incomplete, and the clinical signiﬁ cance 
of this is poorly understood. We now investigated associated factors and the signiﬁ cance of imperfect 
histological recovery in patients in whom the follow-up had been completed.
 METHODS:  Two hundred sixty-three biopsy-proven patients were divided into two groups: histological recovery 
and incomplete recovery after 1 year on gluten-free diet. Serology, laboratory values, bone mineral 
density, and different clinical variables were measured at diagnosis and after 1 year. Gastrointestinal 
symptoms and quality of life were assessed by validated questionnaires. Further, long-term follow-up 
data on mortality, malignancies, and other severe complications were collected.
 RESULTS:  The incomplete recovery group had more severe mucosal damage ( P =0.003), higher antibody values 
( P =0.017), and more signs of malabsorption ( P <0.001) at diagnosis. There was no difference in 
gender, symptoms or quality of life, family history of celiac disease, or comorbidities. At follow-up, 
there was still a difference in antibodies ( P =0.018) and femoral  T -scores ( P =0.024). Histologically 
recovered patients showed better dietary adherence, although it was excellent in both groups (97% 
vs. 87%,  P <0.001). There was no difference in long-term outcomes between groups.
 CONCLUSIONS:  The presence of more severe disease in terms of histology, serology, and signs of malabsorption was 
associated with histological non-response. In patients with high dietary adherence, incomplete villous 
recovery after 1 year does not affect the clinical response or long-term prognosis. A personalized 
approach is required to decide the optimal timing of the follow-up biopsy.
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cost-eff ectiveness of the second biopsy remains obscure ( 9 ). On 
the other hand, persistent villous atrophy predisposes to severe 
complications and increased mortality in the long run ( 6,9,11 ). 
Currently, it is unclear whether there are specifi c patient-related 
factors associated with the speed of villous recovery, whether 
a correlation prevails between clinical outcomes and mucosal 
recovery aft er 1 year on treatment, and whether incomplete 
mucosal recovery aft er 1 year on a gluten-free diet has a long-
term impact ( 5,9–11 ). Understanding these issues would make 
for a more personalized approach to the follow-up of celiac dis-
ease and spare patients and limited health-care resources unnec-
essary invasive examinations.
 Th e objective of this study was to identify patient-related factors 
possibly predicting incomplete histological recovery at follow-up 
biopsy 1 year aft er diagnosis, and to assess the clinical signifi cance 
and long-term consequences of such slowly recovering mucosal 
damage. Th is was established by measuring a wide variety of histo-
logical, serological, and clinical parameters, both at diagnosis and 
aft er 1 year on a gluten-free diet, in a large cohort of adults with 
celiac disease.
 METHODS
 Patients and study design
 Th e study was conducted in Tampere University Hospital and the 
University of Tampere between 1996 and 2009. Altogether, data 
regarding 263 adults with biopsy-proven celiac disease (179 women 
and 84 men, median age 45 (range 15–79) years) were collected 
from our prospective patient series. Th e present study included 
only cases where a fi rst follow-up biopsy had been carried out aft er 
1 year on a gluten-free diet. Further, as there is recent evidence that 
the angiotensin II receptor blocker olmesartan may cause severe 
enteropathy resembling celiac disease ( 13 ), the possible use of this 
drug in our patients was checked. All participants were interviewed 
at the time of the diagnosis and demographic data, family history 
of celiac disease, and celiac disease-associated and other signifi -
cant comorbidities were enquired. Special attention was devoted at 
diagnosis to characteristic clinical manifestations of celiac disease, 
among them anemia, malabsorption, diarrhea, and to the possible 
presence of atypical or extraintestinal symptoms such as arthritis, 
gynecological problems, or neurological symptoms. Duration of 
symptoms before diagnosis was assessed and the symptoms fur-
ther categorized as mild, moderate, or severe. Further, the propor-
tion of subjects detected by screening in at-risk groups, such as 
relatives of celiac disease patients and those with type 1 diabetes or 
autoimmune thyroidal disease, was calculated.
 All patients received comprehensive dietary guidance by a dieti-
tian with expertise in celiac disease and started a gluten-free diet 
following the diagnosis. Adherence to the diet was evaluated by the 
dietitian aft er 1 year, and patients with no gluten or only a minor 
inadvertent gluten intake less than once per month were defi ned as 
adherent ( 14,15 ). Th e patients underwent a follow-up biopsy aft er 
1 year on diet and were divided into two groups based on their 
morphological small-bowel mucosal recovery. Subjects evincing 
mucosal recovery were defi ned as the ‘Recovery group’ and those 
with incomplete morphological recovery as the ‘Atrophy group’. 
Besides the above-mentioned clinical data, the following com-
parisons between groups were carried out both at diagnosis and 
at follow-up biopsy: celiac disease serology, small-bowel mucosal 
histology, laboratory values, bone mineral density (BMD), body 
mass index (BMI), gastrointestinal symptoms, and health-related 
quality of life. In addition, special attention was paid to patients 
who did not show any signs of histological recovery aft er 1 year on 
the dietary treatment. In our setting, aft er the fi rst follow-up biopsy 
patients with good clinical and serological response are assigned to 
secondary or primary health care for further endoscopic and clini-
cal follow-up, and in cases of persistent mucosal atrophy or recur-
rence of symptoms, subjects are referred back to a tertiary center 
for further investigations.
 Long-term follow-up data on the patients’ mortality, malig-
nancies, other gastrointestinal diseases, and osteoporosis were 
collected from their medical records up to present. In addition, 
the degree of gastrointestinal symptoms and quality of life was 
assessed by validated questionnaires among a subgroup of patients 
with a median of 5 years aft er diagnosis (see below).
 Small-bowel mucosal biopsies
 A minimum of six biopsy specimens were taken from the dis-
tal duodenum upon upper gastrointestinal endoscopy. Th ree 
specimens were carefully orientated, processed, and stained with 
hematoxylin and eosin and analyzed under light microscopy. 
Th e degree of morphological small-bowel mucosal damage was 
measured quantitatively using the villous height-crypt depth ratio 
(Vh/CrD). Th is was calculated by measuring the mean height 
of a villus and the adjacent crypt from at least three well-orien-
tated villus–crypt units. Th e fi nal morphological analysis was 
conducted on the most severely damaged biopsy specimen ( 16 ). 
Normal Vh/CrD was considered to be over 2.0 ( 17 ). To ascertain a 
dose response refl ected in outcome measures, the Atrophy group 
were further categorized into those with subtotal or total villous 
atrophy (Vh/CrD below 0.9) and those with partial villous atro-
phy (Vh/CrD 0.9–1.9).
 Th e degree of small-bowel mucosal infl ammation was deter-
mined from the biopsy specimens by measuring the density of 
intraepithelial lymphocytes (IELs), as previously described in 
detail ( 18 ). Briefl y, the IELs were counted in both hematoxylin- 
and eosin-stained and frozen sections with a ×100 fl at-fi eld light 
microscope objective. Immunohistochemical studies were made 
on frozen 5-μ m-thick sections and CD3+ IELs were stained using 
the monoclonal antibody Leu-4 (Becton Dickinson, San Jose, CA). 
Th e density of hematoxylin- and eosin-stained IELs was expressed 
as cells per 100 epithelial cells (reference value over 30 per 100 
enterocytes) and that of CD3+ IELs as cells per mm (reference 
value 37 cells per mm) ( 18 ). Further, the densities of α β + IELs and 
γ δ + IELs were counted in the frozen sections as described previ-
ously ( 19,20 ).
 Serology and laboratory parameters
 Serum IgA-class transglutaminase-2 antibodies (TG2abs) were 
measured by enzyme-linked immunosorbent assay (Celikey; 
The American Journal of GASTROENTEROLOGY    www.amjgastro.com
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Phadia, GmbH, Freiburg, Germany). Values >5.0 U/l for TG2abs 
were considered positive according to the manufacturer’s instruc-
tions. Serum IgA-class endomysium antibodies were assessed by 
an indirect immunofl uorescence method as described previously 
( 21 ). Titers 1:≥5 were considered positive. In cases of selective IgA 
defi ciency, the corresponding IgG-class antibodies were applied. 
Th e serological tests were subjected to meticulous quality assess-
ment as described elsewere ( 22 ). Our laboratory is one of the six 
laboratories in the international quality control network (UK 
NEQAS) for celiac antibody testing. In our settings, the batch-to-
batch variation in serology has been 10–15%. Th e following labo-
ratory parameters were measured using standard methods: blood 
hemoglobin (reference values: men >134 g/l; women >117 g/l), 
mean corpuscular volume (82–98 fl ), ionized calcium (1.16–
1.30 mmol/l), parathyroid hormone (1.0–7.5 pmol/l), serum total 
iron (9–34 μ mol/l), erythrocyte folic acid (200–700 nmol/l), and 
serum vitamin B12 (>150 pmol/l).
 BMD and BMI
 BMD was measured from the lumbar spine and femoral neck 
by dual-energy X-ray absorptiometry (Norland XR-26; Norland 
Corp, Fort Atkinson, WI) following our standard procedure ( 23 ). 
Th e values expressed are standard deviation scores, which com-
pare the individual value with either that of healthy young adults 
( T -score) or the age-matched population ( Z -score) ( 24,25 ). Both 
 T - and  Z -scores were applied here according to the recommenda-
tion of the World Health Organization ( 24 ). Th e individual’s BMI 
was calculated as weight in kilograms divided by the square of 
height in meters (kg/m 2 ).
 Gastrointestinal symptoms and quality of life
 Th e Gastrointestinal Symptoms Rating Scale (GSRS) ( 26 ) was 
used to evaluate the self-perceived severity of patients’ gastroin-
testinal symptoms. Th e scale is well-validated and widely applied 
in celiac disease ( 21,27,28 ). GSRS consists of 15 separate items 
and the total score is the sum of the mean values obtained for 
each separate item. Further, the questionnaire can be divided into 
fi ve subdimensions measuring abdominal pain, gastroesopha-
geal refl ux, indigestion, diarrhea, and constipation. Th e scoring is 
based on a seven-grade Likert scale where higher scores stand for 
more severe gastrointestinal symptoms.
 Th e Psychological General Well-Being Index (PGWB) was used 
to measure self-perceived psychological well-being and quality of 
life ( 29 ). PGWB is a 22-item questionnaire using a six-grade Likert 
scale where high scores indicate better well-being and quality of 
life. Th e separate items can be further divided into six subdimen-
sions measuring anxiety, depression, well-being, self-control, gen-
eral health, and vitality. PGWB is also a well-validated and widely 
used questionnaire in celiac disease ( 14,21,27,28,30–33 ).
 Ethics
 Patient collection was conducted with the permission and accord-
ing to the guidelines of the Ethical Committee of Tampere Uni-
versity Hospital. All celiac disease patients participating in the 
present study gave written informed consent before data collec-
tion. Further, the collection of long-term follow-up data on the 
patients was conducted with the permission of the Department of 
Internal Medicine, Tampere University Hospital.
 Statistical analysis
 Statistical testing was made using PASW version 18 (IBM, New 
York, NY). Results are shown as medians with 25th to 75th per-
centiles (lower and upper quartiles, Q 1 –Q 3 ). Mann–Whitney 
 U -test was used in statistical comparisons between groups in age, 
serology, mucosal histology, laboratory parameters, BMD, BMI, 
GSRS, PGWB, and symptom duration.  χ 2 Test was used in com-
parisons of sex, clinical presentation and severity of the disease, 
presence of comorbidities, adherence to gluten-free diet, and 
family history of celiac disease. Multivariate analysis was further 
applied for variables with statistical signifi cance. A  P -value <0.05 
was considered statistically signifi cant.
 RESULTS
 Histology, serology, and clinical parameters
 By defi nition, at diagnosis all patients here had biopsy-proven 
celiac disease with villous atrophy and crypt hyperplasia (Vh/CrD 
<2.0). Aft er 1 year on a gluten-free diet, the small-bowel mucosal 
morphology had normalized in 178 (68%) patients (Recovery 
group), whereas 85 (32%) showed incomplete mucosal recovery 
(Vh/CrD <2.0, Atrophy group) in the follow-up biopsy. Demo-
graphic data, clinical characteristics, and comorbidities of the 
participants at diagnosis are shown in  Table 1 . Among these, a 
signifi cant diff erence between the groups was seen only in the 
presence of malabsorption at diagnosis, this being more com-
mon in the Atrophy group. Th ere was also a trend toward a higher 
prevalence of histological non-recovery in older patients and sub-
jects with psoriasis and a lower prevalence of ongoing atrophy in 
autoimmune thyroidal diseases, although this was not statistically 
signifi cant ( Table 1 ). Altogether, 21% of the Recovery group and 
25% of the Atrophy group were at least 60 years of age at diag-
nosis, giving an adequate representation of the elderly for the 
analyses. Th ere was no signifi cant diff erence between histologi-
cally recovered patients and those with ongoing atrophy in gender 
distribution, clinical presentations at diagnosis, severity or dura-
tion of symptoms before diagnosis, diarrhea, family history of 
celiac disease, or presence of celiac disease-associated and other 
illnesses ( Table 1 ); also, the prevalence of screen-detected patients 
was comparable in both groups.
 Subjects in the Atrophy group had signifi cantly higher serum 
TG2ab levels at diagnosis ( Table 2 ). Th is diff erence was also 
observed aft er 1 year on a gluten-free diet, but at that time median 
TG2ab values were low and within the reference range in both 
groups ( Table 2 ). Altogether, only 11% of the histologically recov-
ered and 16% of the atrophic patients remained seropositive at the 
time of the follow-up biopsy, the rates at diagnosis being 88% and 
93%, respectively. In all but one initially seropositive subject anti-
body values decreased on diet.
 At diagnosis, patients in the Atrophy group had more severe 
small-bowel mucosal damage as measured by the Vh/CrD 
© 2015 by the American College of Gastroenterology The American Journal of GASTROENTEROLOGY
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compared with those in the Recovery group ( Table 2 ). Further, 
there was a signifi cant diff erence in the speed of mucosal recovery 
between the groups, as the Vh/CrD improved more among his-
tologically healed (change in median ratio 2.1) compared among 
those still atrophic (change in median ratio 0.9) ( P <0.001), dem-
onstrating that more severe villous atrophy at diagnosis also pre-
dicted slower mucosal healing.
 Th ere was no diff erence between the groups in the levels of 
either hematoxylin- and eosin-stained or CD3+ IELs at diagnosis, 
but in the follow-up biopsies the median density of CD3+ IELs was 
signifi cantly higher in the Atrophy group ( Table 2 ). No signifi cant 
diff erence was seen between the groups in the density of α β + or 
γ δ + IELs in either the diagnostic or the follow-up biopsy (data not 
shown).
 Laboratory parameters, BMD and BMI
 The median blood hemoglobin level in women was signifi-
cantly lower both at diagnosis and after 1 year on diet in the 
Atrophy group compared with the Recovery group. A simi-
lar but nonsignificant trend was seen in men ( Table 3 ). The 
serum total iron level was significantly lower in the Atrophy 
group at diagnosis but not at follow-up. There was also a trend 
toward higher parathyroid hormone and lower erythrocyte 
folic acid levels in the atrophic patients at diagnosis. In bone 
both lumbar and femoral  T -scores were lower in the Atrophy 
group; after 1 year on a gluten-free diet, the difference was pre-
sent only in the femur. No significant difference between the 
groups was seen either in lumbar or in femoral  Z -scores or in 
BMI ( Table 3 ).
 Table 1 .  Baseline demographic data, clinical characteristics, 
and associated diseases in 263 celiac disease patients with 
(Recovery) or without (Atrophy) a histological response a to 1 year 
on a gluten-free diet 
  Atrophy, 
 N =85 
 Recovery, 
 N =178 
 P  value 
 Age, median (range) 
(years) 
 48 (18–77)  44 (15–79)  0.068 
 Age over 60 years (%)  24.7%  20.6  
 Females (%)  65  70  0.420 
 Clinical presentation at diagnosis b  (%) 
 Malabsorption  60  34  0.001 
 Diarrhea  20  21  0.897 
  Extraintestinal 
symptoms c 
 13  14  0.176 
 Screen-detected d  22  29  0.543 
 Severity of symptoms at 
diagnosis (%) 
   0.512 
 Mild  87  82  
 Moderate  13  16  
 Severe  0  2  
 Duration of symptoms, 
median (range) (year) 
 2 (0–40)  1 (0–57)  0.219 
 Family history of celiac 
disease (%) 
 37  47  0.129 
 Presence of comorbidities (%) 
  Autoimmune thyroidal 
disorders 
 6  26  0.080 
 Psoriasis  5  3  0.064 
  Type 1 diabetes 
mellitus 
 2  5  0.830 
 Lactose intolerance  5  16  0.385 
 Asthma  3  9  0.579 
 Any malignancy  3  5  0.750 
  Any neurological 
disorders 
 3  12  0.293 
 Hypertension  7  20  0.453 
 Coronary artery disease  4  5  0.429 
 Psychiatric disease  4  9  0.902 
 Ig, immunoglobulin. 
 a Deﬁ ned as a small-bowel mucosal villous height crypt depth ratio >2.0 at the 
follow-up biopsy. 
 b One patient can present with more than one symptom. 
 c Arthritis, dental enamel defects, dementia, dermatitis herpetiformis, glossitis, 
aphthous stomatitis, gynecological problems, myopathy, neurologic symptoms, 
osteoporosis, Sjögren’s disease, chronic eczema, and IgA nephropathy. 
 d Celiac disease in relatives, type 1 diabetes mellitus, and autoimmune thyroidal 
disease. 
 Table 2 .  Serological and histological parameters in 263 
celiac disease patients with (Recovery) or without (Atrophy) a 
histological response a to 1 year on a gluten-free diet 
  Atrophy,  N =85  Recovery,  N =178  P  value 
  Median (Q 1 –Q 3 )  Median (Q 1 –Q 3 )  
 Transglutaminase 2 antibodies (U/ml) b 
 At diagnosis  56.8 (19.1–100.0)  29.5 (7.8–70.8)  0.017 
 After 1 year  1.8 (0.6–3.4)  0.4 (0.0–2.1)  0.018 
 Villous height–crypt depth ratio 
 At diagnosis  0.2 (0.1–0.4)  0.4 (0.1–0.8)  0.003 
 After 1 year  1.2 (0.8–1.6)  2.6 (2.3–2.9)  <0.001 
 IELs (cells per 100 epithelial cells) 
 At diagnosis  46 (36–57)  43 (35–58)  0.739 
 After 1 year  29 (22–40)  26 (19–36)  0.056 
 CD3+ IELs (cells per mm) 
 At diagnosis  76 (53–89)  67 (49–89)  0.353 
 After 1 year  38 (28–58)  35 (23–52)  0.034 
 IEL, intraepithelial lymphocyte. 
 The values are shown as medians with upper and lower quartiles (Q1 and Q3). 
 a Deﬁ ned as a small-bowel mucosal villous height crypt depth ratio >2.0 at the 
follow-up biopsy. 
 b Upper limit of the assay is 100.0 U/ml. 
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 Adherence to the gluten-free diet, gastrointestinal symptoms, 
and quality of life
 Most (87%) patients, both atrophic and recovered, maintained a 
strict diet and only 13% reported dietary lapses, but low adher-
ence to the diet, nonetheless, predisposed the patients to incom-
plete mucosal recovery in the follow-up biopsy ( Table 4 ). Th ere 
was no diff erence between the groups either at diagnosis or aft er 
1 year on treatment in the degree of gastrointestinal symptoms 
and health-related quality of life as measured by the GSRS and 
PGWB total scores ( Table 4 ). No diff erence was found between 
the groups in any of the GSRS and PGWB subdimension scores 
(data not shown).
 A statistically signifi cant diff erence in dose response between 
study outcomes and the severity of mucosal atrophy in the follow-
up biopsy was seen in serology, as patients with subtotal or total 
villous atrophy had lower TG2ab values compared with those 
with partial atrophy (median 0.6 vs. 2.3 U/l,  P =0.017) aft er 1 year. 
Th ere was no signifi cant diff erence in dose response between the 
degree of mucosal damage and any other study outcomes (data not 
shown).
 Multivariate analysis
 In multivariate analysis, only malabsorption at diagnosis was 
found to signifi cantly increase the risk of incomplete villous 
recovery aft er 1 year on diet (odds ratio 4.9, 95% confi dence inter-
val 2.2–10.8).
 Patients with no signs of histological improvement
 Detailed investigation revealed that altogether only 6 (three female, 
median age 45 (range 35–63) years; 2.3% of all patients) out of the 
 Table 3 .  Laboratory parameters, bone mineral density, and body 
mass index in 263 celiac disease patients with (Recovery) or 
without (Atrophy) a histological response a to 1 year on a gluten-
free diet 
  Atrophy,  N =85  Recovery,  N =178  P  value 
  Median (Q 1 –Q 3 )  Median (Q 1 –Q 3 )  
 Blood hemoglobin 1 , women (g/l) 
 At diagnosis  119 (112–126)  131 (125–139)  <0.001 
 After 1 year  127 (120–134)  133 (128–137)  0.029 
 Blood hemoglobin 1 , men (g/l) 
 At diagnosis  142 (135–148)  149 (144–153)  0.069 
 After 1 year  145 (134–150)  147 (147–151)  0.342 
 Serum total iron 2  (μmol/l) 
 At diagnosis  12.0 (8.8–17.6)  18.0 (12.2–21.6)  0.001 
 After 1 year  19.6 (13.4–24.4)  17.6 (14.0–21.5)  0.245 
 Erythrocyte folic acid 3  (nmol/l) 
 At diagnosis  548 (256–481)  423 (296–507)  0.060 
 After 1 year  548 (424–676)  508 (383–650)  0.547 
 Serum vitamin B12 (pmol/l) 
 At diagnosis  294 (190–360)  287 (229–368)  0.414 
 After 1 year  383 (286–464)  341 (269–428)  0.153 
 Ionized calcium 4  (mmol/l) 
 At diagnosis  1.24 (1.23–1.27)  1.25 (1.22–1.27)  0.664 
 After 1 year  1.25 (1.21–1.28)  1.24 (1.21–1,27)  0.708 
 Parathyroid hormone 5  (pmol/l) 
 At diagnosis  6.3 (4.4–8,2)  4.4 (3.4–6.9)  0.065 
 After 1 year  4.6 (3.7–6.9)  4.3 (3.4–6.7)  0.645 
 Lumbar T -score 6  (s.d.) 
 At diagnosis  −1.5 (−2.2 to −0.4)  −1.0 (−1.8 to 0.2)  0.022 
 After 1 year  −1.1 (−2.2 to −0.2)  −0.7 (−1.7 to 0.4)  0.117 
 Femoral T -score (s.d.) 
 At diagnosis  −1.2 (−1.9 to −0.5)  −0.7 (−1.5 to 0.0)  0.016 
 After 1 year  −1.1 (−1.9 to −0.5)  −0.6 (−1.5 to 0.0)  0.024 
 Lumbar Z -score 7  (s.d.) 
 At diagnosis  −1.2 (−1.7 to 0.1)  −0.3 (−1.1 to 1.0)  0.082 
 After 1 year  −0.5 (−1.3 to 0.1)  0.1 (−1.1 to 0.9)  0.376 
 Femoral Z -score 8  (s.d.) 
 At diagnosis  −0.7 (−1.0 to 0.2)  −0.3 (−0.8 to 0.3)  0.153 
 After 1 year  −0.5 (−0.7 to −0.1)  −0.3 (−0.6 to 0.3)  0.323 
 Body mass index 9  (kg/m 2 ) 
 At diagnosis  23.4 (21.3–26.2)  24.6 (22.2–27.7)  0.119 
 After 1 year  23.9 (22.0–27.3)  24.3 (22.1–27.1)  0.823 
 The values are shown as medians with upper and lower quartiles (Q1 and Q3). 
 Variables were available from the following numbers of subjects:  1 153,  2 144, 
 3 142,  4 95,  5 67,  6 152,  7 159,  8 140 and  9 136. 
 a Deﬁ ned as a small-bowel mucosal villous height crypt depth ratio >2.0 at the 
follow-up biopsy. 
 Table 4 .  Strictness of gluten-free diet and GSRS and PGWB 
total scores in 263 celiac disease patients with a histological 
response a (Recovery) or no response (Atrophy) to 1 year on a 
gluten-free diet 
  Atrophy,  N =85  Recovery,  N =178  P  value 
  Median (Q 1 –Q 3 )  Median (Q 1 –Q 3 )  
 Strict gluten-free 
diet, % ( n ) 
 87 (74)  97 (173)  <0.001 
 GSRS total score 
 At diagnosis  2.4 (1.7–2.9)  2.2 (1.6–2.8)  0.138 
 After 1 year  1.5 (1.3–1.8)  1.5 (1.3–2.0)  0.321 
 PGWB total score 
 At diagnosis  98 (87–108)  105 (91–115)  0.260 
 After 1 year  112 (102–118)  111 (100–117)  0.699 
 GSRS, Gastrointestinal Symptom Rating Scale; PGWB, Psychological General 
Well-Being Index. 
 The values, except strictness of the diet, are shown as medians with upper and 
lower quartiles (Q1 and Q3). 
 a Deﬁ ned as a small-bowel mucosal villous height crypt depth ratio >2.0 at the 
follow-up biopsy. 
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87 subjects in the Atrophy group showed no signs of improvement 
in villous architecture aft er 1 year on a gluten-free diet (mean Vh/
CrD at diagnosis 0.4, aft er 1 year 0.2). At diagnosis, four of them 
presented with mild abdominal symptoms and two with signs of 
malabsorption; four had a family history of celiac disease. Before 
treatment, three out of fi ve had positive TG2ab and four out of 
fi ve positive endomysium antibodies, but the antibody values 
were relatively low (TG2ab mean 6.6 U, range 0–15.6 U; endomy-
sium antibody median titer 1:50, range negative—1:200). All six 
reported keeping to a strict gluten-free diet and were seronegative 
at the time of the follow-up biopsy. Five subjects showed good 
clinical response, whereas one presented with relapsing fever and 
hyposplenism aft er 2 years. Further investigations revealed type I 
refractory celiac disease with mesenteric lymph node cavitations 
and widespread total villous atrophy extending to the ileum, but 
there were no lymphomas and markers of type II refractory celiac 
disease were negative.
 Long-term follow-up
 Long-term follow-up data on mortality, malignancies, and 
other complications and comorbidities were available for 
a total of 205 (78%) study patients ( Table 5 ). There were no 
statistically significant differences between the Atrophy and 
Recovery groups in any of the long-term parameters measured 
( Table 5 ).
 DISCUSSION
 In this large cohort of celiac disease patients who had undergone 
a follow-up biopsy aft er 1 year on diet, the most prominent fac-
tor predicting incomplete small-bowel recovery was the presence 
at diagnosis of more severe disease in terms of histology and 
serology and signs of malabsorption. Further, while mucosal 
recovery was still ongoing, most of the clinical parameters 
measured had improved and were already at the same level in 
the Atrophy and Recovery groups, and the groups also showed 
no diff erence in long-term outcomes. Although the patients 
with incomplete recovery represented one-third of the sub-
jects here, we have shown that in a highly adherent population 
at least 96% of patients achieve complete recovery on long-term 
treatment and only 0.3% develop refractory celiac disease ( 12,34 ). 
In accord with this, only 2.3% of all patients here still showed 
no signs of histological improvement aft er 1 year, and only one 
presented with complications and type I refractory disease. 
Th ese fi ndings indicate that follow-up biopsy aft er 1 year corre-
lates poorly with clinical outcome and long-term prognosis, and 
represents only a ‘snapshot’ rather than the end point of ongoing 
mucosal healing.
 Altogether, 68% of the subjects evinced morphological mucosal 
recovery aft er 1 year on diet, which is in fact a relatively high per-
centage compared with previous reports ( 5,6,9 ). Nevertheless, it 
is in line with our previous studies and very likely refl ects the gen-
erally high dietary adherence in Finland ( 4,35 ). Th e good avail-
ability and strict labeling of gluten-free products and fi nancial 
subsidization by the government are all likely to reduce inadvert-
ent gluten intake ( 36 ). Th is was seen in the present study, as both 
the histologically recovered and non-recovered patients showed, 
in global perspective, excellent dietary adherence. It is thus evi-
dent that, in contrast to many previous reports ( 6,10 ), dietary 
lapses explained only a small minority of non-responsive cases 
in this study.
 Th e most conspicuous diff erence here was in the presence of 
more severe mucosal damage in the Atrophy group at diagno-
sis. In accord, Rubio-Tapia  et al. ( 6 ) discovered an association 
between the severity of the baseline damage and slow histological 
recovery. Another recent study ( 37 ) showed that patients with less 
severe atrophy were also more likely to respond to the diet. How-
ever, this was the fi rst time a quantitative approach has been used 
to assess the actual speed (Δ Vh/CrD) of villous recovery and it 
was observed to be lower in the Atrophy group. Th is slower recov-
ery combined with severe atrophy at diagnosis explains why these 
patients had not regained normal mucosa during 1 year despite 
a strict diet. Some studies have indirectly investigated whether 
the speed of histological recovery is associated with the sever-
ity of the baseline damage, but results have been controversial 
( 5,6,9,15,37,38 ). Th is might be explained by diff erences in dietary 
adherence and by the use of inexact grouped classifi cations (e.g., 
Marsh) in histology ( 16 ).
 Another indicator of the presence of more severe disease in the 
Atrophy group at diagnosis was their higher levels of TG2ab, even 
if these antibodies are poor predictors of the severity of histological 
and clinical fi ndings in individual patients ( 9,15,22 ). TG2ab also 
 Table 5 .  Long-term follow-up data on 205 celiac disease patients 
with a histological response a (Recovery) or no response (Atrophy) 
after 1 year on a gluten-free diet 
  Atrophy 
Group,  N =71 
 Recovery 
Group,  N =134 
 P value 
 Duration of follow-up, 
median (range) (years) 
 16 (5–21)  16 (5–20)  0.136 
 Mortality (% ( n ))  14.1 (10)  9.0 (12)  0.259 
 Any malignancy b (% ( n ))  13.3 (8)  6.4 (8)  0.116 
 Lymphoma (% ( n ))  1.4 (1)  1.6 (2)  0.968 
 Other chronic gastro-
intestinal disease c (% ( n )) 
 11.3 (8)  14.2 (19)  0.455 
 Osteoporosis (% ( n ))  14.0 (8)  13.0 (16)  0.850 
 GSRS d total score  1.6 (1.0–4.0)  1.9 (1.0–3.0)  0.132 
 PGWB e total score  109 (52–124)  108 (62–121)  0.416 
 Blood hemoglobin, 
median (range) (g/l) 
 133 (116–173)  132 (111–158)  0.724 
 GSRS, Gastrointestinal Symptom Rating Scale; PGWB, Psychological General 
Well-Being Index. 
 a Deﬁ ned as a small-bowel mucosal villous height crypt depth ratio >2.0 at the 
follow-up biopsy. 
 b Cancers of uterus, breast, lung, pancreas, urinary bladder and prostate and 
lymphoma, sarcoma. 
 c Reﬂ ux disease, collagenous/lymphocytic colitis, diverticulosis, Crohn’s disease, 
ulcerative colitis, gallstones, Barrett’s esophagus, pancreatitis, and cirrhosis. 
 d N =44. 
 e N =44. 
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questionnaires. Further, the fact that follow-up biopsies were 
taken systematically aft er 1 year and were analyzed by quantita-
tive Vh/CrD reduces the risk of misclassifi cation bias ( 16 ). We 
were also able to collect a substantial body of long-term follow-
up data regarding mortality and other complications ( 6 ). Th e 
high dietary adherence in our cohort enabled us to evaluate other 
causes behind non-recovery than the usually dominating poor 
compliance; however, the results may not be directly applicable 
to countries where dietary lapses are common ( 42 ). A limita-
tion is that we were not able to compare subjects consenting to 
follow-up biopsy and those who refused (~15% of subjects in our 
center). Th is may cause bias as non-compliant patients may be 
more prone to refuse, and lack of follow-up biopsy has also been 
associated with increased mortality ( 43 ). Also, no systematic fol-
low-up was undertaken for those with incomplete recovery, as in 
our settings patients with uncomplicated disease are assigned to 
primary health care for further follow-up. Nevertheless, accord-
ing to our clinical practice patients with persistent atrophy would 
have been referred to us for further investigations. Finally, as the 
study was initiated before routine biopsies from the duodenal 
bulb were recommended ( 3 ), they were not systemically taken, 
and thus some cases with lesion only in the bulb might have been 
missed ( 44 ).
 In conclusion, we showed that only the presence of more 
severe disease in terms of histology and serology were associ-
ated with incomplete histological recovery at the follow-up 
biopsy. Moreover, diff erences in the speed of mucosal healing 
were not refl ected in the short- or long-term clinical outcomes. 
Based on these fi ndings a more personalized approach should 
be adopted when deciding the optimal timing of the histological 
follow-up. One year is oft en too short a time for the mucosa to 
recover, and postponing the biopsy, e.g., for another year ( 45 ), 
would presumably result in lower number of cases with ongoing 
atrophy.
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remained at a higher level in the incompletely recovered patients 
aft er 1 year, with the diff erence, however, being small and the 
median values in both groups falling within normal limits. Fur-
ther, most of the patients in the Atrophy group also became seron-
egative, indicating that the disappearance of the antibodies occurs 
faster than the healing of the mucosa.
 Of clinical presentations, the presence of malabsorption was 
associated with histological non-recovery. Th is was most evident 
in the lower levels of iron as well as hemoglobin in the Atrophy 
group. Th ese results, together with the lower BMD  T -scores also 
observed, probably refl ect insuffi  cient absorption of nutrients 
in patients with severe villous atrophy. Previous studies have 
likewise found a correlation between the presence of anemia 
at diagnosis and more severe histological and clinical presen-
tation ( 18,39,40 ). Despite the diff erences in mucosal healing, 
aft er 1 year all laboratory values, excluding a minor diff erence 
in hemoglobin, were comparable in both groups. Th is demon-
strates that, as with serology, on treatment laboratory values 
improve faster than the mucosa. In contrast, BMD, although 
improved, still remained lower in the Atrophy group aft er 1 year 
on diet. Obviously, normalization of BMD takes more than 1 
year to complete.
 Similar to most of the other clinical parameters, we found no 
association between self-perceived symptoms and quality of life 
and mucosal recovery at follow-up. In fact, there was no signifi -
cant diff erence between the groups even at diagnosis, this probably 
refl ecting the high individual variation in these respects. On the 
contrary, there was a trend toward poorer GSRS and PGWB values 
at baseline in the Atrophy group, whereas aft er 1 year the results 
were practically identical. Th ese fi ndings further indicate that his-
tological healing lags behind clinical recovery.
 The poor correlation between histological recovery and 
other outcomes indicates that a follow-up biopsy taken after 1 
year is not an optimal approach in monitoring celiac disease. 
Our long-term follow-up results support this view, as there 
were no differences between the groups in mortality and other 
complications or in gastrointestinal symptoms and quality of 
life. Then again, although their prevalence remains unclear, 
the risk of severe complications in the long run has been asso-
ciated with incomplete mucosal recovery and warrants care-
ful follow-up ( 4,10,41 ). Unfortunately, there are currently no 
sensitive surrogate markers for ongoing mucosal damage, and 
endoscopic investigations are still needed ( 15 ). Nevertheless, 
here only 1 out of 87 subjects evincing incomplete recovery 
after 1 year presented with complications, suggesting that in 
almost all cases it is merely a question of slow mucosal healing. 
Our results support the need to individualize the current pro-
cedures, taking into account both the baseline severity of the 
disease and the dietary response. Whether a routine follow-up 
biopsy is mandatory for all patients who have uncomplicated 
celiac disease with good clinical response is a subject for future 
studies.
 Major strengths of this study are the large number of patients 
and the diversity of outcomes measured, and the use of validated 
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 Study Highlights
 WHAT IS CURRENT KNOWLEDGE 
 ✓  Follow-up biopsies in celiac disease are important in the 
monitoring of mucosal recovery and screening for compli-
cations. 
 ✓  All celiac disease patients do not reach mucosal recovery 
in 1 year’s time despite strict gluten-free diet. 
 ✓  The optimal timing of the follow-up biopsy is unclear. 
 WHAT IS NEW HERE 
 ✓  Only the presence of more severe disease at diagnosis, in 
terms of histology and serology and signs of malabsorption, 
was associated with incomplete mucosal recovery. 
 ✓  The rate of mucosal recovery does not affect patient’s qual-
ity of life and clinical symptoms 1 year after diagnosis or 
long-term prognosis. 
 ✓  Personalized approach is required to decide the optimal 
timing of the follow-up biopsy. 
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SUMMARY
Background
A repeat biopsy is recommended, but often omitted in coeliac disease patients on a
gluten-free diet. The effect of performing or not performing repeat biopsies is cur-
rently unknown.
Aim
To identify factors associated with and the signiﬁcance of lacking biopsy for long-
term outcome. Predictors and the importance of incomplete histological recovery
after 1 year was investigated in re-biopsied patients.
Methods
A total of 760 patients participated in a nationwide follow-up study. Medical data
were gathered via interviews and patient records, and blood samples were drawn for
serology. Current symptoms and well-being were assessed by validated PGWB, SF-36
and GSRS questionnaires.
Results
Malabsorption was more common among those with a repeat biopsy (46%) than those
without repeat biopsy (33%), P < 0.001, as were severe symptoms at diagnosis (24% vs.
16%, P = 0.05) and concomitant gastrointestinal (40% vs. 32%, P = 0.049) or muscu-
loskeletal (35% vs. 27%, P = 0.023) diseases such as arthritis, osteoporosis and back
pain. Repeat biopsy was more rare in subjects diagnosed in private care (11% vs. 23%,
P < 0.001) or by screening (10% vs. 16%, P = 0.010). The groups were comparable as
to current symptoms and dietary adherence, but those without re-biopsy were less con-
ﬁdent of their diet (89% vs. 94%, P = 0.002) and more often seropositive on diet (14%
vs. 9%, P = 0.012). They reported better SF-36 physical functioning (P = 0.043) and
less pain and indigestion (P = 0.013 and P = 0.046 respectively) and total GSRS
(P = 0.052) score. Incomplete mucosal recovery was predicted by more advanced his-
tological (P < 0.001) and serological (P = 0.001) disease at diagnosis, whereas the
groups did not differ in long-term adherence, symptoms, seropositivity, questionnaire
scores, frequency of fractures or malignancies.
Conclusions
Severe disease at diagnosis predicted the record of a repeat biopsy and incomplete
mucosal recovery. Neither lacking biopsy nor incomplete recovery in a relative short
time span of 1 year was associated with poorer long-term outcome, although survival
bias cannot be excluded.
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INTRODUCTION
A careful follow-up of coeliac disease activity after the
initial diagnosis is considered important due to the pos-
sible complications associated with incomplete healing of
the small-bowel mucosa.1, 2 Owing to the lack of sensi-
tive surrogate markers for histological recovery, most
current guidelines recommend a repeat biopsy to be con-
sidered on a gluten-free diet,1–6 this often being executed
approximately 1 year after the diagnosis, even if there is
lack of evidence on the effect of such practice.3, 7–9 On
the other hand, due to its unpleasantness and resource-
consuming nature, the control endoscopy is often omit-
ted in clinical practice, the effect of this on long-term
outcomes being currently unknown.7 Altogether, due to
the scarcity of evidence, this topic has been under active
discussion in the expert guidelines.1
Even if a repeat biopsy is conducted, the signiﬁcance
of possible incomplete villous recovery on dietary treat-
ment remains scantly studied. It has been linked, for
example, to rare cases of refractory coeliac disease and
lymphoproliferative malignancies, but the relevant results
appear to be markedly dependent in a 15-year follow-up
on the study population and the timing of the
endoscopy.1, 3, 8, 9, 11, 12 We have in fact recently shown
that incomplete histological recovery after 1 year on a
gluten-free diet is not associated with reduced short-term
well-being or increased risk of cancer and mortality.8
Furthermore, although after 1 year’s diet up to 50% of
coeliac patients may show signs of villous damage, in the
long run this is seen in less than 10% of cases and only
0.3% have true refractory coeliac disease.8, 10, 12
The rapidly growing number of coeliac disease
patients renders optimal targeting and timing of the
endoscopic follow-up a major public health issue.8–10, 12
To further elucidate these aspects, we investigated factors
associated with the omission of routine a invasive fol-
low-up and the value of a repeat biopsy 1 year after
diagnosis with respect to long-term outcome. Simultane-
ously, we were able to further explore the signiﬁcance of
incomplete histological recovery found in the follow-up
biopsy in a nationwide coeliac disease cohort.
MATERIALS AND METHODS
Patients and study design
The nationwide cross-sectional study was conducted in
Tampere University Hospital and the University of Tam-
pere. The participants were recruited via newspaper
advertisements and with the help of local and national
coeliac disease societies. Inclusion criteria were age
≥18 years and a biopsy-proven coeliac disease diagnosis
at least 2 years before the present study. All voluntary
participants completed validated questionnaires for cur-
rent symptoms and health-related quality of life and
were interviewed systematically by an experienced physi-
cian or study nurse. In addition, blood samples were
drawn for serology and medical records reviewed to con-
ﬁrm the diagnosis and to complement clinical data and
laboratory parameters. Subjects with unclear coeliac dis-
ease diagnosis or substantially lacking medical informa-
tion were excluded. The possible use of olmesartan
therapy was also checked for and considered an exclu-
sion criterion, as it may cause severe enteropathy resem-
bling coeliac disease.13
After collection of study data, the results were com-
pared between subgroups of participants who had either
undergone (Repeat biopsy) or not (No repeat biopsy) a
routine follow-up biopsy approximately 1 year after the
coeliac disease diagnosis. For similar comparison, sub-
jects who had been re-biopsied while on a gluten-free
diet were categorised into those with complete and those
with incomplete histological recovery after 1 year on the
diet.
The study enrolment and collection of personal infor-
mation, blood samples and medical data were conducted
with the permission and according to the guidelines of
the Ethical Committee of the Pirkanmaa Hospital Dis-
trict. All participants gave written informed consent.
Clinical characteristics
The following clinical and demographic data was col-
lected from all participants: gender, age at present and at
diagnosis, clinical presentation at diagnosis, the type
(gastrointestinal symptoms, extra-intestinal symptoms,
screen-detected), duration and severity of symptoms
before diagnosis and also their current persistence, family
history of coeliac disease, possible symptoms in child-
hood, presence of coeliac disease-associated and other
signiﬁcant chronic comorbidities, and site (primary, sec-
ondary or tertiary care, private care) of coeliac disease
diagnosis. Severity of symptoms was further categorised
as mild, moderate and severe as previously described in
detail14.
Small-bowel mucosal biopsies
Data on the biopsies were collected from patient records.
Our national guidelines recommend at least four small-
bowel mucosal biopsies to be taken routinely from each
patient upon coeliac disease suspicion and during the
repeat endoscopy. The histological specimens are
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forwarded to the hospitals’ pathology department, where
the severity of mucosal damage is evaluated in represen-
tative biopsy cuttings. In the present study, the severity
of mucosal lesion was at diagnosis graded into normal,
partial, subtotal or total villous atrophy based on the
original pathology report. Mucosal recovery on gluten-
free diet was deﬁned morphologically based on nor-
malised villous height crypt depth ratio.
Serology and haemoglobin
The values of serum endomysial antibodies at time of
diagnosis, if available, were gathered from patient ﬁles.
Further serum endomysial antibodies and transglutami-
nase 2 antibodies were measured in all subjects at the
time of the study while on a strict gluten-free diet.
Serum IgA-class serum transglutaminase-2 antibodies
were tested by commercial enzyme-linked immunosor-
bent assay (QUANTA Lite h-tTG IgA, INOVA Diagnos-
tics, San Diego, CA). Values >30.0 U/were rated positive
according to the manufacturer’s instructions. Serum
endomysial antibodies were assessed by indirect
immunoﬂuorescence on human umbilical cord 15. Serum
endomysial antibodies titres 1:≥5 were considered posi-
tive and diluted until negative to 1:50, 1:100, 1:200,
1:500, 1:1000, 1:2000 and 1:4000. The values were further
sub-categorised into low (titres 1:5-1:200) and high posi-
tive (1:500-1:4000). In cases of selective IgA deﬁciency
the corresponding IgG-class antibodies were measured.
Blood haemoglobin values and the possible presence of
anaemia at coeliac disease diagnosis were gathered from
the medical ﬁles.
Adherence to the gluten-free diet
Provision of professional dietary advice at coeliac disease
diagnosis was veriﬁed by patient interview and from the
patient records. Current self-reported long-term adher-
ence to the gluten-free diet was inquired and classiﬁed as
“strict” (minor inadvertent lapses less than a few times a
year), “occasional lapses” (lapses less frequently than
once per month) and “normal diet” (more frequent
lapses).16, 17 Alongside adherence, also the patient’s over-
all competency to manage the diet and the possible use
of puriﬁed oats and wheat starch products were
asked.18, 19 Long-term dietary adherence was further esti-
mated on the basis of coeliac antibody positivity at the
time of the present study.
Questionnaires
All questionnaires were ﬁlled in at the time of this study
on a long-term gluten-free diet. Short Form 36 Health
Survey (SF-36), and Psychological General Well-Being
questionnaires (PGWB) and Gastrointestinal Symptoms
Rating Scale (GSRS) were used to assess patients’ self-
perceived quality of life and gastrointestinal symptoms
over time up to this study. SF-36 comprises of 36 sepa-
rate questions which can be divided into eight domains
as follows; physical functioning, role limitations due to
physical problems, bodily pain, general health, vitality,
social functioning, role limitations due to emotional
problems and mental health.10, 16, 20–23 Items are re-
scored from 0 to 100, higher scores indicating better
health and quality of life.
PGWB is a well-validated and widely used question-
naire both in general and in coeliac disease.15, 16, 22 The
22 separate items can be further divided into six sub-
dimensions measuring anxiety, depression, well-being,
self-control, general health and vitality. All items use a
6-grade Likert scale with higher scores representing bet-
ter well-being and quality of life.
Self-perceived severity of gastrointestinal symptoms
was evaluated by the GSRS questionnaire.15, 24 This
comprises of 15 separate items which can be added
together as a total score and divided into ﬁve sub-dimen-
sions measuring abdominal pain, gastro-oesophageal
reﬂux, indigestion, diarrhoea and constipation. The scor-
ing is based on a 7-grade Likert scale, higher scores
reﬂecting more severe gastrointestinal symptom.
Statistical analysis
Continuous variables and questionnaire ﬁndings are pre-
sented as medians with quartiles or ranges. Binominal
and categorical variables are presented as number of sub-
jects and percentages. Continuous variables were studied
using Mann–Whitney test and binominal and classiﬁed
variables using Chi-square test. A <0.05 was considered
signiﬁcant in all analyses. Statistical analyses were made
using the Statistical Package for the Social Sciences
version 20 (Released 2011, IBM SPSS Statistics for
Windows, Version 20.0; IBM Corp., Armonk, NY, USA).
RESULTS
Altogether 791 participants (median age at diagnosis
44 years, females 78%) had conﬁrmed coeliac disease
and were enrolled in further analyses. However, 27 of
them were excluded because it was unclear whether they
had undergone a repeat biopsy and four due to possible
use of olmesartan. Of the ﬁnal cohort of 760 participants
516 (68%) had (Repeat biopsy group) and 244 (32%)
had not (No repeat biopsy group) undergone a follow-
up endoscopy after a median of 1 year.
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Factors predicting record of a repeat biopsy
Patients with severe clinical or histological presentation
or signs of malabsorption at diagnosis were more likely
to undergo a repeat biopsy, whereas it was less common
among those diagnosed in private care or by screening
(Table 1). Record of a histological follow-up was not
associated with the duration or type of symptoms and
serum endomysial antibodies titres at diagnosis, gender,
presence of symptoms during childhood and family his-
tory of coeliac disease (Table 1). Median age at diagnosis
was also comparable in subjects with and without repeat
biopsy (53 vs. 55 years, P = 0.885).
Long-term follow-up data on patients with and
without a repeat biopsy
The median time on a gluten-free diet prior to this study
was 8 years. Coeliac disease patients who had undergone
a repeat biopsy were more often found to suffer from
concomitant Sj€ogren’s syndrome, musculoskeletal disease
or gastrointestinal disease (Table 2). There were no sig-
niﬁcant differences between the groups in the prevalence
of other chronic conditions (Table 2).
Both study groups had received comparable dietary
advice at diagnosis and showed equal adherence at time
of inquiry (Table 3), but those with no repeat biopsy
after 1 year were less conﬁdent as to their current capa-
bility to manage a strict diet. Furthermore, the nonbiop-
sied subjects had signiﬁcantly, even if only modestly,
higher serum endomysial antibodies titres on a long-
term gluten-free diet. There was, however, no difference
between the groups in the presence or severity of current
self-estimated symptoms (Table 3), and, based on the
GSRS questionnaire, patients without repeat biopsy had
even fewer overall gastrointestinal symptoms and less
indigestion (Table 4). There were also no differences
between the groups in respect of most current health
and quality of life measurements except that subjects
without a repeat biopsy reported better SF-36 physical
functioning and bodily pain scores (Table 4).
Predictors of incomplete villous recovery in re-
biopsied subjects
The result of the re-biopsy was available in 476 (92%)
out of the 516 patients undergoing the procedure 1 year
after diagnosis. Altogether 276 (58%) had reached mor-
phological small-bowel mucosal recovery, while in 200
(42%) it remained incomplete. Factors predicting incom-
plete recovery were malabsorption (55% vs. 41%,
P = 0.003), high serum endomysial antibodies titre (46%
vs. 25%, P < 0.001) and severe mucosal damage (total
atrophy 32% vs. 19%, P < 0.001) at diagnosis. The
recovery and nonrecovery groups did not differ in gen-
der, age at diagnosis, family history of coeliac disease,
site of diagnosis, severity and duration of symptoms
before diagnosis or presence of symptoms in childhood
(data not shown). There was also no difference between
the groups in haemoglobin at diagnosis, when analysed
with both genders together, but in separate analysis the
median value was lower in women evincing no recovery
(12.3 g/dL vs. 12.7 g/dL, P = 0.030).
Long-term outcomes in re-biopsied patients with and
without histological recovery
Coeliac disease patients with incomplete mucosal recov-
ery 1 year after diagnosis had more concomitant respira-
tory (15% vs. 22%, P = 0.031) and dermatological
diseases (17% vs. 10%, P = 0.043) at current evaluation,
while there was no differences in the frequency of coeliac
disease-associated and other chronic diseases. Further-
more, the recovery and nonrecovery patients showed
similar severity of current gastrointestinal symptoms and
quality of life as measured by the questionnaires (data
not shown). The groups had also received equally much
dietary advice at diagnosis and did not differ in current
adherence or capability to manage the diet, in record of
regular follow-up, or in use of puriﬁed oats and preva-
lence of serum transglutaminase-2 antibody positivity
(Table 5).
DISCUSSION
The main ﬁnding in the present study was that patients
with or without endoscopic follow-up did not differ in
severity of symptoms or in well-being after a median fol-
low-up time of almost a decade. In addition, the repeat
biopsy and no biopsy groups showed excellent and com-
parable self-reported dietary adherence. Finally, even if a
repeat biopsy had been conducted, incomplete mucosal
recovery 1 year after diagnosis did not affect the long-
term clinical outcomes.
A repeat biopsy after 1 year was undertaken especially
for patients with severe presentation at diagnosis, while it
was more often omitted in screen-detected cases. It would
seem logical that, as also seen in other chronic diseases,25
physicians are keener to follow sicker patients with an
increased risk of long-term complications. Alternatively,
those with milder or screen-detected disease are likely to
be less willing to undergo an unpleasant repeat biopsy
and, in turn, physicians neglect it in view of to the antici-
pated better prognosis. This may also explain the similar
tendency to omit the repeat biopsy in type 1 diabetes
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patients, whose coeliac disease is often found by screen-
ing and who might have an increased risk of endoscopic
complications.26 Repeat biopsies were also more often
taken from patients with concomitant gastrointestinal
and musculoskeletal illnesses, strengthening the concep-
tion that those with comorbidities and ongoing symp-
toms undergo the procedure with a lower threshold.
We also found patients diagnosed in the private sec-
tor to have the repeat biopsy omitted more often than
those diagnosed in public healthcare. This might be
because in private care patients have to pay for the sec-
ond endoscopy themselves. In addition, in Finland
healthcare has evolved around a strong public sector
which, as also seen in the present study, treats most
coeliac disease patients. In contrast, the private sector is
more focused on frontline screening and refers the puta-
tive patients to public healthcare for further diagnosis
and follow-up.28 The results would very likely differ in
countries where a system of private health insurances
predominates, as in the USA.27, 28 What is more, we
found no differences in the rate of re-biopsy between
public healthcare levels. This somewhat unexpected ﬁnd-
ing might be explained by the organised decentralisation
of coeliac disease diagnostics and the use of uniform
nationwide guidelines at all healthcare levels in Fin-
land.26, 29 In fact, nowadays up to 85% of Finnish coe-
liac disease patients are diagnosed and followed in
primary and secondary care.29, 30
Table 1 | Clinical, serological and histological characteristics at diagnosis in 760 coeliac disease patients without (No
repeat biopsy) or with (Repeat biopsy) a follow-up biopsy done
No repeat biopsy
n = 244
Repeat biopsy
n = 516
P-valuen % n %
Females 181 74 413 80 0.093
Clinical presentation*
Malabsorption 80 33 235 46 0.001
Gastrointestinal symptoms 204 84 425 82 0.664
Extra-intestinal symptoms† 97 40 201 39 0.864
Screen-detected 39 16 49 10 0.010
Duration of symptoms before diagnosis 0.571
>5 year 96 42 209 43
<5 year 119 50 245 50
Severity of symptoms at diagnosis 0.052
Severe 40 16 122 24
Moderate 100 41 216 42
Mild 91 37 158 31
No symptoms 13 5 18 4
Symptoms during childhood 72 28 181 35 0.223
Coeliac disease in family 146 63 329 64 0.790
Endomysial antibody titres at diagnosis 0.461
High 1: >200 36 39 77 35
Low 1:5–1:200 47 51 107 49
Negative 10 11 35 16
Severity of villous atrophy at diagnosis <0.001
Total 42 24 124 26
Subtotal 58 34 196 42
Partial 73 42 149 32
Site of diagnosis <0.001
Primary care 41 17 79 15
Private care 57 23 58 11
Secondary care 108 44 250 49
Tertiary care 38 17 125 24
* Patient can present with more than one symptom.
† Arthritis, dental enamel defects, dementia, dermatitis herpetiformis, glossitis, aphtous stomatitis, gynecological problems,
myopathy, neurologic symptoms, osteoporosis, Sj€ogren’s disease, chronic eczema, IgA nephropathy.
Bold values are statistically signiﬁcant.
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Interestingly, based on the GSRS, coeliac disease
patients with a repeat biopsy after 1 year also remained
more symptomatic during the current long-term follow-
up. One reason for this may be the aforementioned
higher prevalence of gastrointestinal comorbidities in this
group. In addition, we have shown that patients with
severe presentation at diagnosis are also more likely to
remain symptomatic on a long-term gluten-free diet.32
Likewise, here those with repeat biopsy had currently
more bodily pain and decreased physical functioning,
Table 2 | Presence of coeliac disease-associated or other co-morbidities during long-term follow-up in 760 coeliac
disease patients without (No repeat biopsy) or with (Repeat biopsy) a follow-up biopsy done
No repeat biopsy
n = 244 Repeat biopsy n = 516
P-valuen % n %
Associated diseases
Sj€ogren’s syndrome 1 0 14 3 0.033
Type 1 diabetes 6 3 9 2 0.090
Thyroidal disease 39 16 83 16 0.973
Other conditions
Musculoskeletal disease* 66 27 182 36 0.023
Gastroenterological disease† 78 32 203 40 0.049
Gynecological disease 39 16 103 20 0.198
Neurological disease 29 12 67 13 0.671
Psychiatric disease 11 5 25 5 0.834
Any malignancy 9 4 24 5 0.547
Any fracture 68 28 141 28 0.857
No comorbidities 38 16 58 11 0.079
* For example, arthritis, osteoporosis, back pain.
† For example, reﬂux, lactose intolerance, gastritis.
Bold values are statistically signiﬁcant.
Table 3 | Long-term follow-up data on 760 coeliac disease patients without (No repeat biopsy) or with (Repeat
biopsy) a control biopsy done while on a gluten-free diet (GFD)
No repeat biopsy
n = 244 Repeat biopsy n = 516
P-valuen % n %
Received dietary advice 231 95 492 95 0.683
Capable of managing GFD 216 89 480 94 0.002
Strictness of GFD 0.374
Strict diet 231 96 499 98
Occasional lapses 9 4 11 2
Normal gluten intake 0 0 0.0 0
Endomysial antibody titres on GFD 0.012
High 1: >200 12 5 7 1
Low 1:5–1:200 20 9 38 7
Negative 1: <5 189 86 486 92
TG2-ab positivity on GFD 39 16 57 11 0.139
Current symptoms 0.268
None 155 78 199 72
Slight 37 19 70 25
Serious 5 3 7 4
GFD, gluten-free diet; Tg2-ab, transglutaminase 2 antibodies.
Bold values are statistically signiﬁcant.
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again probably since they have more musculoskeletal
comorbidities. In contrast, the groups did not differ in
any of the PGWB sub-dimension scores, indicating
that the minor differences seen in the prevalence of
symptoms and comorbidities have no major effect on
self-perceived well-being and quality of life.
Another important ﬁnding was that the omission of a
repeat biopsy 1 year after the diagnosis did not affect
long-term dietary adherence. This suggests that the inva-
sive follow-up does not play a major role in commitment
to the gluten-free diet, at least in Finland, where adher-
ence is generally very good and the additional costs of
the diet remain reasonable.2, 31, 33 Nevertheless, patients
without a repeat biopsy considered their capability to
manage their diet lower and were somewhat more often
seropositive, indicating that a subgroup of patients might
beneﬁt from the endoscopic follow-up.32 Then again, it
might be worthwhile investigating whether the re-biopsy
Table 4 | Gastrointestinal symptoms and quality of life during long-term follow-up in 760 coeliac disease patients
with (Repeat biopsy) or without (No repeat biopsy) a follow-up biopsy done
No repeat biopsy n = 244 Repeat biopsy n = 516
P-valueMedian Quartiles Median Quartiles
GSRS sub-scores
Total 1.8 1.5–2.5 1.9 1.5–2.6 0.052
Indigestion 2.3 1.8–3.2 2.5 1.8–3.0 0.046
Diarrhoea 1.3 1.0–2.3 1.7 1.0–2.0 0.128
Abdominal pain 1.7 1.3–2.7 2.0 1.3–2.3 0.150
Constipation 1.7 1.0–2.7 1.8 1.0–2.7 0.323
Reﬂux 1.5 1.0–2.0 1.5 1.0–2.0 0.468
SF-36 sub-scores
Bodily pain 78 53–90 68 48–90 0.013
Physical functioning 95 80–100 90 75–100 0.043
Role limitations, emotional 100 67–90 100 67–88 0.127
General health perception 65 45–80 60 45–75 0.196
Role limitations, physical 100 25–100 75 50–100 0.223
Vitality 75 53–85 70 55–80 0.583
Social functioning 90 75–100 88 75–100 0.634
Mental health 84 72–100 80 72–100 0.978
PGWB sub-scores
Total 107 95–117 106 94–115 0.515
General health 14 10–15 13 11–16 0.147
Well-being 17 15–20 18 15–19 0.745
Vitality 18 16–20 18 15–21 0.746
Anxiety 25 21–27 25 21–27 0.810
Depression 17 15–18 17 15–18 0.941
Self-control 16 14–17 16 13–17 0.958
GSRS, gastrointestinal symptom rating scale, lower scores indicate fewer gastrointestinal symptoms; PGWB, psychological general
well-being, higher scores indicate better well-being; SF-36, short form 36, higher scores indicate better social functioning.
Bold values are statistically signiﬁcant.
Table 5 | Long-term follow-up characteristics in 476
coeliac disease patients with (Recovery) or without
(Atrophy) histological response at follow-up biopsy
Atrophy
n = 200
Recovery
n = 276
P-valuen % n %
Received dietary advice 154 77 215 78 0.683
Capable of managing GFD 184 92 264 95 0.820
Strictness of GFD 0.060
Strict 195 97 275 100
Occasional lapses 5 3 1 0
Normal gluten use
Use of oats 162 81 231 82 0.947
Regular follow-up 131 66 198 71 0.426
TG2-ab positivity 45 23 79 28 0.497
Any malignancy 9 5 14 5 0.762
Fractures 53 27 80 28 0.859
GFD, gluten-free diet; TG2-ab, transglutaminase-2 antibodies.
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is in fact the main issue here or whether other means of
follow-up combined with enhanced dietary counselling
would be equally effective.34–37
We also sought to identify associated factors and the
long-term signiﬁcance of incomplete histological recovery
1 year after coeliac disease diagnosis in a nationwide
cohort. As with the repeat biopsy, incomplete recovery
was predicted by more severe disease presentation at
diagnosis. Similar associations between advanced disease
and incomplete recovery on treatment have previously
been observed in smaller studies.3, 8, 38, 39 Furthermore,
we recently showed that more ill patients need a longer
time to reach complete mucosal recovery.13 Hence, there
still was villous atrophy in as many as 42% of the
patients here after 1 year on gluten-free diet. Notwith-
standing the differences in the speed of mucosal recov-
ery, long-term damage is present in only 4–6% of
patients, a fraction of what is seen after
1 year.11, 31, 40, 41 Moreover, no more than 0.3% have
true refractory coeliac disease.29 It must be emphasised
that incomplete recovery is not explained by dietary
lapses since, in line with previous ﬁndings by the present
group9 and Haere and associates,35 also the majority of
those without mucosal healing showed excellent adher-
ence to the gluten-free diet.
Notably, the recovery and nonrecovery groups did
not differ in the prevalence of malignancies. This was
in line with our previous study carried out on a differ-
ent patient cohort in a tertiary centre setting8 and pro-
vides an interesting contribution to discussion of the
risk of malignancies and the necessity of a repeat
biopsy. In contrast to our results, Lebwohl and col-
leagues42 found an increased risk of lymphoproliferative
malignancies in patients with persistent villous atrophy,
even if this could only be seen in those diagnosed
before the year 2000. This controversy might be
explained by differences in study design and duration
of follow-up and improvements in the diagnostics and
management of coeliac disease during the past decades.
Since what is involved is a rare complication it is also
possible that statistical signiﬁcance was not reached by
chance only.
The only signiﬁcant long-term difference between sub-
jects with or without histological recovery was the higher
prevalence of dermatological and respiratory comorbidity
in the latter group. In particular, there was no difference
in gastrointestinal symptoms or general well-being even
in the long run, which is in accord with our previous
short-term ﬁndings8 in a tertiary centre. This strengthens
the conception that slower mucosal recovery does not
directly affect the improvement of symptoms and quality
of life in patients on a strict gluten-free diet. The reason
for poorer recovery among those with concomitant skin
and respiratory diseases is unclear and remains a subject
for further studies.
Our major strength here was the large number of rep-
resentative patients diagnosed at different levels of health
care. We also succeeded in collecting a wide variety of
relevant study parameters, and the use of validated ques-
tionnaires increases the reliability and reproducibility of
results. A limitation is that evaluation of the repeat biop-
sies was not centralised.43 Furthermore, the recruitment
of most of the participants through coeliac societies may
increase the risk of selection bias. The analysis of in par-
ticular serious outcomes such as malignancy according
to follow-up histology has also the potential for survival
bias, as sampling was not done at the time of the repeat
biopsy. Finally, we were not able to compare mortality
between the groups, since we did not take a certain pre-
deﬁned sample but instead enrolled existing patients.
Lack of histological follow-up and incomplete mucosal
recovery might be associated with increased mortal-
ity,9, 36 and more studies are needed to further elucidate
this issue.
In conclusion, coeliac disease patients with severe ini-
tial presentation were more prone to undergo a repeat
biopsy after 1 year on diet and were also found to lack
full mucosal recovery if re-biopsied. However, neither
the lack of the repeat biopsy nor histological recovery
was reﬂected in long-term clinical outcomes and dietary
adherence. On the basis of these results, performing a
routine endoscopy 1 year after diagnosis is not necessar-
ily an optimal approach. Instead, we propose a more
personalised follow-up, wherein the repeat biopsy is con-
ducted later, after 2–5 years and only for a selected
group based on age, initial disease severity and response
to the gluten-free diet.
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Introduction: Guidelines recommend regular  follow-up in coeliac  disease,  but effect of  this on long-term
outcomes  remains  unclear.
Aims:  To evaluate predictors and signiﬁcance of long-term  follow-up.
Methods:  677 previously diagnosed  coeliac  patients  were recruited  for a nationwide health  survey.  Med-
ical  data were gathered through interviews and patient records.  Current  symptoms  and quality  of life
were  assessed by  validated questionnaires and blood  samples were drawn  for serology.  All  variables  were
compared  between  patients  with and  without long-term  (>2 years) follow-up.
Results:  15% had  long-term  follow-up,  median duration  10 years. Predictors  (p <  0.05)  for the follow-
up  were immunological (35%  vs. 24%) and circulatory (20% vs.  12%) comorbidities, whereas it was  less
common  in  subjects  with musculoskeletal (23% vs.  34%) comorbidity  and  those not belonging  to  any at-
risk  group (16%  vs. 27%). Patients  with  or  without follow-up  had  comparable  age, adherence  and ability  to
manage  a gluten-free  diet and frequency of seropositivity. Also  questionnaire scores paralleled, but  those
without  follow-up  reported  more overall  symptoms  (16% vs. 26%). Most patients wished for follow-up.
Conclusion:  Only  a  minority  of patients  had regular  follow-up.  However, patients with  and without  the
follow-up  were  comparable in  most long-term  outcomes,  indicating that it  might  not be  always necessary.
The  results call  for more personalized  follow-up policies  in  coeliac  disease.
©  2018  Editrice Gastroenterologica Italiana  S.r.l. Published  by Elsevier Ltd. All rights reserved.
1. Introduction
Coeliac disease is a lifelong gluten-induced autoimmune
enteropathy with a prevalence up to  2% in Caucasian populations
[1].  The only treatment is a strict gluten-free diet,  the initiation of
which usually elicits a clear  clinical and histological response and
disappearance of the disease-speciﬁc autoantibodies [2]. Unfor-
tunately, the high cost and  restrictive nature of the gluten-free
diet predisposes to poor adherence and  subsequently to persistent
enteropathy and an increased risk of  serious complications such as
osteoporotic fractures and  malignancy [3–6]. Moreover, there is a
subgroup of patients with a condition called refractory coeliac dis-
∗ Corresponding author at: Faculty of Medicine and Life  Sciences, University of
Tampere,  FIN-33014 Tampere, Finland.
E-mail address: kalle.kurppa@uta.ﬁ (K. Kurppa).
ease, who  do not attain  adequate clinical and histological recovery
despite a strict diet  and thus have particularly poor  prognosis [7].
In order to ensure proper  adherence and response to the
gluten-free diet and  to detect possible complications, most current
guidelines recommend regular  long-term follow-up in coeliac dis-
ease even  as often  as annually [2,8]. However, there is a paucity of
evidence as to how  the follow-up is actually implemented in clin-
ical practice, and  whether the  absence of follow-up really affects
the long-term coping and health of the  patients [9–15]. Interest-
ingly, in a 15-year follow-up we recently found that the lack  of a
repeat biopsy one  year after coeliac disease diagnosis is not  asso-
ciated with an increased risk  of adverse outcomes such as reduced
well-being or malignancies [16].  This would  indicate that the  asso-
ciation between the  presence of follow-up and the prognosis of
coeliac disease is more complex than one  might expect.
https://doi.org/10.1016/j.dld.2018.05.015
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To further elucidate the signiﬁcance of regular follow-up to the
treatment success in coeliac disease, we  conducted a nationwide
survey and compared various patient-related and  other relevant
factors between large cohorts of coeliac disease patients with or
without long-term follow-up after diagnosis.
2. Materials and methods
2.1. Patients and study design
A nationwide cross-sectional health survey was  carried out in
Tampere University Hospital and the University of Tampere. The
survey was created to investigate variable aspects  of the treat-
ment success in coeliac disease, not just  factors associated with
the long-term follow-up. The  participants were recruited through
newspaper advertisements and  with the  aid of coeliac disease soci-
eties. Inclusion criteria were  age ≥18 years and  a biopsy-proven
diagnosis at least two years before  enrolment. All participants ﬁlled
validated questionnaires on current symptoms and  quality of life
and were interviewed systematically by  a physician or a study
nurse with expertise in coeliac disease. Patients unable to attain
the study center were interviewed by  phone and  questionnaires
were sent by mail. Patient records were  reviewed in order to  con-
ﬁrm the diagnosis and to complement medical data. In addition,
blood samples were drawn for  serological measurements, in  case
of phone interviews this was  done at the  nearest laboratory. Sub-
jects with dermatitis herpetiformis were  excluded owing to  their
different diagnostic and follow-up protocol, as well  as patients with
an unclear diagnosis or substantially incomplete medical informa-
tion. Altogether 677 participants, representing approximately 2% of
the whole Finnish coeliac population [4],  were enrolled for further
analyses.
After data collection the  results were analyzed between
subgroups of participants who either had  or had not  been system-
atically assessed for at least two  years after  the diagnosis by health
care for dietary compliance and  treatment success. This sorting was
based on the patients’ own reporting and  medical record data.  Also
possible clinical and/or serological coeliac disease controls carried
out during health care visits for other conditions were included.
Subgroup analyses were carried out in patients with  only a short-
term follow-up (<2 years) and  those without any  follow-up. The
ﬁndings were compared with  Finnish national recommendations.
In  Finland, the follow-up of coeliac disease is decentralized to  pri-
mary care, with the general practitioners in charge. If needed, the
patient can be referred to a specialist in  a reasonable time frame.
To unify diagnostics and treatment, there  are national Current Care
Guidelines, which recommend a repeat biopsy one  year after diag-
nosis and regular clinical and  serological follow-up at 2–3-year
intervals.
Patient enrolment and collection of study data were conducted
with the permission and according to the  guidelines of the Ethical
Committee of the Pirkanmaa Hospital District. All participants gave
written informed consent.
2.2. Clinical characteristics
The clinical information collected included demographic data,
the type and the severity of  clinical presentation before diag-
nosis, duration of symptoms and their  current self-experienced
persistence. Family history of  coeliac disease, presence of coeliac
disease-associated and other  signiﬁcant chronic comorbidities
were also inquired. The latter  included particularly immunologi-
cal (e.g. asthma, allergies), circulatory (e.g.  hypertension, coronary
artery disease) and musculoskeletal (e.g.  arthritis, ﬁbromyalgia)
conditions. Current or previous smoking and whether the coeliac
disease diagnosis was  made in  primary, secondary or  tertiary pub-
lic care or  in private care were  also inquired. The self-perceived
severity of  clinical presentation was asked  to estimate the burden
of symptoms. These were further classiﬁed into (1)  no symptoms,
(2) mild symptoms such as occasionally disturbing gastrointesti-
nal or extra-intestinal symptoms or a combination of  them and  (3)
severe symptoms seriously disturbing daily  life, such as recurrent
awakenings because of pain or symptoms requiring acute inpatient
care [17].
2.3.  Small-bowel mucosal biopsies
Data on  small-bowel mucosal biopsies were collected from
the patient records. Our national diagnostic guidelines for coeliac
disease recommend at  least four  duodenal biopsies to be taken
routinely from each patient upon coeliac disease suspicion and dur-
ing  the possible repeat endoscopy after one year on  a gluten-free
diet. The histological specimens are forwarded to  the hospitals’
pathology department, where the severity of  mucosal damage is
evaluated in representative and  correctly orientated biopsy cut-
tings. Demonstration of duodenal villous  atrophy is  required for
celiac disease diagnosis. The degree of mucosal lesion has for
decades been graded as partial, subtotal or total villous  atrophy,
these corresponding approximately grades 3a, 3b and  3c in Marsh-
Oberhuber classiﬁcation.
2.4. Celiac  disease serology
Values for serum  endomysial antibodies (EmA) at diagnosis
were gathered from patient records. Furthermore, EmA  and trans-
glutaminase 2 antibodies (TG2ab) were measured in  all patients at
the time of the current study. Indirect immunoﬂuorescence was
used for EmA  measurements as  previously described [18]. Titers
1: ≥5 were  considered positive and diluted until negative to 1:50,
1:100, 1:200,  1:500, 1:1000, 1:2000 and 1:4000. TG2ab were tested
by commercial ELISA (QUANTA Lite h-tTG IgA, INOVA Diagnostics,
San Diego, CA), considering a cut-off >30.0 U/l  positive. Correspond-
ing IgG-class antibodies were measured in cases of  selective IgA
deﬁciency.
2.5. Adherence to the  gluten-free diet
Provision of dietary advice  at coeliac disease diagnosis was
veriﬁed by  patient interview and from patient records. Current
long-term dietary adherence was  also inquired by an  experienced
study nurse/physician with an expertise in  coeliac disease and clas-
siﬁed as “strict” (minor inadvertent lapses less than  a few times  a
year), “occasional lapses” (lapses less often  than once per month)
and “normal diet”. Long-term adherence was  further estimated on
the basis of coeliac antibody positivity at  the time of the present
study. Alongside adherence, patient’s overall competency in man-
aging the  diet and the  possible use of puriﬁed oats was  asked.
2.6.  Questionnaires
Short Form  36 Health Survey (SF-36) and  Psychological General
Well-Being questionnaires (PGWB) were used to assess  patients’
current self-perceived quality of  life and gastrointestinal symptoms
at time of  study.
SF-36 comprises 36  separate questions, divided into eight sub-
dimensions as follows; physical functioning, role limitations due
to physical problems, bodily pain, general health, vitality, social
functioning, role limitations due  to emotional problems and mental
health [19–23]. Items are re-scored from  0 to 100,  higher scores
indicating better health  and quality of life.
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Table  1
Clinical, serological and histological characteristics at diagnosis in 648 celiac  disease patients with or without long-term follow-up.
Long-term follow-up (N = 99) No long-term follow-up (N  = 549) P  value
N % N %
Women  80 80 437 80 0.783
Site  of diagnosis 0.662
Primary  healthcare 18 18 89 16
Secondary/tertiary  healthcare 64 65 379 70
Private  healthcare 17 17 78 14
Symptoms  in childhood 40 41 179 33 0.292
Duration  of symptoms before diagnosis 0.915
>5  year 31 43 221 43
1–5  year 29 30 165 32
<1  year 17 18 94 18
No  symptoms 9 9 38 7
Symptom  at diagnosis1
Gastrointestinal 85 82 457 84 0.590
Malabsorption  48 49 239 44 0.385
Extraintestinal  symptoms 40 40 193 34 0.190
Screening  12 12 67 12 0.962
Risk  group for celiac disease
Family history 74 76 362 67 0.064
Associated  condition3 24 24 101 19 0.186
No  risk group 16 16 146 27 0.025
EmA  positivity at diagnosis 232 88 1724 91 0.812
tTG-ab  positivity at diagnosis 183 90 1365 90 0.852
Severity  of villous atrophy at diagnosis 0.959
Total  atrophy 21 27 121 26
Subtotal  atrophy 29 38 179 39
Partial  atrophy 27 35 159 35
Smoking  0.836
Yes  7 7 48 9
Quit  20 20 112 21
No  71 72 379 70
1Patient can present with more than  one symptom.
Data  were available from more than  90% of the  cases in each  category except: 226, 320, 4190 and 5152.
3Type 1 diabetes mellitus, Sjögren’s disease, IgA  deﬁciency, autoimmune thyroidal disease.
EmA,  endomysium antibodies; tTg-ab,  transglutaminase 2 antibodies.
PGWB is a  well-validated and widely used questionnaire both in
coeliac disease and in general [18,20,22,23]. The  22 separate items
can be further divided into  six sub-dimensions measuring anxiety,
depression, well-being, self-control, general health  and vitality. All
items use a 6-grade Likert scale with  higher scores representing
better well-being and quality of life.
Gastrointestinal symptoms were evaluated by  the Gastrointesti-
nal Symptom Rating Scale (GSRS) questionnaire [18,24]. It  includes
15 separate items which can be added together as a total  score
and further divided into 5  sub-dimensions measuring abdominal
pain, gastro-esophageal reﬂux, indigestion, diarrhea and constipa-
tion. The scoring is based on a 7-grade Likert scale, higher scores
reﬂecting more severe gastrointestinal symptom.
2.7. Statistical analysis
Continuous variables are presented as medians with quar-
tiles or ranges. Categorical variables are presented as  number
of subjects and percentages. Statistical signiﬁcance in differences
between patients with and  without long-term follow-up was  stud-
ied using Mann–Whitney test. Binominal and  classiﬁed variables
were analyzed using Chi-square test.  A p-value <0.05 was  consid-
ered signiﬁcant in all analyses. All analyses were  carried out  using
SPSS 20.0 (IBM Corp., Armonk, NY).
3. Results
The median age of the whole study  cohort was  44 (range 22–89)
years and 80% were women. The median follow-up time  for the
whole study group was 10  (range 2–38)  years.  Out of the 677 par-
ticipants,  99 (15%)  had and  578 (85%) had not received long-term
follow-up for coeliac disease.
3.1. Factors predicting long-term follow-up
Existence of follow-up was predicted by the presence of
immunological (35%  vs. 24%,  p = 0.020) and circulatory (20% vs. 12%,
p = 0.010) comorbidities, whereas it was  less common in subjects
with coexisting musculoskeletal disease (23% vs.  34%, p = 0.045).
Those not belonging to any at-risk group (coexisting type I diabetes,
family history for  coeliac disease) were  more likely to be without
follow-up (Table 1). In contrast, follow-up was not predicted by
other co-morbidities (data not shown), gender, site of diagnosis,
seropositivity for  celiac autoantibodies or severity of histological
lesion at diagnosis, symptoms in childhood, clinical presentation
or duration of symptoms before diagnosis, family risk or associated
condition and smoking (Table 1). Also age  at diagnosis (median 42
vs. 44 years, range  18–75 vs.  18–71 years, p = 0.117) or at  present
(median 54 vs. 54 years, range  22–81 vs.  21–89 years, p = 0.919) did
not signiﬁcantly differ  between patients with and  without follow-
up.
When looking into the short-term characteristic one year after
diagnosis in patients whom the data were available, there was no
signiﬁcant difference between the presence of long-term follow-up
and short-term coeliac autoantibody positivity (regular follow-up
6.3% vs.  no follow-up 15.1%, respectively, p = 0.343; n = 95). Neither
did the groups differ in the prevalence of  histological recovery (fully
normalized 53.0% vs. 60.2%, p = 0.378; n  = 398) after one year on a
gluten-free diet.
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Table  2
Follow-up features in 648 celiac disease patients with or without long term follow-up.
Long-term follow-up (N = 99) No long-term follow-up (N = 549)  P value
N %  N %
Adherence to gluten-free diet 0.741
Strict  diet 94 97 527 98
Occasional  lapses 3 3 11 2
Frequent  lapses 0 0 0 0
Use  of gluten-free oats 82 85 449 83 0.534
Able  to manage the  diet 96 97 503 96 0.381
Symptoms  at the  time of study 0.043
No  81 83 400 75
Slight  12 13 127 24
Severe  3 3 10 2
EmA  positivity at study 7 7 52 9 0.458
TG2-ab  positivity at study 13 13 81 15 0.703
Wish  for regular follow-up 90 92 443 81 0.038
EmA,  endomysium antibodies; TG2-ab, transglutaminase-2 antibodies.
Table  3
Current gastrointestinal symptoms and  quality of  life as measured by validated questionnaires in 648  celiac disease patients or  without long  term follow-up.
Long-term follow-up (N = 99) No long-term follow-up (N = 549) P value
Median Quartiles Median Quartiles
GSRS sub-scores
Total 1.9 1.6–2.5 1.9 1.5–2.7 0.974
Diarrhea  1.7 1.0–2.0 1.3 1.0–2.3 0.311
Constipation  1.7 1.0–2.3 1.7 1.0–2.7 0.313
Indigestion  2.5 2.0–3.3 2.3 1.8–3.3 0.315
Abdominal  pain 2.0 1.5–3.0 2.0 1.5–3.0 0.818
Reﬂux  1.3 1.0–2.0 1.3 1.0–2.0 0.992
SF-36  sub-scores
General health perception 55 40–75 65 50–75 0.088
Role  limitations, emotional 100 67–100 100 67–100 0.455
Vitality  70 51–80 70 55–84 0.506
Bodily  pain 78 48–90 68 57–90 0.516
Social  functioning 88 75–100 88 75–100 0.707
Physical  functioning 93 75–95 90 75–100 0.738
Role  limitations, physical 100 25–100 75 25–100 0.851
Mental  health 80 68–92 80 70–88 0.867
PGWB  sub-scores
Total 108 100–117 106 93–115 0.107
General  health 13 12–16 13 10–15 0.123
Anxiety  25 22–28 25 21–27 0.145
Self-control  16 14–17 16 14–17 0.150
Well-being  18 15–20 17 15–20 0.311
Vitality  19 16–20 18 16–20 0.347
Depression  17 16–18 17 15–18 0.628
GSRS, Gastrointestinal Symptom Rating  Scale, lower scores indicate fewer gastrointestinal symptoms; PGWB, Psychological General Well-Being, higher scores indicate better
well-being;  SF-36, Short Form 36, higher scores indicate better social functioning.
3.2. Long-term outcomes in patients with  and without follow-up
Participants in both follow-up and no-follow up  groups had  sim-
ilar dietary adherence and ability to manage the  gluten-free diet,
as well as use of puriﬁed oats  (Table 2). There was also no  sig-
niﬁcant difference between the groups in current positivity for
coeliac autoantibodies (Table 2)  or in  any of the  questionnaire
scores measuring health-related quality of life (SF-36, PGWB) and
gastrointestinal symptoms (GSRS) (Table 3). However, patients
without regular long-term follow-up suffered more  from current
self-reported overall symptoms (Table  2). In  line,  the GSRS total
(median 1.8 vs. 2.3, p < 0.001), pain (1.7  vs. 2.0, p < 0.014), indiges-
tion (2.3 vs. 2.8, p < 0.001) and  constipation (1.7 vs. 2.3, p < 0.001)
scores were higher in subjects with current self-reported symp-
toms than those without, whereas this  was not seen  in reﬂux  and
diarrhea.
Altogether 98% of patients with regular long-term follow-up
wished for it also in the future, and this  was also  seen in over  80%
of the patients of patients not  currently under follow-up (Table 2).
Most  of these patients wished the follow-up to be  organized in
public healthcare (Fig.  1), whereas there was no major  difference
regarding who should be in charge of the follow-up (Fig. 2).
3.3.  Sub-analysis of patients without any follow-up and
short-term follow-up
Altogether 84 (12%) out of the  677 participants had  not received
any follow-up for coeliac disease after the  diagnosis, while 465
(69%) had  been subject only to short-term follow-up (<2 year).
Compared to patients receiving long-term follow-up, patients
without any follow-up had more  current mild symptoms (27%
vs. 13% p =  0.038). Furthermore, those without any follow-up had
fewer circulatory diseases (18%  vs. 35%, respectively,  p = 0.009) and
a lower desire for regular follow-up (85%  vs. 92%, p  = 0.024) than
those with  long-term follow-up.
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Fig. 1. Patients’ opinion on where the long-term follow-up of celiac disease should
be  organized, divided on basis of  the lack (No follow-up) or  presence (Follow-up) of
current  regular follow-up.
Fig. 2. Patients’ opinion on who  should be in  charge of the  long-term follow-up of
celiac  disease, divided on basis of  the lack (No  follow-up) or presence (Follow-up)
of  current regular follow-up.
4. Discussion
We  found the prevalence of regular long-term follow-up to be
only 15% in Finnish coeliac disease patients [16]. This is  in stark
contrast to our national guidelines which recommend system-
atic clinical and serological follow-up at 2–3 years intervals in all
patients. It is also a markedly lower percentage than reported pre-
viously. In the early 1990s  Bardella et  al. [25] reported a follow-up
rate of 77%. Bebb et al. found  the corresponding ﬁgure to  be 62%,
although only 6% of the patients later  transferred to primary care
received follow-up [26]. In  a study by  Herman et al. 41% of  patients
received a follow-up during the ﬁrst  year after, this percentage
increasing to 89% after ﬁve  years [11]. The results by Bardella et al.
could be affected by the fact  that the  patients were investigated
during their transition from  pediatric to adult  care, at which  time
at least one visit is often scheduled. Another explanation for  the dif-
ferent percentages could be  related to  our practice to refer patients
in primary care soon after the  diagnosis, whereas most of the  previ-
ous studies were carried out  in tertiary centers. We must, however,
emphasize that also the majority of  our patients received short-
term follow-up, including a  follow-up biopsy one  year after the
diagnosis [16].
There are also  further explanations why the long-term follow-
up frequency is low particularly in Finland. Most  of the patients
have only  mild symptoms, reﬂecting the  short diagnostic delay  and
good recognition of  the disease by physicians [27]. This, along  with
the good  dietary adherence, has made severe complications asso-
ciated with advanced or poorly treated coeliac disease rare [4]. As a
result, demonstration of initial treatment response might often  be
deemed sufﬁcient by physicians. From  patients’ perspective, they
may ﬁnd  it hard to  motivate themselves to seek for  healthcare vis-
its when the disease does not  constitute a substantial daily burden.
In Finland public healthcare is accessible equally to all citizen and
active patients would likely have  received a follow-up, further indi-
cating that  they have  not contacted the  healthcare services. Thus,
it is  likely  that, even  if patients would “like” to have a follow-up,
they do  not vigorously seek it  if not organized by the  health care. In
these circumstances, a more  active role  of the healthcare providers
might be required to improve attendance in follow-up [28].
One of the main  arguments for follow-up in  coeliac disease
is the need to monitor dietary adherence. It was  thus of signif-
icance that also patients without follow-up reported excellent
adherence and competence  to maintain a gluten-free diet.  This
was supported by  the low frequency of current coeliac antibody
positivity, although it must  be realized that serology has limited
sensitivity in the detection of dietary lapses  [3]. The  higher preva-
lence of  seropositivity over  against self-reported adherence could
be caused by unrecognized lapses or  via the slow normalization
of high values [13,29–31]. Previously Bardella et al. found  reg-
ular follow-up to  improve adherence in adults [13] and Barnea
et al. reported similar ﬁnding in children [29].  The absence of
such an  association in Finland could be  due to the  high prevalence
of coeliac disease and good  availability of gluten-free products,
and the  widespread knowledge of the  disease among physicians
and food industry. We also wish to emphasize that  previously all
Finnish patients received governmental reimbursement for  dietary
expenses (ended in 2016). Owing to  these particularities, our
results may not be  directly applicable to countries in which  the
condition is rarer  and less well  known.
The majority of  patients were satisﬁed that the  follow-up was
arranged by general practitioners, although one third  would prefer
visits to  a specialist. This is  in line with  the strong public health-
care sector in Finland and a  long tradition of decentralization in
coeliac disease follow-up. This  aspect has  not been  studied using a
similar approach, but Bebb et al. [26] found the preferred method
for follow-up to be  visits to  a  dietician with a possibility to  con-
sult a physician. We  ﬁnd such  a dietician-led clinic  an interesting
alternative, as dietary lapses  are the most common reason for  non-
response in coeliac disease, even in apparently compliant subjects
[32]. However, this  approach would likely provide no major bene-
ﬁts in well-doing and strictly adherent patients. The  possible need
for patients with persistent symptoms to  consult a  physician should
also be taken into account in  these circumstances.
Although most of the long-term outcomes were  comparable
between the study groups, patients without follow-up felt  they
had more current symptoms when asked  as a qualitative estima-
tion. We  recently found persistent symptoms to be common even
in well-treated coeliac disease [33], but  no studies have looked into
the association between ongoing symptoms and  lack of  follow-
up. Interestingly, the difference in symptoms disappeared  when
evaluated by a validated questionnaire, indicating that the  direct
question emphasizes the subjective experience rather than  the
objective magnitude of symptoms. Gastrointestinal symptoms are
common and not always necessarily related to coeliac disease. In
fact, the  median GSRS scores in our treated celiac disease patients
were comparable to the Finnish population [33]. It  might be that
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regular healthcare contacts improve sense of self-capability and
reduce excessive monitoring of symptoms. Accordingly, patients
with irritable bowel syndrome have beneﬁted from physicians’
reassurance on the benignity of their  symptoms [34,35].  Here
it must be realized that the discordance between self-estimated
symptoms and GSRS might be  partly technical, as  the latter  mea-
sures a wide scale of symptoms that can  be even opposing, such  as
diarrhea and constipation.
Strength of the present study was the  large number of patients
diagnosed on different levels of healthcare. We also succeeded
in collecting a variety of clinically relevant parameters, and  the
use of validated questionnaires increases the reliability of results.
As a limitation, patient recruitment by  advertisements and  via
celiac societies predisposes to  selection bias. For example, the  study
information might have reached different age groups and socioe-
conomic classes unequally. Furthermore, although not speciﬁcally
designed as a follow-up study, patients without regular follow-
up could have considered our  survey as  an “extra  visit” and  thus
have been more eager to participate. Additional study limitations
were the lack of data on the patients’ socio-economic status [30,36],
scarcity of short-term serological follow-up data and the use  of
inexact three-point scale in the  evaluation of self-reported symp-
toms. The cross-sectional design also prevented us  from evaluating
the causality in for example the  incidence of comorbidities.
In conclusion, we found follow-up in  coeliac disease not to  meet
the current recommendations. However, the necessity for  rigid
follow-up scheme could be questioned, as there was no differ-
ence between the study groups in most long-term health outcomes.
These ﬁndings call for more  a personalized approach: patients
achieving clear remission could visit healthcare only  if symptoms
reappear or after major life changes, whereas those facing more
challenges might beneﬁt from  more systematic follow-up.
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